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 1 
1 Abstract 
 
Receptor tyrosine kinases (RTKs) and small GTP binding proteins (GTPases) are 
essential regulators of multiple cellular processes, making a tight control of their activity 
crucial for cellular homeostasis. Recently, it was shown that members of a class of 
guanine nucleotide exchange factors (GEFs), the cytohesin family, influence not only 
their canonical target proteins (small GTPases) but also the signaling of RTKs. Most 
prominently, they increase epidermal growth factor receptor (EGFR) activity by directly 
interacting with its intracellular domain. This mechanism is of pathophysiological 
relevance as demonstrated by in vivo studies in animal models and analysis of human 
tumor samples. In this study, I applied a combination of biochemical assays to further 
characterize the interaction between cytohesins and the EGFR.  
Using chemical crosslinking studies supplemented with microscale thermophoresis and 
fluorescence polarization experiments, I provide evidence for the direct interaction of 
the Sec7 domain of cytohesin 2 (ARNO) with the juxtamembrane (JM) domain of EGFR. 
Furthermore, the binding site was found to involve the C-terminus of ARNO Sec7 and the 
N-terminal region of EGFR JM. Together with functional data investigating the 
nucleotide exchange activity of ARNO, these results suggest a model in which the JM 
domain contacts the hydrophobic grove formed by helix F, G and H of ARNO Sec7. This 
interaction provides possible explanations for the positive regulation of EGFR kinase 
activity by ARNO. 
The discovery of non-canonical functions of cytohesins raises concerns about the use of 
GEF inhibitors like SecinH3 as specific inhibitors for Arf GTPases. Therefore, a high 
throughput screening (HTS) assay was established to identify small molecules that 
disrupt the interaction of active Arf6 with its specific effector protein JIP4. Due to very 
similar binding sites for different effector proteins on Arf6, molecules found in this assay 
are likely to exhibit a general inhibitory potential on GTPase signaling. The assay is 
based on fluorescence polarization (FP) and accurately tracks complex formation 
between Arf6 and the leucine zipper II (LZII) domain of JIP4. Tolerance towards 
detergents and organic solvents and an excellent Z’ value observed throughout the 
screening process indicate that the assay is suitable for future HTS applications using 
small molecule libraries optimized towards inhibitors for protein-protein-interactions. 
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2 Introduction 
 
2.1 Cell homeostasis 
 
The interplay and communication of eukaryotic cells depends on the transfer of 
information across and between different membranes. It is of vital importance for cells 
to maintain their physiological balance while still being able to recognize and integrate 
changes in their environment. This requires a highly regulated exchange of information 
and contents between different separated compartments inside and the outside of a cell. 
Intercompartment exchange inside the cell is mainly facilitated by vesicle transport, a 
process governed by small GTPases. In contrast, the integration of signals from the 
outside requires specialized proteins that can cross the plasma membrane barrier: 
transmembrane proteins known as receptors. 
Thus, small GTPases and membrane receptors are critical to maintain the cellular 
homeostasis and are of special interest to this study. Therefore, a detailed description of 
their biochemistry follows.  
 
2.2 Communication with the extracellular space – transmembrane receptors 
 
2.2.1 Transmembrane proteins translate extracellular signals into intracellular responses 
 
The intricate balance maintained in all cells, from single cell organisms to the building 
blocks of complex tissues, needs to be regulated with regard to the environment. 
Therefore, extracellular signals (e.g. growth factors) are recognized at the outside of the 
plasma membrane and transmitted to the interior of the cell. For this purpose an array 
of transmembrane proteins exist that all share a similar organization: They contain an 
extracellular domain for the recognition of signals and binding of signaling molecules, a 
transmembrane domain that anchors the protein in the lipid bilayer, and an intracellular 
domain which is responsible for the initiation of a cellular response. Those proteins act 
as receptors and can, with some exceptions (e.g. receptors that depend on regulated 
proteolysis like Notch-Delta or Wnt, (1, 2)), be grouped into 3 major classes according to 
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their mode of action: G protein coupled receptors, ion channel coupled receptors and 
enzyme linked receptors. 
 
 
Fig. 2.1 The three major classes of transmembrane receptors.G-protein coupled receptors (GPCRs) 
transmit their signal via associated trimeric G-proteins. Ion channels are gates through the membrane that 
allow hydrophilic molecules to pass when appropriately stimulated. Receptor tyrosine kinases (RTKs) 
translate an extracellular signal into intracellular enzymatic activity to promote signal transduction. 
 
G-protein coupled receptors 
 
G-protein coupled receptors are seven span transmembrane proteins that interact with 
a trimeric G-protein (GTPase protein) at the intracellular side of the membrane. Upon 
activation, they promote the exchange of a guanine di-phosphate (GDP) for a guanine tri-
phosphate (GTP) in the  subunit of the G-protein. This activation leads to dissociation 
of the G subunit from the  complex. Both molecules are membrane attached via lipid 
modifications on  and  subunit and initiate signaling cascades governed by adenylate 
cyclase and phospholipase C and their respective second messengers cyclic AMP and 
inositol 1,4,5 trisphosphate/diacylglycerol (3). G has an intrinsic catalytic activity and 
is stimulated to hydrolyze GTP to GDP and inorganic phosphate by associated proteins. 
The following re-association of all three subunits terminates the signal. Hence, the 
default state of the receptors is inactive, ensuring that no unintended activation with 
potentially severe consequences can occur. Specialized members of G-protein coupled 
receptors are the rhodopsin photoreceptors in cells of the vertebrate retina (4) and 
olfactory receptors that integrate taste and smell (5) illustrating the widespread 
importance and diversity of this receptor class. 
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Ion channels 
 
Some receptor molecules respond to the encounter of extracellular ligands by selectively 
disturbing the barrier formed by the plasma membrane. Usually this lipid bilayer 
separates the aqueous solutions on the outside and inside of the cell and allows both 
compartments to have a very distinct composition of molecules. Especially charged 
molecules (ions) can not simple diffuse through the hydrophobic environment and need 
specialized proteins to allow for exchange between outside and inside of a cell. Ion 
concentration changes are of special importance in the nervous system and at the 
neuromuscular junction where the influx of ions results in depolarization and is 
responsible for signal transmission between cells (6). Ion channels are the key players 
mediating this behavior. These channels consist of several subunits that form a pore 
across the membrane that is closed in the inactive conformation. Upon binding of an 
extracellular ligand (e.g. a neurotransmitter like Acetyl-Choline) the receptor undergoes 
a conformational change that opens the pore for specific ions (7, 8). Due to a 
concentration gradient across the membrane this leads to a flow of ions and a change in 
charge and ion concentration close to the membrane. Subsequently, this signal is either 
transported along the cell for signal transmission (e.g. long axons in the nervous system) 
or integrated into a cellular response (e.g. the contraction of muscle cells). Active 
processes are necessary to re-establish the original ion composition inside the cell and 
terminate the signal.  
 
The third class of receptors consists of transmembrane proteins with enzymatic activity 
and is discussed in detail in the following paragraphs.  
 
2.3 Receptors with enzymatic activity – receptor tyrosine kinases (RTKs) 
 
Binding of an extracellular ligand leads to conformational changes in GPCRs and ion 
channels that result in the above described responses. However, proteins of the receptor 
tyrosine kinase (RTK) family are single span transmembrane proteins and 
communication of the signal to the inside via a single helical structureis difficult.    
Therefore, an appropriate ligand is recognized by the extracellular domain and induces 
either the dimerization of two RTK molecules or a conformational change in preformed 
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inactive dimers. This process is essential for signal transmission across the membrane 
and initiation of the kinase activity in the intracellular domain of the proteins.  
Once activated, the dimerized receptor phosphorylates tyrosine residues, either at its 
own C-terminus - a process known as autophosphorylation - or on other target proteins, 
in order to further increase its catalytic activity and to initiatedownstream signal 
transduction (9). 
 
2.3.1 RTKs are vital for physiological processes 
 
Receptor tyrosine kinases (RTKs) are key players in both physiological and 
pathophysiological cell biology. They are known to control cell proliferation, 
differentiation, survival and general metabolism, thereby determining the fate of cells 
in development and homeostasis. The human genome contains 58 RTK family 
members that can be separated into 20 subfamilies with structural differences 
predominately localized to the extracellular domain (10). Despite the diversity 
observed in the RTK family, their general topology as well as the mechanism behind 
their activation remained highly conserved during evolution (10). Fig. 2.2 shows a 
simplified scheme of RTK topology indicating all common structural features shared by 
the family members. The extracellular domain (ECD) is responsible for ligand 
recognition and initiates the conformational rearrangements required for receptor 
activity. Kinase activity takes place inside the cell. A tyrosine kinase domain (TKD) is 
the common feature of RTKs and is divided into a N-lobe and a C-lobe whose relative 
orientation is crucial for catalytic activity. Furthermore, the intracellular part of the 
receptor has a C-terminal part that harbors tyrosine residues as targets for 
autophosphorylation and serves as a regulatory element (11-13). Another crucial 
regulatory part is the juxtamembrane domain (JMD) that spans the region between the 
kinase domain and the membrane. JM domains can have both inhibitory (e.g. Ephrin) 
(14) and activating function (e.g. EGFR) (13, 15). The final common element in the 
receptors is the transmembrane domain (TMD). It is a single  helix that spans the 
plasmamembrane and connects the ECD on the outside with the intracellular parts of 
RTKs. Besides anchoring of the protein in the membrane the TMD is described to be 
involved in dimerization and transmission of conformational changes across the 
membrane (16-18). The presented topology showcases all common features of RTKs 
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required for efficient signaling. Tight control of the interplay between the structural 
elements is necessary to avoid undesired activation with disastrous consequences. 
 
 
Fig. 2.2 A simplified scheme of Receptor tyrosine kinase topology. Shown are all features shared by 
different members of the RTK family. 
 
2.3.2 Mutations in RTKs are the cause for severe pathological phenotypes 
 
The importance of RTKs and associated signaling processes is illustrated by the 
prevalence of pathologies caused by either mutations or inappropriate expression 
levels of the proteins. Indeed, the role of several RTKs in cancer was discovered due to 
oncogenic products of viral origin that could induce transformation of cells via 
activation of RTK pathways (19-21). Later it was discovered that mutations or 
amplifications in the EGFR gene are responsible for brain tumor formation (22). Many 
receptor family members promote cell proliferation or survival and are therefore 
prone to induce malignant transformation of cells when not appropriately controlled. 
In contrast, reduced or abolished signaling activity also has severe consequences. A 
hallmark of Diabetes mellitus type II is insulin resistance caused by a decrease in 
insulin receptor (IR) signaling. Several genetic disorders lead to extreme forms of 
insulin resistance connected to low expression levels of IR protein (23). Furthermore, 
inactivating mutations in the gene for fibroblast growth factor receptor 2 (FGFR2) or 
its ligand FGF10 lead to the developmental pathology known as LADD (lacrimo-
auriculo-dento-digital) syndrome characterized by dysplasias of the anatomical 
structures eye, ear, teeth and digits (24). 
All given examples emphasize the importance of a tightly regulated activation of RTKs 
to ensure physiological signaling. Control elements on different levels of receptor 
biochemistry evolved for this purpose. 
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2.3.3 Ligand binding and dimerization are the initial steps in RTK activation 
 
Binding of an extracellular ligand to RTKs is essential for their canonical activation. In 
some cases, ligand binding induces association of two molecules forming an active 
dimer. This is either achieved by bivalent ligands that connect two receptors with 
symmetrical binding sites (e.g. Kit and its ligand stem cell factors (SCF) or members of 
the VEGFR family (25, 26)), or ligand binding exposes dimerization motifs on the 
proteins that in turn allow association of two molecules. Different modes of ligand and 
receptor contribution to the dimerization interface are known. One extreme is observed 
for RTKs that are preassembled as dimers or oligomers even in the absence of ligand 
(27, 28). Thus, these receptor molecules are sufficient to multimerize independently of 
other binding partners. A prominent example is the insulin receptor (IR). Here, one 
receptor monomer consists of an  and a -subunit that are covalently connected via a 
disulfide bridge (29). Two  subunits are further disulfide-linked to each other to form 
the mature receptor. Insulin binding results in a complex structural rearrangement 
causing receptor activation (30). 
These examples show that dimer formation is required but not always sufficient for 
receptor activation and that other conformational responses are induced to translate 
ligand binding into an intracellular response. 
 
2.3.4 Structural features of tyrosine kinase domains in active and inactive states 
 
The intracellular tyrosine kinase domain (TKD) of RTKs consists of an N-lobe and a C-
lobe forming the active site for substrate phosphorylation in a cleft between them (Fig. 
2.3). All TKDs of RTKs exhibit a very similar conformation when activated (31). This is 
due to the conservation of the phosphotransfer reaction catalyzed by the receptors (32). 
Two of the most prominent structural features determining activity are the “activation 
loop” that serves as the substrate docking site in the active conformation and the C 
helix in the TKD N lobe (Fig. 2.3). Both elements contribute to the transition between 
active and inactive TKD by structurally affecting the binding of substrate and ATP (32, 
33). In the active conformation the C helix is closely packed to the N-lobe. A crucial 
glutamate (Glu, E) makes contact with a lysine (Lys, K) residue in the N-lobe. This 
interaction is essential for the coordination of the  and  phosphate of ATP, and 
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mutations affecting these residues abolish kinase activity (34). In the N-terminal part of 
the “activation loop” is a conserved DFG (aspartate, phenylalanine, glycine) motif. The 
aspartate is engaged in coordinating an Mg2+ ion that is crucial for ATP binding, while 
the C-terminal part of the activation loop serves as a docking site for the substrate that is 
exposed in the active structure of a kinase (32). The actual catalytic loop precedes the 
activation loop and contains a conserved HRD (histidine, arginine, aspartate) motif with 
the aspartate residue serving as the catalytic base and proton acceptor from the 
substrate’s hydroxy group. All mentioned elements have to be aligned in precise spatial 
order to facilitate the phosphotransfer from ATP to a substrate.  
An inactive conformation is structurally defined by a swung-out C helix and a small 
helix formed by the part of the activation loop directly adjacent to the DFG motif (35, 
36). This conformation is known as the CDK/Src-like inactive conformation since it was 
first observed in crystal structures of these kinases. Src kinases are kept inactive via 
intramolecular contacts involving their Src homology 2 and 3 domains (37, 38) and loss 
of contact sites results in constitutively active kinases (39). In contrast, cyclin dependent 
kinases (CDKs) are inactive and become activated only when specific cyclins are 
expressed during the cell cycle (40). A different inactive kinase structure is 
characterized by the DFG-out conformation in which aspartate and phenylalanine have 
switched positions, disturbing Mg2+ binding (41, 42). Although both activation loop and 
C helix are positioned correctly in these receptor molecules, this is not sufficient for 
kinase activity. 
This list of examples illustrates that active conformations are well defined and both 
inactive structures and modes of activity control can vary in different kinases. 
 
 
 
 
Fig. 2.3 Important structural features of an active kinase.This 
schematic representation shows how the activation loop adopts an 
extended conformation while the helix C is “swung in” and allows for 
ion bridge formation between a glutamate (E91) and a lysine (K72) in 
the N-lobe. Additional features not discussed in the text are the P-loop 
that is important for ATP binding and a threonine in the activation 
loop (T197) that is phosphorylated to fully activate the kinase. All 
amino acid positions refer to protein kinase A (PKA). Figure from Jura 
et. al (32). 
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2.3.5 Intrinsic autoinhibition of RTKs 
 
Structural differences among RTKs are mainly observed in their inactive state, which 
allows selective interaction with specific binding partners (32). This is also reflected in 
the different modes of kinase-activity regulation. A single RTK molecule is intrinsically 
autoinhibited to avoid unintended activation of the receptor and downstream signaling. 
Different mechanisms are known that control this cis-autoinhibition, which is crucial for 
the physiological activity of RTKs. The insulin receptor (IR) represents an example for 
autoinhibition via the “activation loop”. A critical tyrosine at position 1162 (Y1162) 
occludes the active site and prevents substrate and ATP binding. Phosphorylation of 
Y1162 in trans after initial receptor activation displaces the “activation loop” and allows 
for a reorientation of the C helix (Fig. 2.3). This dramatically increases kinase activity 
by allowing for optimal positioning of both substrate and ATP at the active site (33). 
Other examples include the fibroblast growth factor receptor (FGFR). The autoinhibition 
is also released via trans phosphorylation of the “activation loop”. However, no direct 
occlusion of the active site via a tyrosine is observed but an inactive conformation is 
favored before phosphorylation (43).  
A second structural element often involved in autoinhibition is the juxtamembrane 
domain (JMD). By making contact to structural elements that are functionally important 
for TKD activity, such as the “activation loop” or the C helix, the JMD promotes an 
inactive conformation that is released by trans phosphorylation of specific tyrosines 
(44). Examples for the JMD mediated activity control are found in the stem cell factor 
receptor KIT and the family of Ephrins (14, 41).  
Less well characterized is the influence of the C-terminal tail on autoinhibition. It is 
suggested that this region can block the binding of substrate to the active site in certain 
RTKs, thereby inhibiting catalytic activity even in otherwise structurally “active” kinases 
(45).  
Autophosphorylation in trans is the common feature in releasing autoinhibition (with 
the exception of EGFR, see below) to fully activate the TKD of RTKs. Basal kinase activity 
required for the first phosphorylation cycle is conferred by extracellular ligand binding 
and the subsequent destabilization of the inactive TKD conformation (10). This level of 
intracellular control via autoinhibition prevents the unintended initiation of RTK 
downstream signaling. 
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2.3.6 Downstream pathways in RTK signaling 
 
RTK activity is tightly controlled regarding the spatial and temporal organization of 
phosphorylation events. The “first phase”-substrates are tyrosines of the receptor (see 
paragraph 2.3.5) causing the release of autoinhibition. These events occur in a precise 
order, gradually increasing kinase activity and creating a positive feedback loop 
essential for full RTK signaling (46, 47). The next steps or “second phase” involves the 
phosphorylation of tyrosine in the C-terminal tail of the receptor (or on adaptor proteins 
like insulin receptor substrate (IRS) for the insulin receptor) creating binding site for 
proteins involved in downstream signaling. Specialized domains like Src homology 2 
(SH2) or phosphotyrosine binding (PTB) domains associate with the phosphorylated 
amino acids at the receptor (48) initiating either a direct response or serving as adaptor 
or docking proteins (Fig. 2.4). For instance, the adaptor protein growth factor receptor-
bound protein 2 (Grb2) recruits the guanine nucleotide exchange factor Son of Sevenless 
(Sos), which in turn activates the small GTPase p21/Ras. This leads to the activation of 
several pathways including the mitogen activating pathway (MAP) that is characterized 
by a cascade of phosphorylation events on the MAP kinases Raf, Mek and Erk (49). This 
ultimately leads to the initiation of gene transcription and results in cellular 
proliferation. 
In other cases effector proteins are directly recruited to the receptor. They are 
multidomain proteins that are recruited to the correct location by phosphotyrosine, 
membrane and protein binding domains. Phospholipase C  (PLC) is a prominent 
example responsible for the signal transduction of different RTKs. It has SH2 domain for 
the interactions with the receptor and pleckstrin homology (PH) domains that facilitate 
binding to phospholipids in the plasma membrane. The multivalency of different binding 
sites increases the affinity of signaling molecules for the appropriate location and also 
provides specificity (“coincidence detection”, (50)) since single binding modules are not 
sufficient for recruitment (51). PLC itself is phosphorylated by the RTK and cleaves the 
phospholipid phosphatidylinositol 4,5 bisphosphate (PIP2) into inositol 1,4,5 
trisphosphate (IP3) and diacyl glycerol (DAG), thereby mediating signal transduction via 
Protein kinase C (PKC) and Ca2+ (52).  
The variety of interacting modules, downstream distribution of the signal, and control 
elements that ensure specificity, allow complex signaling networks to work efficiently, 
thus providing another level of robust control for downstream RTK activity. Since most 
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of the RTK associated pathways have implications in cancer biology (53), a tight control 
of initiation and efficient ways to terminate signal transduction are crucial to prevent 
malignant transformation. 
 
 
Fig. 2.4 Signaling pathways associated with receptor tyrosine kinase activation. Activation of RTKs 
results in a wide variety of different cellular responses such as activation of MAP kinase cascades or the 
activation of major serin/threonine kinases. Different sets of adaptor molecules are employed and 
specialized domains facilitate recruitment of involved proteins to the appropriate sites inside a cell. 
 
2.3.7 Termination of RTK signaling 
 
Receptor tyrosine kinases are never fully inactive but rather stabilized in an inactive 
conformation that can rapidly be resolved by conformational changes upon extracellular 
ligand binding. This, however, leads to spontaneous phosphorylation events even in the 
absence of ligand. One mechanism that is essential to avoid random receptor activation 
is governed by protein tyrosine phosphatases (PTPs). These proteins have a constant 
basal activity that reverses stochastic phosphorylation events and therefore prevents 
receptor activation. PTPs are important for maintaining the cellular signaling 
equilibrium. Their inhibition leads to general activation of RTKs even in the absence of 
ligands (54) and pathophysiological malfunction of PTPs are associated with cancer 
(55). However, PTPs are also important for normal termination of regularly activated 
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RTK signaling. They are recruited via SH2 domains to phosphotyrosines at the receptor 
and hence promote its inactivation in a very efficient negative feedback loop (56).  
Another mechanism for the termination of RTK signaling is controlled by endocytosis, 
ubiquitination and receptor degradation in the lysosomal compartment. After 
stimulation, RTKs undergo endocytosis both in a clathrin dependent and independent 
manner. After endocytosis, RTKs are sorted in the endosomal compartments either to be 
degraded in the lysosome or to be recycled to the plasma membrane (57). The way of 
endocytosis and the fate of activated receptor molecules are influenced by the ligand 
type, abundance and phosphorylation events that occur after stimulation. Some RTKs 
(directly or via adaptor proteins) recruit RING type E3 ubiquitin ligases of the Cbl family 
that facilitate ubiquitination of receptor molecules (58). The resulting ubiquitination 
pattern determines, besides other factors, how endocytosed receptor molecules are 
sorted and whether they are rapidly degraded or maintain to transmit their signal. 
Although endocytosis and lysosomal degradation leads to termination of RTK signaling, 
it is important to mention that receptor signaling continues and is modified during the 
endosomal sorting process (59). It was even proposed that different cellular locations of 
active receptors are associated with pathophysiological relevant signaling outcomes. 
While the bulk transcriptional response seems to be derived from signaling RTKs 
located at the plasma membrane, some cancer relevant targets are expressed in 
response to continuous signaling from internalized receptors (60, 61).  
All described mechanisms of RTK activation, downstream signaling and termination of 
the response illustrate the importance of tightly regulated biochemical pathways to 
maintain cellular homeostasis. A prominent family of RTKs will be discussed below to 
introduce a specific example in more detail and emphasize the characteristics of a 
“special case”.  
 
2.4 The ErbB family of receptor tyrosine kinases 
 
The ErbB (named after the vErb oncogene from avian erythroblastosis virus, (20)) family of 
receptor tyrosine kinases consists of four members that associate in homo- or heterodimers 
to initiate signaling.They have important functions in control of proliferation and 
differentiation, are essential during mammalian development (62) and aberrant activity is 
frequently found in human cancers (63). 
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ErbB family members are activated by epidermal growth factor (EGF) related peptide growth 
factors like EGF or the neuregulins (NRG). These ligands share an EGF like domain and are 
further characterized by three disulphide-bonded intramolecular loops. The ligands have 
preferred binding partners, with EGF or TGF primarily binding to ErbB1 and NRG isoforms 
associating with ErbB3 and ErbB4 (64). 
ErbB1 (or EGFR) and ErbB4 (or Her4) are fully functional and can bind extracellular ligand, 
dimerize and phosphorylate substrates. In contrast, both ErbB2 (Her2/Neu) and ErbB3 
(Her3) exhibit impaired functionality on different levels of receptor activity. ErbB3 shows 
sequence alterations in parts of the tyrosine kinase domain (e.g. the C helix and the 
activation loop, (32)), which leads to severely reduced activity (65). On the other hand, no 
high affinity ligand could be identified for ErbB2 (66). However, heterodimerization with 
other family members enables both ErbB molecules to contribute to signaling that involves a 
variety of downstream effectors, e.g. MAP kinases, PLC or PI3 kinase (Fig. 2.4, (67)).  
 
2.4.1 Ligand binding and heterodimerization contribute to the complexity of ErbB 
signaling 
 
The ErbB family is distinct from other RTKs regarding several aspects of their activation. 
In crystal structures of extracellular domains (ECDs) the dimer interface is solely 
formed by parts of the receptor, without any structural contribution of the ligand (68, 
69). Instead, ligand binding induces a conformational change in the extracellular part of 
the receptor that releases a “dimerization arm” in domain II (of IV) of the ECD. In the 
absence of ligand, an intramolecular “tether” between domain II and IV buries this 
element, thus inhibiting dimerization (70, 71). Once released, receptor association is 
strongly supported by the dimerization arm and conformational changes required for 
full activation take place (72). ErbB2 has no high affinity ligand but association with 
other ErbB isoforms results in high kinase activity due to an intrinsically active 
conformation in its extracellular domain (73). 
The fact that one ligand only contacts one receptor molecule and that the dimerization 
requires no structural ligand contribution explains why different ligands can bind to 
receptor molecules and induce hetero- or homodimers between different ErbB isoforms, 
utilizing a common dimerization motif (the dimerization arm on the receptor). Both the 
bound ligand and interaction partner influence the phosphorylation pattern and thereby 
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the signaling outcome of a receptor pair. The combination of several ligands that can 
initiate the association of a variety of receptor dimers renders the ErbB signaling 
network one of the most complex pathways in cell biology (10).   
In contrast to the canonical way of ligand-dependent dimerization, recent studies 
suggest that EGF receptor molecules form dimers or oligomers at the plasma membrane 
even in the absence of an extracellular stimulus (27). Interaction between the 
transmembrane domains (TMDs) and contributions of parts of the juxtamembrane 
domain (JMD) could explain this observation since both a TM-JM and a JM-TKD 
construct are able to form dimers independent of the ECD (13, 17). The ability to 
spontaneously dimerize raises the question how undesired EGFR activation is prevented 
in the absence of ligand. Again, a specialized mechanism is employed to regulate the 
tyrosine kinase activity of intracellular ErbB domains. 
 
2.4.2 An asymmetric dimer represents the active conformation of EGFR kinase domains 
 
In contrast to other RTKs, ErbB family members are not obviously autoinhibited in cis 
by structural elements of the receptor. Although there is a tyrosine residue (Y845) 
present in the activation loop that is readily phosphorylated upon kinase activation, this 
residue is not essential to maintain the inactive state as observed for many other RTKs 
(74, 75). Instead, the kinase appears to be intrinsically inactive (76) and activation via 
ligand binding involves the formation of an unusual asymmetric dimer (77, 78). In this 
head-to-tail configuration of two receptor molecules one serves as the “activator” 
making contact with parts of its C-lobe to the N-lobe of the second kinase, the “receiver”. 
This stabilizes the active conformation characterized by a swung in C helix and an 
extended activation loop ready for substrate docking. In a monomer, this conformation 
would expose hydrophobic residues to the aqueous environment explaining its intrinsic 
instability (32). Interactions in the asymmetric dimer cover the hydrophobic area and 
stabilize the active conformation. First shown for EGFR, this mechanism is also 
employed by other members of the ErbB family and seems to represent a general 
concept (79, 80).  
Most other tyrosine kinases are stable in their active conformation and have to employ 
autoinhibitory mechanisms to avoid unintended activity while the EGFR behaves more 
like the Ser/Thr kinase CDK (40). This protein requires the presence of cyclins to be 
 INTRODUCTION  
 
 16 
activated by forming a hydrophobic interaction that induces the appropriate kinase 
conformation. Therefore, ErbB receptors prove to be distinct from classical RTKs on 
different levels of their biochemistry.  
 
 
 
 
 
Fig. 2.5 The asymmetric dimer formed by 
two molecules of ErbB family members.All 
members of the family can act as activators. 
However, ErbB3 has a very low kinase 
activity and is therefore a bad receiver. The 
activator induces structural rearrangements 
in the receiver that facilitate enzymatic 
activity (for structural details of an active 
kinase see Fig. 2.3). Figure from Jura et al. 
(32). 
 
2.4.3 Intramolecular modulation of EGFR activity 
 
The tyrosine kinase domains (TKD) of the EGFR can form an asymmetric dimer that 
composes a signaling competent receptor. However, the affinity of this interaction alone 
is not sufficient to promote dimerization (13). Instead, an additional structural element 
is required for dimerization and activation: the juxtamembrane (JM) segment. This 
domain is usually involved in negative regulation of RTK activity (44) but is essential for 
EGFR activation upon ligand binding (81) and allows for in vitro dimer formation of 
EGFR intracellular domain constructs (13). Crystallographic studies show that the C-
terminal part in the JM domain (JM-B or juxtamembrane latch) of the receiver kinase 
binds to the C-lobe of the activator kinase thereby stabilizing the dimer (15). The JM 
latch binding site at the activator kinase is crucial for the interaction and elements that 
block the interface reduce kinase activity. This could explain the regulatory role of the C-
terminal tail of EGFR (82, 83). In an inactive conformation observed for EGFR 
intracellular domains (13, 32) the JM latch binding site is occluded by the C-terminal tail 
providing a mechanism for autoinhibition.  
Apart from the JM latch increasing the affinity in the asymmetric dimer, the N-terminal 
part of the JM domain (JM-A) is also essential in EGFR activity (84). This element forms a 
small coiled-coil structure that promotes receptor association in solution (13). When 
coupled to the transmembrane domain (TMD), the coiled coil interaction needs to be 
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induced by dimerization of the TM helices at their C-termini. However, both the TM and 
the JM-A region support dimerization and thus the activation of EGFR (17, 18). 
The full length receptor is inactive when not bound to an extracellular ligand. Negatively 
charged phospholipids sequester both the TKD and JM-A, leading to inhibition of the 
kinase (18, 85). This inhibition is only released after ligand binding to the extracellular 
domain, inducing the N-terminal association of the TM helices that forces the JM 
domains and in turn the TKDs to associate in an enzymatically competent dimer (17, 18). 
The described model suggests that many structural elements of the EGFR promote 
dimerization, but are intrinsically restrained from activation in the absence of a ligand. 
This autoinhibitory mechanism is unique among the members of the RTK family and 
further shows the distinct properties of the ErbB family RTKs. 
 
2.4.4 Modulation of EGFR activity by other proteins 
 
Positive and negative feedback loops are crucial aspects of all signaling cascades to provide 
both robustness of signal induction and allow for rapid termination of the signaling (10).  
Negative control of EGFR activity is conferred by phosphorylation events in the JM domain. 
Downstream receptor activity via PLC results in protein kinase C (PKC) phosphorylation of 
Thr654 in the JM domain (9), which blocks high affinity ligand binding. Another threonine 
(Thr669) is phosphorylated by the MAP kinase Erk, leading to EGFR inactivation (86). Other 
negative feedback loops involve the described recruitment of PTPs to abolish signaling, and 
the endocytosis and degradation of receptor molecules after Cbl mediated ubiquitination 
(paragraph 2.3.7). Transcription products of the signaling pathway often mediateda delayed 
negative feedback. A well understood example is mitogen induced gene 6 (Mig6). Mig6 
competes with the JM latch for binding to the C-lobe of the activator kinase, thereby 
blocking the formation of the asymmetric dimer (87).  
These observations further emphasize the importance of the JM domain for EGFR activation 
and as a major site for regulation of activity and signaling. 
Upon initial EGFR activation, positive feedback loops ensure a rapid and robust signaling 
response. Activation of ADAM proteases leads to the cleavage of membrane bound heparin-
binding EGF like growth factors that enhance receptor activation via an autocrine loop (88). 
Another interesting example involves PI3K and Rac mediated activation of NADPH oxidase, 
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leading to the production of reactive oxygen species (ROS) that temporarily inactivate PTPs 
in the whole cell by lateral diffusion, thereby driving a more general cellular EGFR response 
(89, 90). 
Factors that directly bind to the receptor molecule and positively influence their activity are 
rare. The few known examples belong to the family of guanine nucleotide exchange factors 
(GEFs) for small GTPases and will be discussed at the end of the next chapter. 
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2.5 Small GTPase and their role in cell biology 
 
In contrast to the trimeric G proteins known from GPCR signaling, small GTP binding 
proteins (GTPases) are monomeric and function as “molecular switches” to control 
biological responses. They are involved in various processes, ranging from signaling and 
transport to cell motility and migration, therefore representing one of the most diverse 
regulatory molecules in a cell. 
 
2.5.1 The Ras superfamily of small GTPases 
 
The Ras (Rat sarcoma) GTPases represent the founding members of the large 
superfamily of small, monomeric GTPases, currently comprising over 150 members in 
humans (91). Based on sequence relationship and biological function they are classified 
into five subgroups: Ras, Rho (Ras homologous), Rab (Ras related in brain), Arf (ADP 
ribosylation factor), and Ran (Ras related nuclear protein). The Ras GTPases are key 
components in signal transduction and initiate signaling in response to growth or 
survival signals (92). Their importance is demonstrated by the abundance of mutations 
in Ras genes that can be observed in cancer (93). Rho GTPases participate in the 
regulation of cytoskeletal organization and signal transduction. (94). Rab and Arf 
GTPases are implied in the trafficking of membrane vesicles. Arfs are predominantly 
involved in traffic between the endoplasmic reticulum and the Golgi along the secretory 
pathway and control endocytosis and recycling to the plasma membrane(95, 96). Traffic 
between different endosomal compartments after endocytosis is regulated by the Rab 
family GTPases (97). Ran, the single member of the fifth class, regulates the transport of 
cargo from and to the nucleus; this protein is crucial for processes as diverse as 
transcriptional control and assembly of the nuclear envelope after mitosis (98). 
Due to the key role these classes of proteins play in essential cellular processes, 
regulatory proteins tightly control their guanine nucleotide binding state and in turn 
their activity.   
 
2.5.2 Small GTPases function as biological switches that are controlled by GEFs and GAPs 
 
Small GTPases function as “molecular switches” that are active when bound to guanine 
nucleotide triphosphate (GTP) and inactive in complex with guanine nucleotide 
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diphosphate (GDP). The active conformation allows for interaction with effector 
proteins that mediate the associated cellular response (Fig. 2.6). Most GTPases bind to 
nucleotides with low nanomolar affinity causing a slow intrinsic nucleotide exchange. 
Regulatory proteins are required to enable rapid activation of GTPases by promoting the 
exchange of GDP for GTP (99). Guanine nucleotide exchange factors (GEFs) destabilize 
the interaction with nucleotides by inducing conformational changes in the switch 1 and 
switch 2 regions as well as the phosphate binding loop of the GTPase (100-102). The 
resulting GTPase-GEF complex is in turn dissolved by other nucleotides that displace the 
GEF and establish a fresh GTPase/nucleotide complex. GDP is usually exchanges for GTP 
due to the higher concentration of nucleotide triphosphates in the cell. Consequently, 
GEF activity leads to activation of the GTPase (Fig. 2.6; (103)). 
GEFs itself are also regulated in a variety of ways to ensure proper initiation of GTPase 
downstream signaling. Localization in the cell, release of autoinhibition and allosteric 
control are possibilities to modify GEF activity. Most GEFs are multidomain proteins that 
contain elements that localize to membranes or interact with other proteins. Moreover, 
intramolecular inhibition by blocking the GTPase binding site is a common theme (104) 
and allosteric regulation, e.g. positive feedback via the active GTPase (105), is employed 
in robust GEF activation. Hence, GEFs integrate a plethora of signals to accurately adapt 
to a given cellular situation. 
To fully function as a molecular switch, GTPases need to return to their original state 
after initial activation. Although the name implies that the proteins are able to hydrolyze 
bound GTP, the intrinsic catalytic activity is low. Efficient inactivation is facilitated by 
GTPase activating proteins (GAPs, Fig.2.6). They induce conformational changes in the 
GTPase that allow coordination of an attacking water molecule required for hydrolysis. 
Moreover, the transition state of the reaction is stabilized by proper orientation of 
suitable amino acids of the GTPase or the GAP (106). Although the detailed mechanism 
varies between different GAPs, the general concept of GTPase activation is very similar 
(103).  
The complete GTPase cycle is required for correct function and problems with either 
activation or inactivation lead to aberrant cellular behavior. Therefore, GEFs and GAPs 
are crucial in the biology of small GTPases by providing accurate control of their activity. 
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Fig. 2.6 Small GTPases are regulated by GEFs and GAPs. 
GTPases that are bound to GTP initiate downstream effector 
signaling. Regulation of the nucleotide binding state is 
facilitated by guanine nucleotide exchange factors (GEFs) and 
GTPase activating proteins (GAPs). Both protein classes are 
essential to establish small GTPases as molecular switches.  
 
2.6 ADP ribosylation factor (Arf) GTPases 
 
The ADP ribosylation factor (Arf) class of small GTPases was originally named for their 
ability to work as cofactors in the ADP ribosylation of G proteins by cholera toxin 
(107). However, their physiological role is that of a GTPase molecular switch. 
The six mammalian members of Arf proteins can be categorized into 3 subclasses based 
on their sequence identity (108). The best-studied member of class I (next to Arf2 and 3) 
is Arf1. Playing an important role in membrane transport along the secretory pathway, 
Arf1 regulates the formation of COPI coated vesicles at the Golgi membrane and 
promotes budding of clathrin coated vesicles (CCVs) on endosomal membranes by 
recruiting adaptor proteins like AP-1 (96). Moreover, Arf1 regulates cytoskeletal 
elements that are required for maintaining the integrity of the Golgi network (109). The 
function of class II Arfs (Arf4 and Arf5) is still unclear, but they are thought to be 
involved in membrane trafficking by formation of heterodimers with class I Arf proteins 
(110). Arf-like (ARL) proteins resemble Arfs structurally, but their functions in cell 
biology are distinct from the classic Arfs (111). 
Arf6 is the sole member of mammalian class III Arf proteins. It has widespread influence 
on cellular behavior with special importance in endocytosis and endosomal recycling 
(96).  
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2.6.1 Arf6 is implicated in endocytosis, endosomal recycling and cytoskeletal 
organization 
 
Arf6 is the least conserved member of the mammalian Arf family. This is also reflected in 
its function and localization. While the other Arf proteins are found predominantly on 
Golgi membranes, Arf6 localizes to endosomes and the plasmamembrane to promote 
vesicle formation.  
 
Arf6 in endocytosis 
 
Arf6 regulates endocytosis at the plasma membrane, both in a clathrin dependent and 
independent manner. Clathrin mediated endocytosis is regulated by the presence of 
phosphatidylinositol 4,5 bisphosphate (PI(4,5)P2) in the membrane, which is  produced 
by Phosphatidylinositolphosphate 5 kinase (PIP5K). This enzyme is directly activated by 
Arf6 and needs phosphatidic acid, generated by Arf6 regulated Phospholipase D (PLD), 
as a cofactor (112). Clathrin independent endocytosis is regulated by shaping the lipid 
landscape in a similar way (96, 113). Full completion of endocytic trafficking requires 
the inactivation of Arf6 after vesicle budding. ArfGAPs are essential for this process and 
hydrolysis-deficient Arf6 mutants result in the accumulation of aberrant vesicle 
structures (114). 
Endocytosis has implications in cell signaling since GPCRs and some RTKs (like c-Met 
and VEGFR) are internalized in an Arf6 dependent manner after activation (115, 116). 
Thereby, Arf6 activity has a regulatory effect on receptor function. 
 
Arf6 in endosomal recycling and cytoskeletal organization  
 
Membrane proteins such as the different receptor classes discussed before are 
internalized via endocytosis and sorted into the endosomal compartment. From there, 
they can either be degraded by lysosomal targeting or recycled to the plasma 
membrane. Thus, small GTPases can influence signaling processes governed by 
endocytosed proteins through regulating their fate regarding endosomal sorting (117).  
Arf6 is involved in different endosomal recycling processes. Stimulation-dependent 
recycling of membrane proteins requires Arf6 activation and subsequent signaling 
involving PLD (118) and components of the “exocyst” complex (119). Furthermore, GTP 
hydrolysis stimulated by ArfGAPs is essential to complete the process (120). This is also 
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true for constitutive recycling of “bulk membranes” and proteins, a process that depends 
on the Arf6 GTPase cycle and ensures an equilibrium in membrane trafficking (121). 
Moreover, transport of membrane components to defined sites in a cell and 
reorganization of the membrane environment is crucial for phagocytosis and cell 
migration (96) suggesting a role for Arf6 in these vital processes.  
Arf6 influences the remodeling of actin filaments, leading to the formation of 
“membrane ruffles”, an initial step in cell migration (122). This involves the recruitment 
and regulation of Rac1 and is accompanied by changes in the lipid environment (123). 
Additionally, endocytosis of cell-cell-contact mediating proteins like E-cadherin allows 
cells to leave their microenvironment in an Arf6 dependent manner (124). All these 
processes are essential in normal cell migration; and deregulation in certain cancers 
leads to invadopodia formation and metastasis (125), making Arf6 a crucial target for 
cellular activity control.  
 
 
 
 
 
 
 
 
 
 
Fig. 2.7 The role of Arf GTPases in vesicle transport. 
Arf1 regulates vesicle transport along the secretory 
pathway. In contrast, Arf6 is involved in endocytosis 
and endosomal recycling. Hence,it influences important 
cellular processes associated with and at the plasma 
membrane. 
 
2.6.2 Guanine nucleotide exchange factors (GEFs) for Arf GTPases 
 
Activation of Arf GTPases is facilitated by specific GEFs. The common structural motif in 
Arf GEFs is the Sec7 domain. This domain is approximately 200 amino acids long and got 
its name from the yeast homolog Sec7p that is involved in Golgi-associated protein 
transport (126). High molecular weight Arf GEFs can be found in all eukaryotes, with 
orthologs from yeast to mammals. They are big multidomain proteins and 
predominantly act on class I and class II Arfs (127). Thus, they control membrane 
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trafficking along the secretory pathway and their inhibition via brefeldin A (BFA) leads 
to the disintegration of the Golgi (128, 129). In contrast, small molecular weight Arf GEFs 
are BFA resistant, function mainly at the plasma membrane and also catalyze exchange 
on Arf6. The four members of the cytohesin family and EFA6 represent this class of Arf 
GEFs.  
The structure of Sec7 domains in complex with Arf proteins shows that the  helices F,G 
and H form a hydrophobic grove that is important for GTPase binding. Furthermore, a 
hydrophilic loop formed between helix F and G (the F-G loop) is highly conserved and 
crucial for GTPase binding and exchange activity (101, 130). Particularly important is a 
glutamate residue (position 156 in cytohesin 2), which catalyzes nucleotide exchange by 
displacing the magnesium ion important for nucleotide binding in the GTPase. This 
glutamic finger is essential for exchange activity (131).  
Apart from a Sec7 domain-containing GEF, Arf GTPases require the presence of lipid 
membranes for their activation. An N-terminal myristoyl modification on the GTPase 
mediates membrane recruitment of the active form. When inactive, it blocksthe Sec7 
binding site, inhibiting the exchange reaction (132). The presence of membranes 
promotes dislocation of the myristoyl moiety and the adjacent peptide helix, resulting in 
a modest nucleotide exchange rate (133) that is subsequently increased by efficient 
binding of Sec7 domain-containing GEFs.  
The requirement for both, the correct membrane environment and a suitable GEF, 
provides a sophisticated way to limit the activation of Arf GTPases to the appropriate 
location and activating protein. Further control is provided on the level of GEF activity. A 
prominent example will be given with a more detailed introduction to cytohesins.  
 
2.6.3 Cytohesins: a class of GEFs for Arf GTPases 
 
There are four mammalian isoforms of cytohesins. They belong to the low molecular 
weight Arf GEFs and are characterized by a distinct domain structure. The central Sec7 
domain responsible for the catalytic activity is flanked by an N-terminal coiled coil (CC) 
domain and a C-terminal pleckstrin homology (PH) domain. The CC domain mediates 
protein-protein interactions and can induce dimerization of cytohesins. On the other 
hand the PH domain is required for recruiting cytohesins to their target membranes 
through binding to phosphatidylinositolphosphates (134). Furthermore, the PH domain 
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has a binding site for active Arf6 that is employed to indirectly interact with the 
membrane via the GTPase, thereby creating a positive feedback loop (135). 
Like other GEFs, cytohesins are intrinsically autoinhibited. A C-terminal polybasic region 
(PBR) is responsible for an intramolecular inhibition, which is resolved upon binding of 
the target membrane. By recruiting Arfs and GEFs to membranes, futile or deleterious 
GTPase activation is avoided, ensuring accurate control of Arf mediated cellular 
processes on the level of both proteins.  
Although the exchange activity of cytohesin 2 or ARNO (Arf nucleotide binding site 
opener) in vitro is high for Arf1 and lower for Arf6 (136), the major physiological target 
for the GEF appears to be Arf6, due to its localization at the plasma membrane (137). 
Chemical inhibition of exchange activity results in reduced levels of Arf6GTP in cells. 
However, under the same conditions, Golgi integrity is not affected, indicating that Arf1 
function is not impaired (138). This example illustrates how proper localization can 
regulate cellular processes independent of direct protein-protein interactions.  
The different levels of Arf activity control provide further evidence for their importance 
in cell biology.  
 
2.6.4 Known inhibitors for Arf signaling 
 
The wide variety of Arf6 functions and control mechanisms indicate a complex network 
involved both upstream and downstream of the GTPase. A detailed dissection of the 
protein functions would be beneficial to gain a better understanding of the physiological 
and pathophysiological effects of Arf6. 
One way to study the contribution of a protein in certain cellular pathways is to remove 
it from the cell and investigate the resulting phenotype. Genetic methods like knockout 
or RNA interference can be employed to reduce protein abundance. However, gene 
knockout is time consuming and even transient reduction of protein levels via RNA 
interference requires a cellular response over a longer period of time. Therefore, 
methods that directly inhibit the present protein pool are advantageous,providing a 
rapid way to generate effectsthrough loss of protein function. Small molecule inhibitors 
are an elegant tool to modulate protein function in vitro, in cells and even in animal 
models. 
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Brefeldin A (BFA) is a fungal toxin that inhibits Arf functions. Treating cells with this 
compound inhibits the secretory pathway and induces disintegration of the Golgi by 
inhibiting class I and class II Arfs (139). It was shown that the inhibition is mediated 
through stabilization of the complex between Arf and the Sec7 domain-containing 
exchange factor (128). This prevents the formation of a nucleotide-containing Arf 
complex and thereby terminates the GTPase cycle. However, BFA only binds to Arf in 
complex with specific GEFs (140). Low molecular weight Arf GEFs are not affected. A 
computational biology approach guided by structural data of an Arf1/ARNO Sec7-
complex was employed to generate an inhibitor for low molecular weight GEFs. The 
identified compound, LM11, acted similar to BFA by stabilizing the Arf-Arf GEF 
interaction and preventing nucleotide binding (141) illustrating the broad applicability 
of this inhibitory mechanism. 
Another small molecule inhibitor that is used in studies on Arf GTPases is SecinH3 (138). 
It inhibits the exchange activity of different cytohesins, thereby reducing the level of 
active Arf GTPases both in vitro and in cells and is frequently employed as an indirect 
Arf6 inhibitor (142, 143). Similar to the mode of action of BFA and LM11, SecinH3 
modulates Arf activity upstream of the GTPase function by preventing its activation. This 
could cause unexpected side effects in cellular studies due to “off target” effects not 
mediated by the small molecule inhibitor itself but by the inhibited upstream protein. An 
interesting example is the effect of cytohesins on RTK signaling that was discovered 
with the help of SecinH3. 
 
2.6.5 Cytohesins and RTK signaling 
 
With the discovery of SecinH3 as a specific inhibitor for cytohesins, it was shown that 
Arf GEFs have functions in cellular pathways that are distinct from their canonical role 
in Arf activity control. Initially, an effect on insulin signaling was observed in 
mammalian cells and in Drosophila that was linked to reduced insulin receptor signaling 
caused by cytohesin inhibition(138, 144). Subsequently,the stimulatory effect of 
cytohesins on insulin signaling was found to be dependent on their direct interaction 
with the scaffold protein CNK1 (Connector enhancer of KSR 1, (145)).  
The epidermal growth factor receptor (EGFR) is also regulated by cytohesins. However, 
in contrast to insulin signaling, cytohesins directly interact with the intracellular part of 
 INTRODUCTION  
 
 27 
the receptor and promote autophosphorylation and general kinase activity by inducing a 
conformational change (146). This represents the first example of a direct positive 
regulation of an RTK from the inside of the cell. The importance of this effect is 
illustrated by the overexpression of cytohesins in lung cancer cells and the inhibition of 
tumor growth observed in SecinH3 treated mice (146). Therefore, cytohesins emerge as 
a potential new target in tumor therapy. However, the detailed mechanism behind the 
activating effect of cytohesins on EGFR is elusive and more information is required to 
fully harness the potential of this novel discovery. 
In several other cases, GEFs were found to be involved in RTK signaling. Cytohesins 
were also implicated in VEGFR signaling by promoting surface expression of the 
receptor (147) and a role in several cancer types is described (148, 149). Very recently, 
the GEF DOCK7 was found to regulate bouton formation in specialized interneurons. The 
effect was caused by modulating the activity of the EGFR family member ErbB4 and 
involved an interaction of between receptor and GEF (150). Interestingly, both the effect 
of DOCK7 on ErbB4 and of cytohesins on EGFR are independent of the catalytic activity 
of the GEF proteins, suggesting important physiological roles apart from their canonical 
functions. It is important to note that SecinH3 inhibits cytohesin’s activity on Arfs as well 
as RTKs, demonstrating that a small molecule inhibitor can influence different aspects of 
protein biochemistry. 
These examples demonstrate potential problems that can arise when using upstream 
inhibition to study protein functions and make an argument for different approaches 
that are currently rare in research focused on small GTPases. 
 
 
Fig. 2.8 The influence of cytohesins on different receptor tyrosine kinase pathways. Cytohesins 
regulate RTK associated signaling pathways on different levels. This complex contribution to receptor 
signaling was only recently discovered and raises important questions about RTK activity regulation.  
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2.6.6 The Arf6 effector protein JIP4 
 
An alternative to upstream inhibition of GTPase function is downstream inhibition. 
Active GTPases bind to a variety of effector proteins to mediate different cellular 
functions. Effector proteins are expected to bind to the switch I, switch II and 
interswitch regions on Arf GTPases given that these structural elements undergo major 
conformational changes upon nucleotide exchange (151). Blocking effector interaction 
abolishes downstream effects and can be employed to control Arf signaling. Although 
different Arf proteins have distinct roles in cell biology, the GTP associated conformation 
in their switch region is very similar (151, 152). This is reflected by the fact that some 
Arf effectors bind to more than one isoforms, preventing discrimination on this level 
(96).  
However, there are effector molecules that provide specificity towards single Arf 
isoforms. The protein c-Jun N-terminal kinase (JNK)-interacting protein 4 (JIP4) is a 
well-described example for a specific Arf6 effector. JIP4 serves as a scaffold protein in 
JNK and MAPK signaling and coordinates the recruitment of kinesins and dyneins to 
microtubules (153, 154). By competing with kinesin 1 for JIP4-binding, active Arf6 
modulates microtubule transport and is required for successful abscission during 
cytokinesis (155).  
Recently the binding site of Arf6 on JIP4 was narrowed down to the second leucine 
zipper domain (JIP4 LZII) and a fragment comprising only amino acids 392-462 was co-
crystallized to obtain a detailed structural picture of the interaction (156). Therefore, 
JIP4 LZII represents the minimal Arf6-binding motif, making it suitable to screen for 
inhibitors that abolish the protein-protein interaction in order to modulate Arf6 
downstream signaling. 
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3 Aims and Significance 
 
Receptor tyrosine kinases (RTKs) are key players in the regulation of vital cellular 
processes like survival, growth and proliferation. The identification of cytohesins as 
intracellular activators of epidermal growth factor receptor (EGFR) signaling opens new 
possibilities for the therapeutic use of specific inhibitors to counteract aberrantly 
activated EGFR signaling, for example in cancer. To fully explore the therapeutic 
potential and understand the molecular events behind the observed effects, a more 
detailed understanding of the structural interplay between EGFR and cytohesins is 
required. This study aims to elucidate the mechanism involved in ARNO (cytohesin 2) 
mediated EGFR activation by employing biochemical methods to investigate the 
interaction and enzymatic regulation. Different constructs of ARNO and EGFR are 
analyzed to define the binding interface of the complex and to evaluate their enzymatic 
activity in vitro. Additionally, x-ray diffraction analysis of protein crystals should yield a 
high-resolution structure of the interacting proteins. A comprehensive model of the 
EGFR interaction with ARNO will help to understand and experimentally address this 
novel biochemical phenomenon. 
Furthermore, identification of an Arf6-specific small molecule inhibitoris approached by 
a high throughput screening (HTS) effort. The small GTPase Arf6 is a molecular 
regulator of vesicle trafficking between the plasma membrane and the endosomal 
compartment. It is crucial for the regulation of receptor signaling, cell motility and the 
final steps of cell division. Hence, it has a multitude of different implications in both 
normal and aberrant cellular behavior (e.g. metastasis in cancer). The scientific interest 
in this protein is high, as illustrated by various studies using indirect Arf6 inhibitors. A 
prominent example is the cytohesin inhibitor SecinH3 that is frequently used to 
indirectly decrease Arf6 activity. However, the recently identified Arf6-independent 
functions of cytohesins in RTK signaling complicate the interpretation of results 
obtained with these inhibitors. Thus, this study aims to develop an assay for the 
discovery of Arf6 inhibitors that act downstream of its activation. The specific Arf6 
effector JIP4 is employed in an assay that monitors complex formation, and can 
therefore be used in a high throughput screening to identify small molecules that block 
the interaction. Potential hits have to be verified in independent assays in order to 
obtain suitable molecules with the desired inhibitory activity. 
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4 Results 
 
4.1 High throughput screening (HTS) for a small molecule inhibitor of the 
GTPase Arf6 
 
There are six members in the family of mammalian Arf proteins that are characterized 
by high sequence homology and very similar 3D structures (96, 152, 157). 
Discrimination between different family members is a big challenge in the development 
of inhibitory molecules. Attempts to select an aptamer specifically binding and inhibiting 
Arf6 have not been successful in the past (unpublished data). This excludes the very 
promising option of establishing an aptamer displacement screen similar to the ones 
successfully used before to identify small molecules inhibiting different domains of the 
guanine nucleotide exchange factor (GEF) ARNO (158, 159). However, natural effector 
molecules of Arf GTPases are able to distinguish between the different Arf family 
members. A direct screen for inhibitors that can displace a selective effector from an 
active GTPase provides a promising alternative to the aptamer based method and 
exploits a new and promising area of drug development. 
The effector molecule c-Jun N-terminal kinase interacting protein 4 (JIP4) was shown to 
bind to Arf6 but only weakly to Arf1 via its leucine zipper 2 (LZII) domain. Furthermore, 
a crystal structure of the complex is available that enables rational modifications in the 
process of assay development (156).Therefore, this protein is well suited for the 
envisioned task. To establish an in vitro binding assay it is required to: 
 
1.  Provide a sufficient amount of pure protein. 
2. Establish and in vitro assay to monitor binding of the interaction partners. 
3. Optimize the established assay for high throughput screening (HTS) applications. 
 
The experimental steps leading to achieve the mentioned goals are described in the 
following paragraphs. 
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4.1.1 Expression and purification of st13 Arf6 and JIP4 LZII (AA 392-462) 
 
An n-terminally truncated form of Arf6 was expressed as a strep-tagged protein in E.coli 
and purified via a single step purification protocol using streptactin high capacity resin 
(data not shown). The obtained protein was at least 95% pure and could be purified in 
sufficient amounts (20mg protein from 1l bacterial culture) for the following 
experiments. 
The JIP4 LZII domain was expressed as a fusion protein with glutathione S transferase 
(GST; expression plasmid pGST1 JIP4LZII was a kind gift of Julie Menetrey, Laboratoire 
d’enzymologie et biochimie structurales, Gif-sur-Yvette). After affinity purification of the 
fusion products with glutathione resin the GST tag was cleaved using recombinantly 
expressed Tobacco Etch Virus (TEV) protease (160). After removing TEV using a NiNTA 
resin, free JIP4 LZII was further purified via a Superdex 200 size exclusion 
chromatography column (Fig. 4.1). This final step removes higher molecular weight 
impurities and small aggregates that are not possible to be separated from the target 
protein via centrifugation but could disturb the intended binding assays by unspecific 
association. 
 
Fig. 4.1 Purification of JIP4 LZII (392-462). The indicated samples were taken during the purification 
process, separated on a 10% Tris-Tricine PAGE gel and stained with Coomassie Brilliant Blue. JIP4LZII 
runs slightly below the 10kDa marker band (expected MW: 9kDa). For purification details see text and 
Materials and Methods. 
 
4.1.2 Exchange activity of the purifiedst13Arf6 in an invitro assay 
 
To proof that the recombinantly expressed GTPase is suitable to be used as a model for 
the physiological situation, the ability of the guanine nucleotide exchange factor (GEF) 
ARNO to exchange GTP for GDP was investigated. Arf6 preloaded with GDP is incubated 
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with the ARNO Sec7 domain in the presence of excess GTP. An increase in tryptophan 
fluorescence can be observed when nucleotide exchange takes place.  
Despite the fact that ARNO was described to be a better GEF for Arf1 than for Arf6 (136) 
it is suitable for investigating Arf6 functionality in vitro(161). A clear exchange could be 
observed on Arf6 with concentrations of GEF down to 12.5nM (Fig. 4.2). As expected the 
exchange activity on Arf1 is higher (Fig. 4.2). However, it is clear that the recombinantly 
expressed truncated form of Arf6 used in this study is functional in a nucleotide 
exchange assay and therefore suitable for the intended screening approach.  
 
 
Fig. 4.2 Nucleotide exchange activity of ARNO Sec7 on Arf1 and Arf6.The indicated concentrations of 
ARNO Sec7 were incubated with GDP loaded Arf GTPases in the presence of excess GTP. Nucleotide 
exchange results in an increase in tryptophan fluorescence. The upper curves illustrate the change of 
fluorescence over the course of the experiment (one representative example). The early parts of the 
curves (150s for Arf1 and 300s for Arf6) were fitted to a linear regression model and the resulting slope is 
plotted in the column diagrams (n = 6). 
 
4.1.3 Labeling of purified proteins for subsequent assay development 
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To find inhibitors that disturb the binding of JIP4LZII to active Arf6 an assay monitoring 
the interaction in an easy to evaluate readout needs to be established. Several 
biophysical methods are available (and described in paragraphs 4.1.4, 4.1.6 and 4.1.7) 
for this purpose and many of them require a non-reversible, e.g. covalent, modification 
of the interaction partners with chemical groups that provide them with certain 
characteristics (e.g. fluorescence) that are in turn employed to determine molecular 
interactions. Therefore, both of the purified proteins were covalently attached to either 
fluorescein or biotin for fluorescent detection or immobilization. 
JIP4 LZII was labeled with fluorescein using iodoacetamido (IAA) functionalized reagent 
to selectively label thiol groups found in cysteine residues. The purified JIP4 LZII domain 
only contains one cysteine assuring a selective labeling at one position of the protein. 
Figure 4.3a and b show that the labeling is very efficient. Modification of JIP4 LZII can be 
observed in a band shift in a Coomassie stained SDS PAGE gel (Fig. 4.3a). Additionally UV 
irradiation shows that the altered migration behavior of the labeled protein can be 
explained by a fluorescent moiety covalently attached to the protein (Fig. 4.3b) since 
only the IAA fluorescein treated sample results in a visible band. 
Arf6 was labeled with biotin using amine reactive NHS esters. These groups react with 
lysine residues as well as the N-terminus of a protein if those are surface exposed. NHS 
biotin treated Arf6 was immobilized on a nitrocellulose membrane and could be 
detected via an anti-biotin antibody conjugated to fluorescein while both unlabeled Arf6 
and JIP4LZII were not detected (Fig. 4.3c). Although this assay is not quantitative it 
shows successful conjugation of biotin to Arf6.  
 
Fig. 4.3 Covalent modification of JIP4 LZII and Arf6. IAA fluorescein labeled JIP4 LZII (labeled “FL”) 
was separated on a 10% Tris-Tricine SDS PAGE gel. Modification with fluorescein results in a change in 
running behavior of JIP4 LZII as observed in a Coomassie brilliant Blue stained gel (a). Furthermore, the 
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label is detected by UV irradiation (fluorescence, b). Biotin modified Arf6 is detected with anti-FITC 
antibodies after immobilization on a nitrocellulose membrane (DotBlot, c). 
4.1.4 An luminescent oxygen channeling (LOC) assay detects the binding of different 
GTPases to their effector proteins 
 
For luminescence oxygen channeling (LOC), or Amplified Luminescent Proximity 
Homogenous Assay (ALPHA) screen, experiment the interaction partners have to be 
immobilized specifically on either donor or acceptor beads. Interaction of the 
immobilized partners brings both beads in close proximity and allows the transfer of 
singlet oxygen generated by the donor beads upon irradiation with light of 680nm 
wavelength to the acceptor beads. This results in emission of light of 520nm-620nm by 
the acceptor beads. The singlet oxygen has a half-life of approximately 4µs and can 
diffuse up to 200nm from donor to acceptor beads. In contrast to techniques like Förster 
Resonance Energy Transfer (FRET) this allows for detection of a macromolecular 
interaction without detailed knowledge of the interaction site and the spatial orientation 
of the protein labels (162).  
There are different options available for the immobilization of the proteins to ALPHA 
screen bead. Fluorescein modified JIP4 LZII and biotin conjugated Arf6 incubated with 
appropriate beads generate a signal that indicates the formation of JIP4 LZII complex 
with Arf6 and the attached donor and acceptor beads (Fig. 4.4a). Another option is the 
immobilization of one interaction partner using specific antibodies and protein A 
coupled beads. This circumvents the need to covalently modify one interaction partner 
and allows the detected of proteins in complex solutions, e.g. endogenous GTPases in 
cell lysates (see paragraph 4.1.5). The proof of principle was demonstrated using Arf1 
and its effector protein GGA3 (Golgi-associated,  adaptin homologous, Arf interacting 
protein 3; (163); Fig. 4.4b) and the Rho GTPase Rac1 with p21-activated kinase (Pak; 
(164); Fig. 4.4c). However, for Arf6 and both GGA3 and JIP4 LZII it was not possible to 
generate an ALPHA screen signal using the antibody based approach. Given that both 
proteins are described as Arf6 effector proteins (156, 165, 166) and are suitable to 
generate a signal in a LOC based assay with either biotin modified (Fig. 4.4a) or His 
tagged Arf6 (167) the problems observed could be attributed to antibody binding.  
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Fig. 4.4 A LOC assay to detect the interaction between small GTPases and specific effector 
molecules. a) JIP4 LZII fluorescein and Arf6 biotin were immobilized on appropriate donor and acceptor 
beads resulting in an increase in luminescence The decrease in signal observed for high concentrations of 
Arf6 is due to the “hook-effect”. Free Arf6 biotin competes with binding of the immobilized proteins when 
the bead binding sites are saturated. b and c) Arf1 and Rac1 were immobilized via specific antibodieson 
protein A acceptor beads. The respective effector proteins GGA3 and PAK1 are biotin modified and 
coupled to streptavidin donor beads. The white bars indicate GDP bound GTPases while black bars 
represent GTP bound proteins. 
 
4.1.5 An antibody based luminescent oxygen channeling assay measures GTPases activity 
in cell lysates 
 
The described ALPHA screen assay with antibodies recognizing the GTPase allows the 
detection of unlabeled proteins in a complex mixture of components. Although it proved 
to be not suitable for the intended screening for Arf6 the assay provides an opportunity 
to establish a method to measure the activation state of GTPases in cell lysates. 
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It was possible to detect endogenous amounts of GTP loaded Rac1 in lysates of both 
NIH3T3 and HeLa cells (Fig. 4.5a and b). The amounts of lysate required to obtain a 
detectable signal are at least one order of magnitude lower than in conventional 
pulldown assays (Fig. 4.5c). This could prove to be a valuable alternative for those 
assays to quantify activation states of small GTPases given appropriate antibodies to 
detect the GTPase of interest.  
 
Fig. 4.5 LOC assay for the detection of active GTPases in cell lysates.A and b) The indicated amounts 
of cell lysate protein (preloaded with GTP or GDP) were incubated with the specific effector protein PAK1 
immobilized on streptavidin donor beads. Specific antibodies are used to couple the endogenous GTPases 
to protein A acceptor beads. A specific signal was observed for both cell types with only 4µg of cellular 
protein. White bars indicate GDP loaded GTPases and black bars represent GTP loaded GTPases. C) 
Biotinylated PAK1 was immobilized on streptavidin agarose beads and incubated with the indicated 
amounts of cell lysate. Precipitated Rac1 was separated on SDS PAGE, blotted on a nitrocellulose 
membrane and detected with Rac1 specific antibodies. This experiment illustrates that 10 times more cell 
lysate (weak rac1 band detected with 40µg lysate) is required to detect GTP bound Rac1 when PAK1 is 
used to co-precipitate endogenous amounts of active GTPases from cell lysates.  
 
4.1.6 A pulldown assay using GST tagged JIP4 LZII predominantly precipitates active Arf6 
 
Pulldown assays are traditionally used to show complex formation between two 
proteins of interest. Precipitation of the complex is achieved by immobilization of one 
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interaction partner to an appropriate resin (e.g. agarose beads). If both proteins are 
precipitated with the resin it is expected that they form a stable interaction.  
GST tagged JIP4 LZII can be immobilized on glutathione conjugated resin. Arf6 
preloaded with GTP is efficiently co-precipitated with JIP4 LZII while GDP bound Arf6 
and Arf1 do not bind as efficient to the effector protein. Furthermore, soluble JIP4 LZII 
without the GST tag can productively compete with the immobilized form indicating a 
specific interaction between active Arf6 and JIP4 LZII (Fig. 4.6a and b). In contrast, 
soluble JIP4 LZII does not compete with the precipitation of GTP loaded Arf1 by GGA3, a 
different effector protein for Arf GTPases (163, 165, 166). Both the specificity of JIP4 for 
binding Arf6 over Arf1 and the specificity in competing for effector binding argues for a 
very selective interaction that can be an excellent starting point to identify small 
molecules that selectively disturb Arf6 interaction with JIP4 or other effectors. 
 
Fig. 4.6 Pulldown of Arf1 and Arf6 with specific effector proteins. JIP4 LZII GST was immobilized on 
glutathione agarose beads and incubated with Arf1 or Arf6, preloaded with either GDP or GTP, in the 
presence and absence of soluble JIP4 LZII as a competitor. GTP bound Arf6 is efficiently co-precipitated 
while Arf6 GDP and Arf1 GTP show only weak association with the effector bound beads (a, Coomassie 
stained SDS PAGE gel). Specific detection of both GTPases via Western Blot and antibody labeling shows 
that soluble JIP4 LZII competes for effector binding to Arf6 (b, JIP4) but not to Arf1 (c, GGA3). 
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4.1.7 A high throughput screening (HTS) compatible assay for protein-protein-interaction 
(PPI) inhibitors based on fluorescence polarization (FP) 
 
High throughput screening for small molecule inhibitors requires the employed assay to 
be optimized for this special purpose. It has to be possible to perform the reaction in one 
tube (one well of a microtiter plate) in a homogenous mixture without the need for wash 
steps. Furthermore, the assay readout should be simple and stable over a definite time. 
If one or more of those criteria are not matched, screening will become complicated or 
even impossible with increasing quantity of small molecules. A co-precipitation assay as 
described in paragraph 4.1.6 is not suitable since it requires both extensive washing 
steps and evaluation of the results by separating the precipitated proteins via 
polyacrylamide gel electrophoresis (PAGE). Although the LOC assay described in 
paragraph 4.1.4 is suitable for HTS, it is a financially demanding method. To avoid 
problems associated with those two methods, a fluorescence polarization (FP) assay 
was established that provides an alternative that is easily applicable in a HTS setup. 
Fluorescence polarization requires one molecule, ideally the smaller interaction partner, 
to be fluorescently labeled. When excited with polarized light tumbling and movement 
of the molecule during the time between excitation and emission (the fluorescence half-
life) leads to a change in the polarization of the emitted light (159, 168). A small 
fluorescent molecule exhibits a low polarization of the emitted light. Binding of an 
interaction partner increases the size of the fluorescently labeled particle and in turn 
reduces the molecular motions that lead to a decrease in polarization. Hence, the FP 
value increases (Fig. 4.7a).  
JIP4 LZII labeled with iodoacetamido (IAA) fluorescein was incubated with increasing 
concentrations of either GTP (active form) or GDP (inactive form) bound Arf6 and GTP 
bound Arf1. Active Arf6 binds with a Kd value of 0.6µM, which is in accordance to 
published data generated using surface Plasmon resonance (SPR) measurements (156). 
Inactive Arf6 (Kd=1.8µM) and active Arf1 (Kd=14µM) bind to JIP4 LZII with lower 
affinity. This demonstrates the specificity of the effector towards active Arf6. 
Additionally the FP values are stable over several hours (data not shown) further 
establishing this approach as suitable for HTS.  
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Fig. 4.7 Fluorescence polarization (FP) experiments with Arf GTPases and JIP4 LZII fluorescein.A 
small fluorescently labeled protein exhibits a low FP value due to a high molecular mobility. Binding of an 
interaction partner increases the size of the fluorescent complex, decreases the mobility and leads to an 
increase in FP (a). JIP4 LZII fluorescein was incubated with Arf6 loaded with GDP or GTP and Arf1 loaded 
with GTP. Arf6 GTP efficiently associates with JIP4 LZII while both GDP bound Arf6 and Arf1 exhibit a 
lower affinity for the effector protein (b). 
 
4.1.8 The increase in fluorescence polarization is reversible and specific for JIP4 and Arf6 
 
Further investigating whether the increased FP value observed when incubating JIP4 
LZII fluorescein with Arf6GTP reflects specific association I used different control 
proteins. Only titration of Arf6 leads to an increase in FP but no change is observed with 
increased concentration of bovine serum albumine (BSA), Erk2 or the intracellular 
domain (ICD) of the EGF receptor (Fig. 4.8a). Furthermore, the FP values of JIP4 LZII FL 
in presence of Arf6 can be reduced by addition of increasing concentrations unlabeled 
JIP4 LZII (Fig. 4.8b) indicating both specificity and reversibility of the complex 
formation. In addition to the data from paragraph 4.1.7 the described results suggest 
that the assay is suitable for monitoring the specific interaction between Arf6 and its 
effector JIP4. 
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Fig. 4.8 JIP4 LZII and Arf6 generate a specific signal in a fluorescence polarization assay.The 
indicated proteins were incubated in increasing concentrations with fluorescein labeled JIP4 LZII. An 
increase in FP is observed for JIP4 LZII and Arf6 but not with the tested control proteins (a). A complex 
between Arf6 GTP and fluorescein labeled JIP4 LZII was incubated with increasing concentrations of 
unlabeled JIP4 LZII. This results in a decrease in FP indicating that complex formation is specific and 
reversible (b). 
 
4.1.9 Neither addition of DMSO nor detergent impairs the fluorescence polarization 
assay 
 
Another important aspect in the development of assays for drug development is their 
stability towards detergents or solvents used to store small molecules in libraries. The 
addition of detergents can reduce aggregation of small molecules, an effect that can lead 
to false positive results. Those “promiscuous” inhibitors (169) inhibit a wide variety of 
biological assays and are therefore not specific. Dimethylsulfoxide (DMSO) is a common 
solvent for the storage of stock solutions in compound libraries. The compounds 
screened in this study are stored in DMSO as well and therefore the biological assay 
needs to tolerate low concentrations of the solvent. 
The addition of up to 0,1% Triton X 100 or 10% DMSO has no influence on the outcome 
of the FP assay (Fig. 4.9 a-c). Similar results are obtained with the detergent Tween 20 
(data not shown).  Furthermore, the assay readout was stable in reaction volumes as low 
as 10µl facilitating the use of 384 well plates. 
An important parameter indicative of the quality of a HTS assay is the Z’ value (170): 
 
Z’ = 1-(3*((positive)+(negative))/(µ(positive)-µ(negative))) 
 
 RESULTS  
 42 
The described assay had resulted in a Z’ value close to 0.9 when performed under 
screening conditions (2µM Arf6, 250nM JIP4 LZII fluorescein, 384 well plate, 0,05% 
TritonX100, 5% DMSO) making the assay an excellent choice for the desired screening. 
HTS was performed with the help auf K. Rothscheid using an in-house compound library 
with 17000 small molecules and a final compound concentration of 30µM. 
 
 
Fig. 4.9 Stability of the fluorescence polarization based screening assay towards Dimethylsulfoxide 
(DMSO) and detergent.Fluorescein labeled JIP4 LZII was incubated with the indicated reagents in the 
absence (grey bars) or presence (black bars) of saturating concentrations of Arf6 GTP. Neither DMSO nor 
Triton X 100 influence the change in FP observed (a and b). The combination of both reagents alsohas no 
effect (c). 
 
4.1.10 Screening results and primary hit evaluation 
 
The screening yielded nine compounds that reduced the FP value below the threshold of 
five standard deviations below the mean of the positive control (Fig. 4.10a). To confirm 
the results the assay was repeated manually using increasing concentrations of the 
initially identified compounds. Three of them had no effect in the rescreen while three 
more hits reduced the fluorescence polarization below the value of the negative control 
when used in high concentrations (30µM). Indeed those molecules exhibit a very high 
fluorescence in the range of fluorescein (Fig. 4.10b) and their presence in high 
concentrations leads to artificially reduced fluorescence polarization. The three 
remaining primary hits are depicted in Fig. 4.10c and were further analyzed. 
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Fig. 4.10 Results of the screening for small molecule inhibitors of the Arf6 interaction with JIP4. 
Nine primary hits were identified in the screening (a). The dashed line indicates the threshold for primary 
hits (5 standard deviations below the positive control). No reproduction of the results was possible for 
three of the compounds (“-“). Furthermore, three different compounds exhibit a very high intrinsic 
fluorescence (“F”) that interferes with the assay readout (b). The three remaining compounds shown in 
(c) were further tested. 
 
4.1.11 Thalidomide has no effect in the FP assay employed in the screening 
 
The hit compound KR2 3H8 (Fig. 4.10c) is structurally very similar to thalidomide (Fig. 
4.11) a compound that became popular as a drug due to its tremendous effect on the 
development of unborn infants when consumed by the pregnant mother. Affected 
children exhibit defects in limb development resulting in shortened or missing arms 
(phocomelia or amelia). The malformations are caused by defects in angiogenesis during 
embryonic limb formation (171, 172). Migration of cells controlled by extracellular 
factors is extremely important for the angiogenic process (173) and a defect in the 
control of these events can lead to severe problems. Since Arf6 is involved in cell 
migration (96) inhibition of its function could provide another possible effect 
 RESULTS  
 44 
explanation for the observed phenotype thalidomide and its derivatives were promising 
compounds for further analysis. 
I tested both enantiomers of thalidomide, since they exhibit distinct biological activities. 
However, neither isomer changes the fluorescence polarization in the Arf6 JIP4 LZII 
interaction assay (Fig. 4.11). Furthermore, both forms of thalidomide have a lower 
autofluorescence than compound KR2 3H8. These results suggest the need for a 
fluorescent independent assay to confirm the initial hits.  
 
 
Fig. 4.11 Thalidomide has no effect on the association of Arf6 with JIP4 LZII in the fluorescence 
polarization assay. Up to 50µM of both enantiomers of thalidomide were incubated with fluorescein 
labeled JIP4 LZII in the presence of saturating concentrations of Arf6 GTP. No reduction of the FP values 
was observed even for the highest employed thalidomide concentration (n=3). 
 
4.1.12 The hit compounds have no effect on binding of Arf6 to JIP4 LZII in a pulldown 
assay 
 
Fluorescent assays are prone to yield false positive hits due to intrinsic fluorescent 
properties of the compounds used in the screening. A different assay was therefore 
employed to exclude false positive hits due to fluorescent artifacts. The pulldown assay 
described in paragraph 4.1.6 is well suited for this purpose. The initially identified small 
molecules had no effect on the amount of Arf6 co-precipitated with GST tagged JIP4 LZII 
(Fig. 4.12). The results indicate that the primary hits are false positive due to intrinsic 
fluorescence of the identified compounds. 
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Fig. 4.12 Pulldown of Arf6 with immobilized JIP4 LZII in the presence of hit compounds. JIP4 LZII 
GST was immobilized to glutathione coupled agarose beads and incubated with GTP bound Arf6 in the 
presence of 30µM of each hit compound shown in Fig. 4.10 or DMSO (“-“). Samples were separated on a 
SDS PAGE gel and transferred onto a nitrocellulose membrane prior to decoration with specific antibodies 
against Arf6. The compounds have no influence on the amount of Arf6 co-precipitating with JIP4 LZII GST 
(“pulldown”). 
 
 
No small molecules that inhibit the interaction between Arf6 and JIP4 were identified. 
However, the screening assay developed is very stable, shows an excellent Z’ value and 
is therefore easily applicable in HTS approaches. Furthermore, alternative methods are 
presented that can quickly exclude false positive hits or confirm the effect of identified 
compounds. 
In addition to the established aptamer displacement screens (158, 159) and assays 
monitoring enzymatic activity (174) this assay provides another approach to identify 
inhibitory compounds for biological systems.   
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4.2 The influence of cytohesins on EGF receptor signaling 
 
The recent identification of cytohesins as cytosolic factors that positively influence EGF 
receptor signaling revealed a novel aspect of this vital mitogenic pathway (146). A 
detailed knowledge of the mechanism behind the influence of cytohesins on the EGFR is 
required to understand implications of this finding in a specific physiological or 
pathophysiological situation, e.g. the control of normal cellular growth and malignant 
transformation in cancer.  
The observed effect is dependent on a direct interaction between the Sec7 domain of 
cytohesins and the intracellular domain of the EGFR receptor and no additional factors 
are required to observe an effect in vitro(146). Further elucidation of the mechanism is 
approached by using purified components of the system. Therefore, both biochemical 
and structural  (x-ray crystallography) methods were employed in order to dissect the 
interaction between the Sec7 domain of cytohesin2 (ARNO) and the intracellular domain 
of the EGFR. 
 
4.2.1 Purification of proteins for crystallization and biochemical studies 
 
Recombinant expression of the involved proteins was done in E.coli for the ARNO Sec7 
constructs and in Sf9 insect cells for EGFR constructs respectively. All constructs were 
purified using NiNTA affinity chromatography followed by size exclusion 
chromatography (SEC) after cleavage of the His-tag using either TEV or Thrombin 
protease. Removal of the affinity tag yields recombinant proteins that closely resemble 
their endogenous form. This increases the chance to obtain proteins with natural 
conformations and therefore reduces artificial effects occurring in the in vitro setup. 
Fig. 4.13 shows the three general steps during the purification process exemplified by 
the construct EGFR ICD1022 (EGFR 669-1022). The first purification step results in a 
crude product (Fig. 4.13a). The purity of the protein is thereafter increased after 
protease cleavage and gel filtration (Fig 4.13b and c). Other constructs used in this study 
are mentioned in their respective paragraphs and purified as described above. The 
employed EGFR constructs contain only the intracellular soluble part of the receptor. 
Both the extracellular domain and the transmembrane region are omitted to obtain a 
soluble protein. The resulting intracellular domain is kinase competent (13) and 
 RESULTS  
 48 
sufficient to associate with ARNO (146). Additionally the receptor constructs lack the C-
terminal tail (CTT), a flexible part of the protein that contains the major 
autophosphorylation sites. The presence of the CTT leads to difficulties observed during 
purification (data not shown, purification performed by Volkmar Fieberg) and is 
therefore avoided. However, Tyr1016 of the CTT remains in all employed constructs to 
investigate autophosphorylation activity. 
A major difference between the EGFR constructs used in this study is the presence or 
absence of the juxtamembrane (JM) domain. While EGFR ICD1022 contains this n-
terminal part of the protein, EGFR KC1022 (EGFR 672-1022) lacks it. These constructs 
can be used to investigate the binding site of ARNO at EGFR in vitro.  
While most of the constructs were stable in solution, EGFR ICD1022 precipitates in 
concentration above 3 mg/ml. This poses problems for the use in crystallography when 
protein stability is required in highly concentrated solutions for a longer period of time 
(days to weeks).  
 
 
Fig. 4.13 Purification of Epidermal Growth Factor Receptor (EGFR) constructs (EGFR ICD1022).The 
indicated samples were taken during the purification process, separated on a 12% SDS PAGE gel and 
visualized with Coomassie Brilliant Blue staining. The gels show the enrichment of target protein via 
affinity purification using a NiNTA column (a), TEV cleavage of the affinity tag and inverse affinity 
purification to remove uncleaved protein and the protease (b), and a final size exclusion chromatography 
(SEC) step on a Superdex200 column (c). For details see Materials and Methods. 
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4.2.2 Dynamic light scattering (DLS) and circular dichroism (CD) spectroscopy of the 
purified proteins 
 
Dynamic light scattering (DLS) can be used to evaluate the aggregation behavior of 
purified proteins and allows for estimation of the average particle size in a solution. 
Figure 4.14a shows that the ARNO Sec7 domain is not aggregating in solution and is 
represented by particles of approximately 30kDa (R=3nm) fitting the expected values 
very well (MWARNOSec7=24kDa). However, for EGFR ICD several more prominent 
populations of higher molecular weight peaks are observed (main peak at R=85nm; 
30000kDa). It has to be considered that the intensity of the detected scattered light is 
not in a linear correlation to the absolute abundance of the corresponding particle size 
in a mixture. In fact particles of higher molecular weight scatter more and result in 
higher peaks. The first peak observed (Fig. 4.14b) corresponds to a dynamic radius of 
approximately 5nm (resulting in a molecular weight of 45kDa). Although it contributes 
only weakly to the total intensity of scattered light, the particles of the corresponding 
size still account for over 80% of the mixture. The EGFR ICD1022 monomer has a 
molecular weight of 44kDa and fits to the particle size observed in the first peak. In 
contrast to published data, no peak representing a dimeric EGFR is observed (13). 
Nevertheless other peaks indicate either aggregates or higher order oligomeric protein 
formations (Fig. 4.14b). A tendency to aggregate could explain the visible precipitation 
of EGFR ICD in solutions of higher concentration and would render the construct not 
suitable for crystallization. 
Circular dichroism (CD) spectroscopy is employed to determine the secondary structure 
elements found in a macromolecule. For the ARNO Sec7 domain the peak at 222nm is 
typical for a predominant  helical structure that is expected in this protein (Fig. 4.14c). 
Although a second peak at around 208nm is characteristic for predominant helical 
elements in a protein too, the lack of this peak can be explained by the fact that the CD 
signal at lower wavelength is often disturbed by the buffer components and therefore 
not reliable. Other typical structural elements, however, exhibit a distinct spectrum with 
either a peak around 215nm ( sheet) or a peak below 200nm and a plateau in the 
higher wavelength region (random coil). 
It was not possible to obtain suitable CD curves for EGFR ICD1022. Both the intensity 
and the shape of the curve are not of sufficient quality to deduce information about the 
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secondary structure of this construct (Fig. 4.14d). This finding is another indication for a 
heterogeneous population of macromolecules in the solution. 
 
 
Fig. 4.14 Dynamic light scattering (DLS) and Circular dichroism (CD) measurements for ARNO Sec7 
and EGFR ICD1022. DLS shows one homogenous population of particle size contributing to the detected 
scattered light for ARNO Sec7 (a) but several higher molecular weight particles result in light scattering in 
samples containing EGFR ICD1022 (b). Plotted are the relative intensities of scattered light that is 
calculated to be caused by particles of the corresponding size. The CD curve observed for EGFR ICD1022 
shows low ellipticity values making interpretations regarding the secondary structure difficult (d). ARNO 
Sec7 results in a clear peak at 222nm (c). Although no complete -helical spectrum is observed, the 
results argue for a secondary structure dominated by -helices (see text). 
 
4.2.3 Functional characterization of the purified constructs 
Both ARNO and EGFR exhibit enzymatic activity that can be evaluated in vitro to 
examine functionality and therefore quality of the recombinant constructs. Using the 
assay described in paragraph 4.1.2 it was shown that the Sec7 domain of ARNO is able to 
exchange nucleotides on the GTPase Arf1 (Fig. 4.2a) proving its biological activity.   
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The kinase activity of EGFR constructs can be measured by evaluating the 
phosphorylation of tyrosine residues in the C-terminal tail (CTT) of the protein. 
However, the construct EGFR ICD1022 has a truncated CTT with only one 
phosphorylation site (Tyr1016). This results in a kinase to substrate ratio of 1:1 and is 
no good system to evaluate enzymatic activity. Therefore, a biological substrate of the 
kinase was used in molar excess to measure activity. The protein Phospholipase C  
(PLC) is phosphorylated at a tyrosine in its Src Homology 2 (SH2) domain. The SH2 
domain was purified as a GST fusion protein and employed in a kinase assay that 
measured phosphorylation via Western Blot detection with phosphotyrosine specific 
antibodies. The EGFR construct lacking the juxtamembrane (JM) domain (EGFR KC1022) 
shows only weak activity with phosphorylation observed only after long incubation 
times (up to one hour). In contrast the presence of the JM domain in EGFR ICD1022 
results in a dramatically increased activity leading to maximum phosphorylation after 5 
minutes. This is in accordance with published data (13, 15) that highlights the 
importance of the JM domain for kinase activity.  
 
 
Fig. 4.15 Kinase activity assay for purified EGFR constructs.The described EGFR constructs were 
incubated with the SH2 domain of the natural substrate PLC in the presence of ATP. Samples were taken 
after the indicated times, separated by SDS PAGE and phosphorylation was detected using -phospho-
tyrosine antibodies (anti pY) after transfer of the proteins onto a nitrocellulose membrane. While EGFR 
KC1022 is only weakly able to phosphorylate the substrate, EGFR ICD1022 rapidly phosphorylates the 
SH2 domain of PLC . 
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4.2.4 Thermal stability of ARNO Sec7 and EGFR constructs 
 
Purified EGFR ICD1022 is not stable when stored at high concentration and precipitates 
in vitro. To address this issue a quantitative stability assay was employed in order to 
optimize buffer conditions and increase stability of the protein. Using an 
environmentally sensitive fluorescent dye (SYPRO Orange) it is possible to follow the 
unfolding of proteins in solution and determine their thermal stability by monitoring the 
change in fluorescence in a temperature gradient (175). SYPRO Orange increases its 
fluorescent intensity upon binding to hydrophobic patches that are exposed in unfolded 
proteins. Plotting the fluorescence intensity against the temperature results in a curve 
as seen in Figure 4.16a and c. The inflection point of the curve marks the melting 
temperature and represents a quantitative value to measure the thermal stability of the 
protein. Determination of the melting temperature is facilitated by plotting the change in 
fluorescence at a certain temperature against the temperature (the derivative of the 
aforementioned curve). Here the local maximum represents the melting temperature 
and is easy to observe as a peak in the curve (Fig. 4.16b and d).  
ARNO Sec7 and the EGFR construct lacking the JM domain (EGFR KC1022) have a 
similar melting temperature around 51°C. However, the presence of the JM domain in 
EGFR (EGFR ICD1022) results in a lower thermal stability and a melting temperature of 
44°C (Fig. 4.16a and b).  
In order to increase the thermal stability of EGFR ICD1022 I tested different buffer 
conditions and additives to evaluate their influence on the observed melting 
temperature. The non-hydrolysable ATP analogue Adenylyl-imidodiphosphate 
(AMPPNP) competes with ATP for binding to the active site of the kinase and therefore 
blocks catalytic activity. The addition of AMPPNP increases the thermal stability of EGFR 
ICD1022 resulting in melting temperature of 55°C (Fig. 4.16c and d). These findings 
suggest that a reduction in kinase activity leads to increased thermal stability since both 
EGFR KC1022 and AMPPNP blocked EGFR ICD1022 have a higher melting temperature 
than fully active EGFR ICD1022. 
 
 RESULTS  
 53 
 
Fig. 4.16 Thermal stability of purified proteins determined by a Thermal Shift assay. The indicated 
proteins were slowly heated in the presence of the environmentally sensitive fluorescent dye SYPRO 
Orange. Unfolding of the protein results in an increase in fluorescence and unfolding at low temperature 
indicates instability of the tested proteins. While ARNO Sec7 and EGFR KC1022 exhibit a comparable 
melting temperature, EGFR ICD1022 unfolds earlier in the gradient (a and b). The addition of AMPPNP 
strongly enhances the thermal stability of EGFR ICD1022 indicated by the shift in melting temperature (c 
and d). Plotted are the fluorescent intensities against the temperature in a) and c) or the change in 
fluorescence intensity at a temperature against the respective temperature in b) and d) (n=3). 
 
4.2.5 Investigation of the interaction between ARNO and the EGF receptor 
 
Recently it was shown that the Sec7 domain of ARNO directly interacts with the 
intracellular part of the EGFR (146). To further investigate the interaction an assay 
based on chemical crosslinking was established. Crosslinking reagents such as 
Bis(sulfosuccinimidyl)suberate (BS3) are bivalent molecules that can form covalent 
bonds to specific reactive groups in biological macromolecules. BS3 has two 
succinimidyl groups that react with primary amines present at the N-terminus of a 
protein and at lysine side chains. If two amines on two different molecules react with the 
same BS3 molecule both are covalently connected and the complexes becomes visible on 
a denaturing polyacrylamide gel. Since the linker between the two reactive groups is 
short (11.4 Å for BS3) only molecules that are in close proximity to each other (e.g. due 
to direct interaction) can be crosslinked.  
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This approach allows detection of transient interactions since the binding partners are 
irreversibly coupled once they form a crosslinking susceptible conformation. 
 
As a proof of principle, known interaction partners for ARNO and the EGFR intracellular 
domain were crosslinked. The GTPase Arf1 forms a complex with ARNO during the 
nucleotide exchange reaction (176, 177) and Mig6 (mitogen induced gene 6) is an 
intracellular negative regulator of EGFR activity (87, 178). Both proteins can be 
crosslinked to their respective interaction partners in vitro (Fig. 4.17 a and b) 
demonstrating the feasibility of the assay to detect molecular interactions involving the 
two proteins of interest. 
 
 
Fig. 4.17 Chemical crosslinking of ARNO Sec7 and EGFR construct with known interaction partners. 
The bivalent amine specific crosslinker Bis(sulfosuccinimidyl)suberate (BS3) was employed to covalently 
connect protein complexes. ARNO Sec7 and Arf1 (a) and different EGFR constructs with Mig6 EBR S1 (b) 
were incubated with BS3. Crosslinks were visualized via Coomassie Brilliant Blue stain after separation of 
the reaction on SDS PAGE gels. Mig6 associates with the kinase core of EGFR and therefore forms 
crosslinks with all EGFR constructs. EGFR K745M is a kinase inactive mutant that no longer binds the ATP 
essential for enzymatic activity. 
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4.2.6 EGFR constructs containing the juxtamembrane domain can be crosslinked to 
ARNO Sec7 
 
The EGFR receptor intracellular domain is known to associate in homo-dimers and this 
conformation is required for activity of the kinase (77). The juxtamembrane (JM) 
domain is crucial for dimer formation (13, 15) and lack of this domain results in severely 
reduced kinase activity (Fig. 4.15). Crosslinking of EGFR ICD1022 results in an 
additional band at 90kDa (Fig. 4.18a, lane 4). The same band is observed for EGFR 
ICD1022 K745M (Fig. 4.18a, lane 6). Lysine at position 745 (position 721 in the mature 
EGFR) is crucial for ATP binding and therefore kinase activity (179). Replacing this 
amino acid with methionine renders the receptor catalytically inactive. However, both 
constructs contain the JM domain and the molecular weight of the observed band fits to 
an EGFR dimer. In contrast no crosslink is observed for EGFR KC1022 (Fig. 4.18a, lane 8) 
supporting the importance of the JM domain for dimer formation. 
In addition to the 90kDa crosslink another band appears when ARNO Sec7 is added to 
the EGFR constructs containing the JM domain (Fig. 4.18a lane 10 and 12). With a 
molecular weight of 65kDa this crosslinking product fits the size of an EGFR-ARNO 
complex. The presence of the JM domain is required for the formation of this complex 
since EGFR KC1022 is not crosslinked to ARNO Sec7 (Fig. 4.18a, lane 14). These results 
highlight the importance of the juxtamembrane domain for the interaction of EGFR and 
ARNO and are supported by results from microscale thermophoresis (data not shown, 
experiments performed by Anton Schmitz) and fluorescence polarization experiments 
(Supplementary Figure 7). 
Furthermore, no crosslinking is observed between EGFR ICD1022 and the GTPase Ran 
(Fig. 4.18b, lane 14) indicating specificity of the assay. Although the nucleotide exchange 
active domain of the bacterial protein DrrA forms a crosslink with EGFR ICD1022 (Fig. 
4.18b, lane 12) this interaction is not dependent on the presence of the JM domain since 
EGFR KC1022 can also be crosslinked (Supplementary Figure 9). 
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Fig. 4.18 Chemical crosslinking of EGFR with ARNO Sec7 and control proteins. The indicated proteins 
were incubated with BS3 and the resulting crosslinking products were separated on SDS PAGE gels and 
stained with Coomassie Brilliant Blue. EGFR forms a crosslink with ARNO Sec7 when the juxtamembrane 
(JM) domain is present in the employed construct (a). Other proteins do not crosslink to EGFR in a JM 
dependent manner (b and Supplementary Figure 9). 
 
4.2.7 The EGFR juxtamembrane domain is a binding site for ARNO Sec7 
 
The presence of the JM domain is important for crosslinking to ARNO Sec7. However, it 
is unclear whether the JM domain binds to ARNO or dimerization of EGFR molecules 
induced by the presence of the JM domain is required for binding and the formation of 
crosslinks. The EGFR JM domain was solid phase synthesized and contained both the JM-
A and JM-B region of the domain (13). Two N-terminal tryptophans were added to the 
peptide to allow concentration determination in solution using absorbance at 280nm. 
Crosslinking of the EGFR JM domain in the presence of ARNO Sec7 results in an 
additional band at approximately 27kDa (Fig. 4.19a, lane 10). This indicates the 
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formation of an ARNO Sec7 complex with EGFR JM. Both a scrambled version of the JM 
domain peptide and the unrelated JM domain of the insulin receptor (IR) show no 
crosslinks when incubated with ARNO Sec7 (Fig. 4.19a, lane 12 and 14).  
The two control proteins Ran and DrrA form no crosslink with ARNO Sec7 (Fig. 4.19b) 
supporting the hypothesis that the JM domain of EGFR is a specific binding site for 
ARNO. 
 
 
Fig. 4.19 Chemical crosslinking of the juxtamembrane domain of EGFR with ARNO Sec7. The 
indicated constructs were crosslinked using BS3, separated on a SDS PAGE gel and stained with 
Coomassie Brilliant Blue. ARNO Sec7 crosslinks only to the JM domain of EGFR but not to a scrambled 
EGFR JM construct or the JM domain of the insulin receptor (IR) (a). Furthermore, EGFR JM forms no 
crosslinks with DrrA or Ran (b). 
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4.2.8 Crosslinking with lysine mutants of ARNO Sec7 
 
Chemical crosslinking with amine reactive groups depends on the presence of lysine 
residues in the interacting proteins. Therefore, mutation of lysines close to the 
interaction site would reduce crosslinking efficiency and vice versa reduced crosslinking 
efficiency indicates that a lysine residue is close to the interaction site. 
The EGFR JM domain has only two potential crosslinking sites, the N-terminus and one 
lysine very close to the N-terminus (8th amino acids in the peptide). The close proximity 
suggests that both amines are redundantly involved in crosslinking. Indeed although the 
N-terminus is not required for crosslinking, its covalent modification results in a 
reduction of crosslinking efficiency between ARNO Sec7 and EGFR JM (Suppl. Figure 5). 
In contrast the ARNO Sec7 domain contains 11 lysine residues making the identification 
of crosslinking relevant residues more complex. Constructs containing mutations of 
single lysines or groups of lysines located in certain parts of the protein were employed 
in order to investigate crosslinking behavior. The amino acids were replaced by 
arginines to minimize effects caused by a change in surface charge in the mutants. 
Figure 4.20 shows the division of ARNO Sec7 in three parts in which lysines are mutated 
to obtain the constructs “N” (K->R 57,64,70,71,77,78), “M” (K->R 102,108,159) and “C” 
(K->R 207,244). In the following paragraph these mutants are employed to narrow 
down the potential binding site of ARNO Sec7 for EGFR JM. 
 
 
Fig. 4.20 Structural representation of the ARNO Sec7 lysine residues mutated for crosslinking 
analysis. 
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4.2.9 The C-terminal part of ARNO Sec7 is important for crosslinking 
 
Mutation of the lysine residues at position 207 and 244 in ARNO Sec7 (construct “C”) 
results in a decrease in crosslinking both with the EGFR intracellular domain (EGFR 
ICD1022) and with the JM domain peptide (Fig. 4.21a and b, compare lanes 4 and 6). In 
contrast mutation of all lysines in the N-terminal and the middle part of ARNO Sec7 
(construct “NM”) has no influence on crosslinking efficiency with EGFR ICD1022 (Fig. 
4.21a, lane 8) indicating that lysines in the C-terminal part are required for efficient 
crosslinking. However, crosslinking of ARNO Sec7 “NM” to EGFR JM provides 
contradictory results since reduced crosslinks are observed (Fig. 4.21b, lane 8; see 
discussion). To substantiate the importance of the C-terminus for crosslinking the ARNO 
Sec7 constructs “M” and “MC” were employed (Fig. 4.22a and b). While mutation of 
lysine residues in the middle part (“M”) of the protein has no influence on crosslinking 
with EGFR ICD1022 and EGFR JM, additional mutation of lysines 207 and 244 in the C-
terminal part (“MC”) results in significantly decreased efficiency (Fig. 4.22a and b, lane 
12 and 14). This establishes one or both of the C-terminal lysines of ARNO Sec7 as 
important for crosslinking to EGFR.  
 
 
Fig. 4.21 (a) Lysines in the C-terminal region of ARNO Sec7 are important for chemical crosslinking 
with EGFR ICD1022. The indicated ARNO Sec7 mutants were crosslinked to EGFR ICD1022 using BS3, 
separated on a SDS PAGE gel and stained with Coomassie Brilliant Blue. The mutation K745M in EGFR 
ICD1022 has no influence on crosslinking but results in a stabilized protein. A reduction in crosslinking 
efficiency is observed when Lys207 and Lys244 are replaced by arginines (“C”) but not when all other 
lysines are mutated in ARNO Sec7 (“NM”, see Figure 4.20). 
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Fig. 4.21 (b) Lysines in the C-terminal region of ARNO Sec7 are important for chemical crosslinking 
with EGFR JM. The indicated ARNO Sec7 mutants were crosslinked to EGFR JM using BS3, separated on a 
SDS PAGE gel and stained with Coomassie Brilliant Blue. A reduction in crosslinking efficiency is observed 
when Lys207 and Lys244 are replaced by arginines (“C”) and when all other lysines are mutated (“NM”). 
However, this also results in increased ARNO dimer crosslink formation. 
 
 
Fig. 4.22Lysines in the C-terminal region of ARNO Sec7 are important for chemical crosslinking 
with EGFR constructs. ARNO Sec7 mutants were crosslinked to EGFR ICD1022 (a) or EGFR JM (b) with 
BS3. The reactions were separated on SDS PAGE gels and stained with Coomassie Brilliant Blue. Mutation 
of lysines in the C-terminal part of ARNO Sec7 severely reduces crosslinking efficiency both to EGFR 
ICD1022 (a) and EGFR JM (b). 
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4.2.10 Lysine 244 is a major crosslinking site for EGFR at ARNO Sec7 
 
Knowing that the C-terminal part of the ARNO Sec7 domain is critical for efficient 
crosslinking the question arises if both or actually just one lysine is responsible for the 
observed effect. ARNO Sec7 K244R shows reduced crosslinks both with EGFR ICD1022 
and EGFR JM (Fig. 4.23a and b, lane 8). The reduction is comparable to the effect 
observed for double mutant at position 207 and 244 (“C”, Fig. 4.23a and b, lane 6). 
Furthermore, replacing only lysine 207 by arginine has no effect on crosslinking (Fig. 
4.24a and b, compare lane 4 and 10). These results establish lysine at position 244 in 
ARNO as an important determinant for crosslinking to EGFR constructs and allow for 
speculations about the binding site (see discussion). 
 
 
Fig. 4.23 Chemical crosslinking of EGFR constructs to ARNO Sec7 is reduced in the absence of 
Lys244.The indicated ARNO Sec7 constructs were crosslinked to EGFR constructs with BS3, separated on 
SDS PAGE gels and stained with Coomassie Brilliant Blue. Replacing Lys244 in ARNO Sec7 with arginine 
has the most pronounced effect on crosslinking to EGFR ICD1022 (a) and EGFR JM (b). No other lysine 
mutation shows comparable effects on crosslinking. 
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Fig. 4.24 Summary of crosslinking results obtained with ARNO Sec7 lysine mutants. The indicated 
ARNO Sec7 constructs were crosslinked to EGFR constructs with BS3, separated on SDS PAGE gels and 
stained with Coomassie Brilliant Blue. Only mutating Lys244 in ARNO Sec7 shows a consistent effect on 
crosslinking both to EGFR ICD1022 (a) and EGFR JM (b). 
 
4.2.11 In vitro nucleotide exchange on Arf1 catalyzed by ARNO is inhibited in the presence 
of EGFR JM 
 
The interaction between EGFR and ARNO raises the question whether it has an influence 
on other functions of ARNO. Therefore, the EGFR JM peptide was added to the nucleotide 
exchange reaction monitoring ARNO activity on Arf1. Indeed the exchange rate is 
reduced in the presence of EGFR JM in a dose dependent manner (Fig. 4.25) suggesting a 
functional effect of EGFR binding to ARNO.  
The presented data strongly argue for a direct and specific interaction between ARNO 
and EGFR with functional consequences for both proteins (146). However, a detailed 
picture of this interaction is not possible to deduce from the results. Therefore, a 
different method is required to obtain more information on a molecular level. 
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Fig. 4.25 ARNO catalyzed nucleotide exchange on Arf1 in the presence of the JM domain of EGFR. 
Arf1 preloaded with GDP was incubated with ARNO Sec7 and excess GTP in the presence of increasing 
concentrations of EGFR JM (a) or a scrambled version of the domain (b, EGFR JM scr). Error bars 
represent SEM (n=4 for EGFR JM; n=2 for EGFR JM scr). 
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4.3 Investigation of the ARNO EGFR interaction using x-ray crystallography 
 
Obtaining detailed information about the structure of the complex between ARNO and 
EGFR can provide insights into the mechanism of ARNO dependant receptor activation. 
Protein crystallization and structure determination using x-ray diffraction provide an 
elegant method to generate structural data with very high atomic resolution.  
 
4.3.1 Analytical gel filtration analysis of the ARNO EGFR complex 
 
The formation of crystals suitable for x-ray diffraction analysis requires a pure and 
homogenous solution of the molecule of interest. For a co-crystal this involves the 
purification of a stable complex and the exclusion of single proteins from the crystal 
solution. Due to the higher molecular weight of the resulting complex, separation from 
monomers can be achieved via size exclusion chromatography (SEC).  
In order to evaluate the suitability of SEC for this purpose ARNO Sec7 and Arf1 were 
mixed and applied to a SEC column. The resulting elution profile shows a peak at 31 min 
while the single proteins elute after 34 min (ARNO Sec7) or 36 min (Arf1) respectively 
(Fig. 4.26b). The earlier elution indicates a larger complex with a molecular weight of 
approximately 44kDa (Fig. 4.26a). The size of the complex fits to a 1:1 complex between 
ARNO Sec7 and Arf1. Additionally both proteins elute after the same time as seen by SDS 
PAGE analysis (Fig. 4.26b). 
In contrast both EGFR ICD1022 and a mixture of the receptor with ARNO Sec7 result in 
the same elution profile with a peak after 33 min tailing towards later elution times (Fig 
4.26c). The close proximity of the monomer peaks make it difficult to evaluate complex 
formation by SDS PAGE since both proteins elute at approximately the same time and 
co-elution is no indication for complex formation. The juxtamembrane (JM) domain of 
EGFR is sufficient to interact with ARNO Sec7 (paragraph 4..2.7) and its small size makes 
it separable from the exchange factor via SEC. Hence, co-elution of ARNO Sec7 and EGFR 
JM in an analytical gel filtration experiment would indicate complex formation. 
However, the JM domain interacts with the matrix of the SEC columns making 
interpretation of these results difficult (Supplementary Figure 8). These results suggest 
that complex purification via SEC is not possible prior to crystallization. 
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Fig. 4.26 Analytical size exclusion chromatography (SEC) of ARNO Sec7 complexes.ARNO Sec7 was 
incubated with Arf1 (b) or EGFR ICD1022 (c) and separated on a Superdex 200 column. Peak fractions 
were collected and analyzed on SDS PAGE gels using Coomassie Brilliant Blue staining. A molecular weight 
standard was employed to evaluate the size of the eluting proteins/complexes (a). 
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4.3.2 Crystallization trials for ARNO Sec7 in complex with the juxtamembrane domain of 
EGFR 
 
Biochemical data suggests that the interaction between EGFR and ARNO involves and is 
dependant on the juxtamembrane (JM) domain of EGFR (paragraph 4.2.6 and 4..2.7). 
Furthermore, an intracellular EGFR construct containing the JM domain was not stable 
after purification (EGFR ICD1022, paragraph 4.2.4). Therefore, the initial crystallization 
screens were performed using a mixture of ARNO Sec7 with the JM domain of EGFR.  
Two ARNO Sec7 constructs were used that differ at their N-terminus. While ARNO Sec7 
52-256 is also used in other crystallization studies (130, 180), the shorter construct 
ARNO Sec7 61-246 represents the minimal functional domain as described in the 
studies. Both constructs are active in the exchange of nucleotides on Arf1 (data not 
shown) and crosslink to EGFR JM (Supplementary Figure 10). The JM peptide was used 
in molar excess to ensure saturation of ARNO Sec7 with the binding partner (from 2x to 
20x molar excess).  
For the shorter construct only one condition yielded crystals (Fig 4.27a) that could be 
reproduced and were suitable for further analysis. However, no x-ray diffraction was 
obtained from the crystals rendering them useless for the purpose of structure 
determination. 
The longer ARNO Sec7 constructs could be crystallized in the presence of EGFR JM under 
many different conditions (e.g. Fig 4.27b and c). Unexpectedly all crystals analyzed from 
that screening did not show an additional electron density apart from the ARNO Sec7 
structure indicating that either EGFR JM is not present in the crystal or it is too flexible 
to result in a clear diffraction pattern. 
These results show two potential problems that need to be addressed to optimize 
crystallization efforts: the complex between ARNO Sec7 and EGFR JM is either not stable 
enough to allow co-crystallization or the tendency of ARNO Sec7 to crystallize alone 
renders this effort difficult. 
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Fig. 4.27 Crystals obtained with ARNO Sec7 in the presence of EGFR JM. ARNO Sec7 61-246 was 
crystallized in the presence of 20x molar excess EGFR JM. Crystals appeared after 3 days (100mM NaOAc 
pH 4.6, 20mM CaCl2, 30% 2-methyl pentanediol) but show no diffraction (a). ARNO Sec7 52-256 
crystallized in the presence of 2x excess EGFR JM under several conditions (b: 100mM MES pH 6, 20% 
PEG6000; c: 200mM di-ammonium-tartrate, 20% PEG3350). 
 
4.3.3 N-terminal truncated ARNO Sec7 constructs show less efficient crystallization 
 
ARNO Sec7 61-246 could not form crystals under many different buffer conditions while 
the longer construct ARNO Sec7 52-256 crystallizes readily (paragraph 4.3.2). Reducing 
the chances of ARNO Sec7 to crystallize alone could increase the chances to obtain a 
crystal of the desired complex. Therefore, several intermediate N-terminal truncations 
of the longer construct were designed to test their crystallization behavior. 127 buffer 
conditions were employed to evaluate six different ARNO Sec7 constructs. 
Indeed a gradual decrease in the number of different conditions allowing for crystal 
growth is observed with reduction in N-terminal length (Fig. 4.28a). However, the 
crystals that do grow become visible after similar incubation times indicating that the 
kinetic of crystal growth is not impaired by N-terminal truncations.  
Using the shortest construct that still crystallized (ARNO Sec7 59-256) another screen in 
the presence of 2x molar excess EGFR JM was performed. ARNO Sec7 in the absence of 
EGFR JM was crystallized in parallel under all tested conditions. From 1152 tested buffer 
conditions, 166 supported ARNO Sec7 crystal growth and 51 conditions allowed for 
crystal growth in the presence of EGFR JM (Fig. 4.28b). However, 50 of those conditions 
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did not distinguish between the absence and presence of EGFR JM (Fig. 4.28b). 
Nevertheless the found crystals were reproduced if possible and analyzed using x-ray 
diffraction (two out of 6 suitable crystals are shown in Fig. 4.28c).  
None of the analyzed crystals yielded a structure with an additional electron density 
that represents the EGFR JM domain. These results indicate that a simple mixture of the 
two proteins might not be suitable to obtain the desired co-crystals. 
 
 
Fig. 4.28 N-terminal truncation of ARNO Sec7 results in less efficient crystallization. ARNO Sec7 52-
256 was successively shortened at the N-terminus in two amino acid steps. 112 different buffer conditions 
that allowed for crystal growth of the longest construct in many cases were used to study the 
crystallization behavior. Truncation of the N-terminus results in decreased number of conditions that 
support crystal growth (a). The constructARNO 55-256 precipitated readily and therefore did not yield 
many crystals. The construct ARNO 59-256 was employed in a screen with 2x excess EGFR JM and yielded 
several crystals that were dependent on the presence of EGFR JM (in the initial screen) and sufficiently 
large to analyze (b). Two different crystals are shown as an example that could be reproduced after the 
initial crystallization screen (c: 180mM tri-ammonium citrate, 20% PEG3350 left and 100mM MES pH 6, 
200mM CaAcetate, 20% PEG8000 right). 
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4.3.4 Genetic fusion of ARNO Sec7 to the EGFR JM domain 
 
Proteins that are not able to form a complex in solution that is stable enough to promote 
crystal growth can be expressed as a single fusion protein. The constructs both 
interaction partners separated by a flexible linker of amino acids that allows for 
conformational changes required for physiological arrangements. An example for a 
suitable linker can be found in the transcription factor Oct1 connecting the DNA binding 
domain and the transcriptional activator domain of this protein (181). Different variants 
of this amino acid sequence have successfully been used to stabilize and crystallize low 
affinity complexes (182).   
The JM domain of EGFR was fused to the N-terminus and the C-terminus of ARNO Sec7 
using three different linker lengths to create a total of 6 different constructs (Fig. 4.29a).  
Purity and quality of the constructs is important since long flexible parts like the 
employed linkers could lead to protein instability. However, purification of the different 
fusion constructs was possible and resulted in homogenous proteins (Fig. 4.29b). 
Moreover electrospray ionization mass spectrometry (ESI MS) analysis confirmed that 
the purified products have the expected molecular weight (Fig. 4.29c) making them 
suitable for crystallization. 
 
4.3.5 ARNO Sec7 genetically fused to EGFR JM as constructs for crystallization 
 
ARNO Sec7 modified with a flexibly attached EGFR JM domain at the C-terminus 
crystallizes under several different conditions (e.g. Fig. 4.30a). However, when 
modifying the N-terminus of ARNO Sec7 with the linker and EGFR JM sequence, 
crystallization is impaired. This is in accordance to the finding that the N-terminus of 
ARNO Sec7 is crucial for the formation of protein crystals (paragraph 4.3.2 and 4.3.3).  
To obtain suitable results, a micro seeding approach was employed to improve both size 
and quality of the crystals (Fig. 4.30b, for details see Materials and Methods).  
Suitable diffraction data for structure determination could be collected for all six 
different fusion proteins. However, again no electron density for the EGFR JM domain 
could be located in the structural models calculated with the obtained data.  
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Fig. 4.29 Fusion construct of the juxtamembrane domain of EGFR to ARNO Sec7. Using three 
different linker lengths (15, 23 and 37 amino acids, sequence depicted in (a), amino acids in brackets are 
only present in the long linker constructs), six constructs with EGFR JM connected to the N-terminus or 
the C-terminus of ARNO Sec7 were obtained. SDS PAGE analysis and Coomassie Brilliant Blue staining (b), 
and mass spectrometry (ESI MS, data summarized in c) confirmed the integrity of the fusion proteins. 
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Fig. 4.30 Crystals grown from ARNO Sec7-EGFR JM fusion proteins. C-terminal fusion of EGFR JM to 
ARNO Sec7 resulted in readily crystallizing constructs (a, Sec7-LL15-JM: 100mM BisTris pH 6.5, 200mM 
NaI, 20% PEG3350, Sec7-LL23-JM: 200mM Tri-Lithium-Citrate, 20% PEG3350, Sec7-LL37-JM: 100mM 
Tris pH 8.5, 200mM MgCl2, 20% PEG8000). In contrast fusion of EGFR JM to the N-terminus of ARNO Sec7 
reduced the ability to crystallize. Optimization of the initially found conditions via microseeding yielded 
crystals that were suitable for analysis (b, 100mM BisTris pH 6.5; 25% PEG3350; for details see 
Materials and Methods). 
 
4.3.6 Fusion of two copies of EGFR JM to ARNO Sec7 
 
It is yet unknown whether the EGFR interacts with ARNO in a 1:1 ratio. Several studies 
suggest that the juxtamembrane domain indeed forms dimers via its N-terminal JM-A 
part (13, 17). If dimer formation is required for interaction with ARNO, a fusion 
construct with a 1:1 ratio between ARNO and EGFR is not feasible to support complex 
formation. 
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To exploit this possibility, two copies of the EGFR JM domain were genetically fused to 
ARNO Sec7.  The two JM domains in these constructs are separated by a 23 amino acid 
linker sequence that is identical to one linker used to connect ARNO Sec7 with the first 
JM sequence (Fig. 4.31a). This linker length is sufficient to cross the distance required 
for JM-dimer formation as observed in NMR structures (17). 
It was not possible to express and purify a construct of two JM domains N-terminally 
fused to ARNO Sec7 (Fig. 4.31b). In contrast C-terminal fusion of two JM domains to 
ARNO Sec7 results in a protein that can be purified (Fig. 4.31c). Although the resulting 
product is not very pure it was successfully employed in crystallization. The obtained 
crystals yielded good diffraction patterns. However, no part of the EGFR JM domain or 
the linker sequence could be identified in the resulting structural models of the fusion 
proteins. 
 
Fig. 4.31 Fusion of two copies EGFR JM to ARNO Sec7. The employed constructs are illustrated in (a). 
Protein purification was followed by analyzing samples on SDS PAGE gels stained with Coomassie Brilliant 
Blue (b and c). Fusion of two EGFR JM copies to the N-terminus of ARNO Sec7 resulted in an unstable 
protein that could not be purified efficiently (b). Fusion at the C-terminus of ARNO Sec7 was possible. The 
molecular weight of the main species was found to fit to the expected fusion protein as verified by mass 
spectrometry. 
 
In summary x-ray crystallography was not successful to generate structures of a 
complex between ARNO and EGFR using the juxtamembrane domain as the interaction 
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partner for ARNO. Future studies should focus on different constructs or structural 
methods (e.g. NMR analysis) in order to circumvent the described problems.
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5 Discussion 
 
5.1 Screening for Arf6 specific small molecule inhibitors 
 
5.1.1 Purification of the constructs N13 Arf6 and JIP4 LZII 392-462 
 
While purification of N-terminally truncated Arf6 was straight forward, some 
optimization of the purification process was required for the JIP4 LZII domain. In 
contrast to the published protocol (156) I employed size exclusion chromatography 
(SEC) as the final step of the purification.  
While both the TEV protease (pI: 8,7) and other contaminating proteins could be 
removed by anion exchange chromatography as described by Isabet et al. (156), a high 
amount of free GST was still present after this purification step (data not shown, 
pIJIP4LZII: 4,7 pIGST: 5.7 GST). Not all of the free GST stayed attached to the glutathione 
matrix after over night digest. Therefore, it was a major issue to remove the remaining 
molecules. GST has a molecular weight of approximately 26 kDa and forms homodimers 
in solution (183, 184). The resulting difference in molecular weight between JIP4 LZII 
(18kDa/dimer, (156)) and the GST dimers (52kDa) made it possible to use size exclusion 
chromatography to separate both proteins and obtain pure JIP4 LZII. Two molecules 
that are supposed to be separated via SEC should have a molecular weight ratio of at 
least 2:1. In the described case the ratio is 2,9:1 and therefore suitable for successful 
separation. Indeed the purification data shows that both GST and other high molecular 
weight contaminations could be reduced using SEC (Fig. 4.1). One problem that 
remained with the modified method of purification was the TEV protease that was 
added for the cleavage of the GST-JIP4 LZII fusion protein. The molecular weight of the 
protease is approximately 27 kDa and therefore very close to the MW of a JIP4 LZII 
dimer. Hence, this protein was removed from the solution after cleavage but before SEC 
by incubation of the sample with NiNTA agarose matrix. The protease has a His tag for 
purification and can therefore be removed by incubation with such a matrix. The 
optimized protocol resulted in very pure JIP4 LZII in sufficient amounts for the high 
throughput screen and the following validation assays. 
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5.1.2 In vitrofunctionality of the purified Arf6 construct 
 
The Sec7 domain represents the common structural element in guanine nucleotide 
exchange factors (GEFs) for Arf GTPases. To test the activity of purified Arf6 I employed 
and in vitro exchange assay with the Sec7 domain of cytohesin 2 (ARNO). It is described 
that ARNO Sec7 has a higher in vitro exchange activity towards Arf1 than towards Arf6 
(136). However, Sec7 domains from two Arf GEFs that prefer Arf6 over Arf1 (EFA6 and 
GEP100) showed no activity on Arf6 in my hands (data not shown). Therefore, the assay 
was conducted using ARNO Sec7. In accordance with the literature the observed 
exchange activity was higher for Arf1 than for Arf6. However, the observed activity 
shows that the purified Arf6 construct is capable of binding to physiological interaction 
partners (161) and that nucleotide exchange occurs under appropriate conditions. 
Further evidence for a functional Arf6 construct is provided by the interaction assay 
with JIP4. The effector protein is able to discriminate between the active (GTP bound) 
and inactive (GDP bound) conformation of the GTPase. Moreover the Kd values observed 
are in accordance with published data using Surface Plasmon Resonance (SPR) 
technology. Moreover the affinity for active Arf1 was more than one order of magnitude 
lower than for Arf6, an observation that is also supported by the literature (Fig. 4.7, 
(156)). The obtained results suggest that the employed system of interacting proteins is 
suitable to resemble a physiological situation essential for Arf6 downstream signal 
transduction.    
5.1.3 Differences between GDP and GTP bound Arf6 in binding to JIP4LZII 
 
A clear discrimination between GDP and GTP bound Arf6 was possible in the JIP4 LZII 
based fluorescence polarization (FP) assay. However, the difference in affinity is lower 
that expected for GTPase-effector pairs. 
The binding site of Arf6 on JIP4 was determined to the region between amino acids347-
480(155) and later further reduced to amino acid 392-462 (156). However, it is not clear 
whether other parts of the protein play a role in discriminating between the active and 
inactive form of Arf6. In fact no binding studies were performed addressing this issue in 
the major publication describing the crystal structure of the GTPase-effector complex 
(156). The relatively small difference in binding affinity measured by fluorescence 
polarization could therefore bethe result of missing parts in JIP4that contribute to 
active/inactive discrimination under physiological conditions.  
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Another potential in vitro bias can be attributed to the GTPase side of the interaction. 
The Arf6 construct used in this study lacks the N-terminal 13 amino acids. In cells this 
part forms a small  helix that is lipid modified with a myristoyl moiety at glycine in 
position two of the protein. The lipid modified helix is involved in membrane binding 
and localization of Arf GTPases and plays an important role in the activation inside the 
cell (132, 185). The lack of the N-terminal helix allows for in vitro activity in the absence 
of membranes that are required for sufficient activation of full length Arf6.  
The effector binding site of small GTPases is located to switch I, switch II and the 
bridging interswitch region (Fig. 5.1 shows a crystal structure of Arf6 highlighting the 
important regions in both conformations). Furthermore, the N-terminal helix is part of 
the switch machinery that undergoes drastic conformational changes upon nucleotide 
exchange (101, 133, 152, 157). In the Arf6 GDP structure, the helix associates with the 
core molecule (152) thereby stabilizing a conformation that buries the interswitch 
region in the protein. GTP binding results in a translocation of the interswitch region 
and a reorientation of the N-terminal helix that forms lipid contacts in the presence of 
membranes (151). This explains the requirement of lipids for proper nucleotide 
exchange since the hydrophobic moieties exposed upon GTP association destabilize the 
protein conformation in the absence of lipid bilayers. 
The rather small differences in binding affinity of JIP4 LZII to active/inactive Arf6 can be 
explained in context of the lack of the N-terminal helix. The GDP bound conformation 
lacks the intramolecular contacts of the N-terminal helix. Hence, it is tempting to 
speculate that the resulting conformation is not stable and switches between the 
inactive form and an “active like” conformation that can still be recognized by effector 
proteins. Indeed it was shown that N13 Arf6 GDP is partially unstructured in solution 
(186) supporting the idea of a heterogeneous mixture of different conformations. This 
could explain the small difference in the observed affinities for active and inactive Arf6 
that is not expected considering other known GTPase-effector pairs like Ras and the Ras 
binding domain of Raf (187).  
Further experiments are required to support these hypotheses. Full length 
myristoylated Arf constructs in the presence of membrane models, e.g. liposomes or 
NanoDiscs, and longer constructs of JIP4 provide a system that is closer to the 
physiological situation. This could elucidate the binding of both proteins and the 
differences between active and inactive Arf6 in effector recognition. 
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Fig 5.1 Crystal structures of Arf6 in the “active” and “inactive” conformation. The cartoon 
representation illustrates conformational changes observed upon nucleotide exchange in the GTPase Arf6. 
The most prominent features undergoing conformational rearrangement are: the N-terminal helix 
(green), switch I (purple), switch II (red) and the interswitch region (orange). Structural models: PDB 
1EOS (152), PDB 2J5X (151). 
 
5.1.4 Differences between the FP assay and the pulldown assay 
 
While in the FP assay only a small difference in binding of active and inactive Arf6 to 
JIP4 LZII is observed, the pulldown assay employed in paragraph 4.1.6 shows that only a 
negligible amount of GDP bound Arf6 can be precipitated with immobilized JIP4 LZII. 
Insufficient loading with the respective nucleotide in the FP assay can be excluded by 
employing constitutively active or inactive mutants of Arf6 (Q67L and T44N 
respectively). Both constructs show binding as the wild type preloaded with the 
respective nucleotide (Supplementary Fig. 1). Hence, other factors seem to contribute to 
the differences observed in the pulldown and FP assay. A major difference between the 
two assays is that the pulldown works with immobilized, GST tagged JIP4 LZII while the 
FP assay is performed in a homogenous solution with only slightly altered JIP4 LZII. It is 
possible that immobilization of the effector or the GST tag itself has an influence on the 
binding of GDP bound Arf6. 
Another possibility could be that kinetic aspects of the binding play an important role in 
the discrimination between active and inactive Arf6. If GDP bound Arf6 has a very fast 
off rate (koff) when binding the effector JIP4, it is possible that the bound GTPase 
dissociates from the immobilized effector in the pulldown assay during the required 
wash steps of the assay. In contrast the same off-kinetic would result in a reasonably 
high dissociation constant in a homogenous steady state assay like the FP assay given an 
equally fast on kinetic (kon). Since Kd = koff/kon, a protein-protein complex with a low Kd 
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value can still dissociate with high frequency and therefore appear not stable in a 
pulldown assay. A fast intramolecular dynamic induced by an unstable conformation 
could be one explanation for a fast dissociation for Arf6 GDP (see paragraph 5.1.3). The 
observed binding event might actually represent a mixture of several interactions with 
the inactive conformation of Arf6 as one extreme and an “active like” conformation due 
to the missing N-terminal helix as the other. In a steady state assay (like FP) this results 
in an average of the combined affinities. In contrast in a pulldown assay low affinity 
intermediates can get lost during wash steps and do not contribute to the observed 
association with the effector. The obtained results would argue for an unstable complex 
between 13 Arf6 GDP and immobilized JIP4 LZII that might be caused by structural 
artifacts due to the missing N-terminal  helix. 
 
5.1.5 The concept of the screening assay 
 
Arf GTPases have crucial functions in cells. They regulate membrane traffic along the 
secretory and endosomal pathway ensuring a tight balance of transport processes. From 
all mammalian Arf proteins Arf6 is the most distantly related one. Although it shares 
67% sequence identity with Arf1 (188) it represents a special case. Knock down of single 
class I or class II Arf isoforms shows no severe membrane traffic phenotype indicating 
that their functions are partially redundant (110). In contrast, Arf6 is the sole member of 
class III Arf proteins and is involved and essential in diverse processes from membrane 
traffic and endocytosis to cytoskeletal organization and transport (96). Therefore, Arf6 
is an interesting protein for cell biological research and small molecule inhibitors 
suitable for in vivo studies are of great interest in the scientific field (142, 143). However, 
all known inhibitors for Arf GTPases target the GTPase before or during their activation 
(128, 138, 141). Thereby they prevent the initiation of downstream effector signaling by 
indirect inhibition of the GTPase. Most GEFs have some intrinsic specificity towards 
certain Arfs, however, they rarely act on only one (96, 136). By inhibiting the upstream 
activator it is very likely to obtain “off target” effects that lead to difficulties in the 
interpretation of experimental data from complex systems like cells or animals. 
Although inhibitors like SecinH3 are excellent tools to study GEF biology, a direct 
correlation with the activity of a specific GTPase is hardly possible (138, 146). 
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For a more specific inhibition it would be beneficial to directly target the GTPase of 
interest and inhibit downstream signaling from this step on. Signal transduction via 
small GTPases always involves downstream effector proteins that associate with the 
active conformation of the GTPase. The structural features responsible for effector 
binding of Arf proteins are the switch I, switch II and interswitch regions (Fig. 5.1). 
Although the detailed interactions are distinct for different effector proteins the general 
binding site is limited to the mentioned elements. This leads to overlapping binding sites 
of different effectors (156, 189) and suggests that binding of one protein prevents the 
association of another (Fig. 5.2). Hence, by blocking the general binding site for effector 
proteins it can be possible to prevent downstream signaling in general. In contrast to 
many other Arf effectors, JIP4 shows a high degree of specificity towards binding of Arf6 
(156), hence it occupies and blocks the Arf6 effector binding site but not that of other Arf 
isoforms. Indeed pulldown analysis shows that soluble JIP4 LZII can displace an effector 
from Arf6 but leaves the interaction between Arf1 and GGA3 intact (paragraph 4.1.6). 
This supports the hypothesis of a specific binding site block for Arf6. Small organic 
compounds that displace JIP4 LZII from Arf6 and obtain the mentioned characteristic 
have the potential to act as Arf6 downstream signaling inhibitors. However, it is also 
possible to identify compounds that specifically disturb the JIP4 interaction with Arf6 
but no other effector binding. In this case a less general Arf6 inhibitor would result. 
 
 
Fig. 5.2 Occupancy of the switch and interswitch regions of Arf GTPases by different effector 
proteins. The proteins JIP4 (PDB 2W83 (156)) and GGA3 (PDB 1J2J (189)) cover similar binding sites at 
the respective Arf GTPase. Indicated features: switch I (purple), switch II (red), interswitch region 
(orange), effector protein (cyan). 
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5.1.6 Results of the screen and challenges in finding PPI inhibitors 
 
The search for small molecule inhibitors involves using big libraries of “drug like” 
compounds that can be systematically tested for their activity in a suitable assay. In this 
study a fluorescence polarization based assay was employed to monitor the binding 
between Arf6 and its effector JIP4. Throughout the screening of 17000 compounds the 
assay proved to be stable and the overall Z’ value obtained was 0.85, which is very close 
to the initial test results of 0.9 indicating an excellent performance of the assay under 
real HTS conditions. The obtained values were stable even over night at room 
temperature. To summarize the FP assay performed robustly in a HTS setup and 
screening of approximately 1000 compounds per day was possible although this value 
could easily be increased when using a full automated pipetting setup. 
Nine small molecules were identified as primary hits leading to a hit rate of 0.06%. This 
value is in the normal range for published HTS approaches (190). The primary hits were 
identified as false positives using a fluorescence free pulldown assay. The effect of the 
compounds on JIP4 LZII binding to Arf6 monitored in the FP assay was not confirmed 
when both proteins are co-precipitated. Indeed, the identified hit molecules exhibit an 
intrinsic fluorescence in the spectral range of fluorescein. This can be a major reason for 
false positive results when using fluorescence polarization. Therefore, an independent 
assay is required to verify compounds with suspiciously high fluorescence. The well-
known molecule thalidomide shows striking similarity to one of the identified hit 
compounds (KR2 3H8). However, in contrast to the screening hits it has no intrinsic 
fluorescence and shows no effect in the fluorescence polarization assay further 
supporting that the screening hits are false positives.  
No inhibitors for the JIP4 interaction with Arf6 could be identified in this study. Protein-
protein interactions (PPIs) pose a general problem for drug discovery. Today’s 
compound libraries are dominated by the drug discovery efforts of the past that were 
focused on GPCRs and enzymes (191). Some features of such drug-like small molecules 
are summarized by the “Lipinski rule of 5” and include the molecules to be not bigger 
than 500Da (192), a characteristic that decreases the chance to disturb a large PPI 
interface. Therefore, compounds employed in traditional screening approaches are not 
well suited for the discovery of PPI inhibitors and large libraries are required to find 
suitable hits (193). Although several studies exemplify that successful identification of 
PPI inhibitors is possible, the screening efforts behind the resulting compounds involved 
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large libraries and the logistic and financial support of big companies (194, 195). 
Moreover in contrast to other “druggable” protein-protein interactions (196) the JIP4-
Arf6 interface is devoid of clear hotspots (156) indicating a more general contribution of 
the whole binding surface. This requires even more specialized and optimized libraries 
(e.g. by using larger molecules or natural products) to find hits that specifically disturb 
such interaction.  
The studied interaction shows features that make it difficult to be targeted by small 
molecules when using traditional compound libraries for screening. However, distinct 
approaches were developed to tackle protein-protein interfaces in a specific manner. 
 
5.1.7 Alternative approaches for the identification of protein-protein-interaction (PPI) 
modulators 
 
Finding small molecule inhibitors for protein-protein-interactions (PPIs) is challenging 
and successful identification usually requires specialized compound libraries of 
sufficient size. A different class of molecules suitable for disturbing PPIs are stabilized  
helical peptides designed with knowledge of the complex interaction surface. The 
interface involved in PPIs often contains  helical elements (197) and  “hot spot” 
residues that are especially important for the interaction. Disturbing the binding site 
with small peptides that resemble crucial elements of the interface is therefore a 
promising approach in PPI inhibitor development. With this methods it was possible to 
inhibit the formation of a competent NOTCH transcription factor complex using 
hydrocarbon stapled  helical peptides (198) or prevent the activation of Ras by its GEF 
Sos with the help of hydrogen bond surrogate helices (199).  
One method involves intramolecular covalent connections between non-adjacent 
backbone carbon atoms that replace a hydrogen bond formed between position i and 
i+4 in an -helical structure (200, 201). Another approach confers helical properties by 
the introduction of artificial amino acids at appropriate positions in the primary 
sequence (198, 202). Modification of the resulting peptides is possible to optimize cell 
permeability or reduce side effects or toxicity (203). An active endocytic pathway 
facilitates the cellular uptake of peptides and enables intracellular effects without 
resulting in endosomal degradation due to high proteolytic resistance of the peptides 
(198, 199). 
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The JIP4 LZII binding site forms a helical coiled coil domain (156) and hence represents 
a potential example for employing a short stabilized peptide to disrupt the Arf6-JIP4 
complex. However, the formation of a JIP4 dimer is required for efficient binding to Arf6 
since amino acids from both monomers make contact to one GTPase. To obtain a 
molecule that inhibits general effector association by blocking the binding site at Arf6, a 
peptide helix mimic needs to contain crucial elements for dimer formation as well as for 
Arf6 binding. The amino acids from position 412 to 424 of JIP4 form the major 
hydrophobic interface involved in the interaction with Arf6. Additional residues make 
hydrophilic contacts to Arf6 via hydrogen bonds. Hence, the minimal JIP4 motif 
containing all amino acids involved in binding spans position 412 to 432 (156). 
However, a peptide of 20 amino acids could pose problems regarding membrane 
permeability and limit the potential modifications due to the final size of the molecule. It 
is crucial to balance size and affinity in designing small  helical peptide mimics that can 
be suitable for blocking the Arf6 interface responsible for effector binding. In contrast to 
other Arf binding partners (189), there is no obvious “hot spot” residue essential for the 
interaction with JIP4. Therefore, selective removal of single residues is not expected to 
abolish binding but rather only slightly reduce the affinity.  
Helical peptide mimics represent a promising alternative to small organic compounds 
when targeting PPIs. The JIP4 LZII binding to Arf6 shows some features that are also 
found in interactions that have been successfully disturbed by this method. Thus using 
peptide mimics is a promising approach to obtain inhibitors for Arf6 downstream signal 
transduction.  
 
 
Fig. 5.3 JIP4 LZII dimer with highlighted structural features involved in Arf6 binding. Two molecules 
JIP4 LZII form a coiled coil structure that is stabilized by leucine residues (yellow stick representation). 
The amino acids colored in red (sticks) are involved in the binding to Arf6. The highlighted regions (pale 
purple and light blue) represent fragments of the protein that could be employed to design a small peptide 
inhibitor (for detail see text). PDB 2W83 (156). 
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5.1.8 Summary I 
 
It was possible to purify functional Arf6 and JIP4 LZII of high quality that could be 
employed to establish a HTS assay. During a screen of 17000 compounds the assay was 
stable and proved to be robust in the presence of most of the small molecules. Although 
no inhibitor for the interaction of Arf6 with JIP4 was identified, the system is readily 
applicable for screening of bigger or more specialized compound libraries that are 
optimized for finding protein-protein interaction inhibitors. Moreover it is a convenient 
and reliable tool to test modulators of the interaction in vitro (e.g. peptide inhibitors). 
Furthermore, an interesting observation is that JIP4 LZII only weakly discriminates 
between active and inactive Arf6. This either represents a physiological peculiarity of 
the interaction or points to an important structural role of the N-terminal helix in Arf6 
to confer specificity in active and inactive conformations. 
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5.2 Structural and biochemical analysis of the interaction between EGFR and 
ARNO 
 
5.2.1 Inactivation of the EGFR kinase construct increases its stability in solution 
 
The purification of constructs for crystallography was straightforward for ARNO Sec7. In 
contrast the EGFR intracellular domain (including the juxtamembrane (JM) region, 
ICD1022) was unstable after purification and visibly precipitated when stored at 
concentrations suitable for crystallography. Investigation of the thermal stability in a 
fluorescence based thermal shift assay revealed that the presence of the JM domain 
results in a decreased melting temperature when compared to the JM free intracellular 
EGFR (KC1022). Since the JM domain is crucial for kinase activity of the soluble receptor, 
one can speculate that an “active” conformation causes protein instability. Different 
conformations are required to enable phosphotransfer catalyzed by protein kinases 
(32). While the ones represented in crystal structures are likely stable, some others 
could result in destabilized proteins in the absence of factors that are present in the cell 
during the physiological process. 
This idea is supported by the fact that addition of a non-hydrolysable ATP analogue 
(AMPPNP) stabilizes EGFR ICD1022 leading to an increase in the melting temperature 
observed in the assay mentioned above. AMPPNP blocks the catalytic cycle of the kinase 
in a pre-phosphotransfer step thereby prohibiting conformations that occur afterwards. 
Furthermore, it is important to mention that crystal structures of the EGFR intracellular 
domain are generated with inactive forms of the kinase by either omitting the JM 
domain from the protein (13, 77), adding small molecule inhibitors (76) or by 
introduction of inactivating mutations (15). In accordance with the published 
information regarding the EGFR constructs employed for crystallization the EGFR 
mutant K745M was stable after purification in the presence of the JM domain.  
The mutant EGFR construct is promising for the generation of co-crystals with ARNO 
Sec7 since it still binds to the exchange factor as shown by crosslinking and exhibits 
increased stability.  
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5.2.2 Activity of the purified EGFR constructsin vitro 
 
The purified EGFR construct intracellular domain 1022 (ICD1022) contains the 
juxtamembrane (JM) domain and is therefore expected to be competent to 
phosphorylate substrate proteins. Indeed it was shown that the purified protein 
phosphorylates the SH2 domain of phospholipase C, a natural substrate of the kinase. 
Furthermore, autophosphorylation of Tyr1016 is observed indicating full functionality 
of EGFR ICD1022 both as a kinase and a substrate. In accordance with published data it 
was shown that the juxtamembrane (JM) domain is essential for efficient 
phosphorylation of substrates by EGFR since the construct kinase core 1022 (KC1022) 
shows only weak catalytic activity. These results demonstrate that the recombinantly 
expressed EGFR variants employed in this study behave similar to full length constructs 
in cellular assays (13). Therefore EGFR ICD1022 and EGFR KC1022 are suitable to study 
receptor biochemistry using purified components. 
 
5.2.3 The juxtamembrane domain is the binding site for ARNO at EGFR 
 
The juxtamembrane (JM) domain of EGFR is a crucial structural element in the 
activation of the kinase (13, 15). Interestingly binding of the positive EGFR regulator 
ARNO is also dependent on the presence of the JM domain indicating that it either 
directly involved as a binding site or indirectly influences the conformation of the 
receptor to associate with ARNO. Crosslinking assays with the isolated JM domain as 
well as JM-containing and JM-devoid EGFR ICD constructs show that this receptor part is 
both required and sufficient for ARNO binding showing that the JM domain represents a 
direct binding site. However, it cannot be excluded that other structural features of the 
receptor modulate binding. 
It was shown that ARNO induces a conformational change in EGFR (145) suggesting that 
an active conformation is induced. The JM domain indeed is also a crucial element in the 
negative control of EGFR activity in a cellular environment by association with the 
plasma membrane, thereby preventing the formation of an asymmetric dimer (17, 18). 
The direct interaction of ARNO with the JM domain suggests a role in facilitating the 
required reorientation of the JM domains. However, more detailed knowledge of the 
interaction on a structural level is required to support this hypothesis.  
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Negative feedback in a cellular system is mediated via the JM domain as well. 
Phosphorylation of Thr654 and Thr669 by PKC or Erk respectively leads to reduction of 
EGFR activity (9, 85). By blocking access of these regulatory kinases through sterically 
blocking the JM domain, ARNO could inhibit the negative feedback and thereby sustain 
the response of EGFR after activation. 
However, ARNO Sec7 has a direct effect on the activity of the purified EGFR intracellular 
domain (145) indicating that conformational stabilization of the active conformation 
also occurs in absence of membranes or other regulatory molecules. Therefore, a 
potential role of ARNO in EGFR activation can affect several aspects in the cellular 
context. 
 
5.2.4 ARNO binds to EGFR independent of the activity of both proteins 
 
It was previously shown that the exchange activity of ARNO is not required for its effect 
on EGFR. A catalytically inactive mutant still increases EGFR phosphorylation levels 
inside the cell and stimulates autophosphorylation in an in vitro assay (145). Studies in 
the presence of the ARNO Sec7 inhibitor SecinH3 support these finding since addition of 
the inhibitor does not influence crosslinking efficiency (Supplementary Figure 2) while 
it inhibits EGFR activity in cells (145). Neither the known catalytic function nor binding 
to the receptor alone can explain the effect of ARNO on EGFR signaling. Hence, a so far 
unknown conformational or catalytic mechanism that is inhibited by SecinH3 but not 
simply explained by steric hindrance could cause the observed effects. 
Moreover the catalytic activity of EGFR is also not required for the interaction with 
ARNO Sec7. Both the inactive mutant K745M and addition of AMPPNP (Supplementary 
Figure 3) has no influence in the crosslink assay. This indicates that ARNO binding 
occurs even to intrinsically inactive receptors, a mechanism that could be important to 
position the activator at its target to ensure rapid response after external stimulation. 
Additionally, phosphorylation of the EGFR in the presence of ATP has no effect on the 
interaction with ARNO (Supplementary Figure 3), further supporting the idea of an 
association that is not dependent on receptor activation. 
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5.2.5 The C-terminus of ARNO Sec7 is an important crosslinking site for EGFR 
 
By systematically removing lysine residues in the ARNO Sec7 domain it was possible to 
deplete the protein of crosslinking sites in certain surface areas. Evaluation of 
crosslinking efficiency allowed for classification of the residues regarding their 
importance in the assay. This can be used to obtain indirect information about the 
binding site in for EGFR on ARNO. Since the reagent employed for crosslinking in this 
study (Bissulfosuccinimidylsuberate) only tolerates two residues to be separated by 
11.4 Å, an important residue has to be close to or at the actual binding site. 
Only one single lysine was identified as an important crosslinking site (Lys 244). The 
mutation of other lysines has no effect on crosslinking. It is important to mention that 
the evaluation of N-terminal lysine mutations is difficult. They result in proteins that are 
difficult to purify due to precipitation. Furthermore, crosslinking results with different 
EGFR constructs are not consistent. While a reduction in crosslinking is observed for 
ARNO Sec7 and EGFR JM, EGFR intracellular domain crosslinks are not influenced.  
Additionally a dramatic increase in homodimerization and a severe reduction of 
exchange activity (Supplementary Figure 4) indicates that these constructs aggregate 
and are therefore not suitable for the experiments.  
Although the reduction in crosslinking efficiency is modest it is striking that only 
removing Lys 244 shows an effect while lysines located in the middle or C-terminal part 
of ARNO Sec7 do not contribute to crosslinking. This indicates that binding of EGFR 
takes place at the C-terminus of the Sec7 domain.  
 
5.2.6 A preliminary model for the interaction between EGFR and ARNO 
 
ARNO increases the autophosphorylation of EGFR (145). Therefore, one can expect that 
it bind to the receptor while leaving the active conformation intact or even inducing it. 
Active EGFR is characterized by the formation of an asymmetric dimer that allows one 
monomer (activator kinase) to stimulate the other (receiver kinase) (76). It was further 
demonstrated that the EGFR JM domain is essential for stabilizing this conformation (13, 
15). Fig. 5.4 shows an EGFR dimer and illustrates how the JM domain of the receiver 
kinase makes contact with the C-lobe of the activator. While the binding interface of the 
JM domain with the other kinase is not available for interaction with ARNO, the opposite 
site can be engaged.  
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Modification of the N-terminus of EGFR JM constructs with either fluorescein or biotin 
results in a reduction of crosslinking (Supplementary Figure 5). Furthermore, the only 
lysine in this construct is located at position ten of forty amino acids. This locates 
potential crosslinking sites to the N-terminal region of EGFR JM. In addition to the 
information from paragraph 5.2.5 one can speculate that the N-terminus of EGFR JM is 
close to the C-terminus of ARNO Sec7 when crosslinked. However, both JM-A (N-
terminal part) and JM-B (C-terminal part) of the juxtamembrane domain are required 
for efficient crosslinking (Supplementary Figure 6) indicating a larger interaction site 
with a head-to-tail conformation of ARNO Sec7 and EGFR JM. Taking into account that 
the isolated JM domain of EGFR influences the nucleotide exchange catalyzed by ARNO 
Sec7 on Arf1 it is reasonable to assume that the receptor and the GTPase have similar 
binding sites. The helices F, G and H in ARNO Sec7 create a hydrophobic grove that 
serves as the binding site for Arf1 (204). The C-terminus crosses this grove and Lys 244 
is aligned in close proximity to it (Fig. 5.4). If the EGFR JM domain associates in a head-
to-tail conformation with ARNO Sec7, it would nicely fit into the hydrophobic grove 
generated in ARNO Sec7. Therefore, it might compete with Arf1 for binding and explain 
the observed inhibition of nucleotide exchange. Indeed several hydrophobic residues 
are located in EGFR JM that are not involved in formation of the asymmetric dimer and 
can therefore be engaged in association with the hydrophobic grove in ARNO Sec7 (Fig. 
5.4). It is important to note that three leucine residues located in the LRRLL-motif close 
to the C-terminus of JM-A are buried in the plasma membrane in inactive receptors (17, 
18). This disturbs the formation of an asymmetric dimer and engaging the LRRLL motif 
in an interaction outside the lipid bilayer could result in release of the inhibition. Indeed 
NMR studies suggest that the leucines form an antiparallel JM-A helix dimer thereby 
facilitating the receptor activation by releasing the helices from the plasma membrane 
(13, 17). It is tempting to speculate that ARNO has a similar effect on receptor 
conformation. Both release of inhibition by membranes and stabilization of the 
asymmetric dimer via association with the JM domain to cover hydrophobic residues 
can lead to increased catalytic activity. 
This hypothesis needs confirmation by studies performed in a membrane environment. 
NanoDiscs or liposomes can serve as in vitro model systems and allow to gain a more 
detailed understanding of how lipids and membrane recruitment influence the 
interaction. Furthermore, structural studies can yield information about the complex 
between ARNO and EGFR in atomic detail.  
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Fig. 5.4 Crystal structures of ARNO Sec7-Arf1 and the EGFR asymmetric dimer. A: A hydrophobic 
grove formed by the helices F,G and H in ARNO Sec7 (dark green helices in ARNO Sec7 colored in pale 
green) serves as the binding site for Arf1 (blue). The magnified region (grey box in overview) shows a 
loop in Arf1 (orange) that interacts with this grove. The important crosslinking site Lys244 in ARNO Sec7 
is shown as a red stick representation. PDB 1R8Q (204) B: The JM domain of the acceptor kinase (orange) 
contacts the C-lobe of the donor kinase (blue) in the EGFR asymmetric dimer. The magnified region (grey 
box in overview) shows hydrophobic residues in the EGFR JM domain (green stick representation) that 
are not involved in asymmetric dimer formation and could therefore make contact to the hydrophobic 
grove in ARNO Sec7. The only lysine in EGFR JM is shown as a red stick representation. PDB 3GOP (15). 
 
5.2.7 Purification of complexes by size exclusion chromatography and initial 
crystallization trials 
 
Size exclusion chromatography (SEC) is often employed to separate a complex of two 
proteins from the monomers for crystallization. This was not successful for ARNO Sec7 
and the different EGFR constructs from this study. Interestingly the EGFR construct 
alone elutes as a monomer, which is in contrast to published data suggesting a stable 
receptor dimer for proteins containing the JM domain (13). Hence, it is not unambiguous 
to conclude whether a complex between ARNO Sec7 and the intracellular domain of 
EGFR is formed. However, no separation from the monomers is possible.  
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Furthermore, the JM domain of EGFR shows no interaction with ARNO Sec7 in a SEC 
experiment (Supplementary Figure 8). It is important to note that no elution peak was 
observed for the JM domain alone during the measurement. This indicates an unspecific 
interaction of the peptide with the size exclusion matrix and makes drawing conclusions 
regarding the interaction of ARNO Sec7 with EGFR JM difficult.  
Nevertheless no complex was purified and crystallization condition screens were 
performed with solutions containing ARNO Sec7 and EGFR JM in different molar ratios. 
Up to 20 times excess of EGFR JM was added to drive the equilibrium towards the ARNO 
Sec7-EGFR JM complex. Unexpectedly depending on the ARNO Sec7 construct, no well 
diffracting crystals were obtained (ARNO Sec7 61-246) or only ARNO Sec7 was resolved 
in the electron density (ARNO Sec7 52-256). This implicates two problems: 1) the N-
terminal helical part of ARNO Sec7 is important for crystal package and 2) ARNO Sec7 
with the N-terminal helix crystallizes readily, thereby potentially prohibiting the 
formation of a crystal in complex with EGFR JM. Problems for the co-crystal formation 
arise if the interaction is rather transient and ARNO Sec7 crystallization removes free 
protein from the solution that in turn can no longer form the desired complex (Fig. 5.5). 
 
 
Fig. 5.5 Different equilibria that influence the formation of an ARNO Sec7 EGFR JM co-crystal. ARNO 
Sec7 alone crystallizes readily (1). Thus, free protein is removed from the solution that can no longer bind 
to EGFR JM (3). Hence, the chances to obtain a co-crystal (2) are reduced. Shifting the equilibria (1) and 
(3) by reducing the ability of ARNO Sec7 to crystallize (paragraph 5.2.8) or increasing the local 
concentration of EGFR JM at ARNO via genetic fusion of the interaction partners (paragraph 5.2.9) could 
promote the formation of desired crystals. Free EGFR JM can only diffuse into an Apo-crystal of ARNO 
Sec7 if the binding does not destroy the crystal packing (4).  
 DISCUSSION  
 92 
5.2.8 Crystallization of N-terminal truncated ARNO Sec7 constructs 
 
One option to solve the potential problems illustrated in Fig. 5.5 is to employ ARNO Sec7 
constructs that show less efficient crystallization. From the results obtained with ARNO 
Sec7 61-246 it is clear that the N-terminal part is critical for crystal formation. The 
intermolecular contacts observed in the ARNO Sec7 crystal explain the contribution of 
the N-terminus (Fig. 5.6). It is involved in forming contacts with neighboring monomers 
in the crystal lattice and thereby promotes structured association of single molecules. In 
order to obtain ARNO Sec7 construct that crystallize less frequently we designed 
constructs with successive truncation of the N-terminus. Crystallization trials 
demonstrated that the truncated construct indeed formed crystals less frequently. With 
a reduced crystallization rate of ARNO Sec7 alone we anticipated that a complex is more 
likely to form. However, co-crystallization with EGFR JM did not yield crystals that 
contained both proteins. The resulting structure models show no electron density apart 
from ARNO Sec7. 
It was possible to show that the N-terminal region of ARNO Sec7 (amino acids 52-261) is 
crucial for crystal formation. Nonetheless shifting the crystallization equilibrium of the 
protein by N-terminal truncation did not have the desired effect on co-crystallization.   
 
5.2.9 Fusion constructs allow for stabilization of transient complexes 
 
A transient complex is difficult to crystallize since a constant pool of homogenous units 
(in our case ARNO Sec7-EGFR JM complexes) is required for a crystal lattice to form. 
Therefore, stabilization of the complex was achieved by genetically linking the 
interaction partners. This results in a dramatic increase in the local concentration of 
both proteins and should enhance complex formation. A flexible amino acid linker is 
found in the transcription factor Oct-1. A detailed study on the function of the linker 
regions shows that different linker length are suitable to connect two domains and still 
allow complex conformational rearrangements required for protein function (181). 
Fusion of two low affinity interaction partners via a linker region designed from this 
example was successfully employed to obtain crystal structures of protein complexes 
(182). Therefore, ARNO Sec7 was genetically fused to EGFR JM both at its N-terminus 
and C-terminus in order to stabilize the interaction and increase the chance of crystal 
formation. Using three different linker lengths I tried to balance the flexibility required 
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for productive interaction of the fused proteins and the negative effects that flexible 
parts in a protein can have on crystallization.  
The purified constructs were active in nucleotide exchange on Arf1 albeit to a lesser 
extend than wild type ARNO Sec7. Indeed C-terminal fusion of EGFR JM to ARNO 
resulted in a reduction of activity below 25% (Supplementary Figure 4). This is in 
accordance with the inhibitory effect of soluble EGFR JM on the exchange reaction (Fig. 
4.25) and suggests that the fusion constructs allow normal interaction of ARNO Sec7 
with EGFR JM. In contrast the N-terminal fusion of EGFR JM shows a less pronounced 
exchange inhibition (Supplementary Figure 4). These observations support a binding 
model, in which the C-terminal part of ARNO Sec7 makes contact with the N-terminus of 
the JM domain. This conformational rearrangement is facilitated by the tail-to-head 
orientation in the C-terminal fusion proteins. Simple folding back of EGFR JM towards 
ARNO Sec7 results in proper orientation of the proteins. In contrast the N-terminal 
fusion proteins exhibit a larger separation of the potential interaction sites making 
proper binding less likely. Supported by the crosslinking data that argues for an 
important contribution of the C-terminus of ARNO Sec7 and the N-terminus of EGFR JM 
it is possible to speculate that the binding site is actually located near the C-terminus of 
ARNO Sec7. 
 
5.2.10 How ARNO Sec7 crystallizes in the presence of other proteins 
 
The functional ARNO Sec7 construct fused to EGFR JM was than employed for 
crystallization. Suitable crystals were obtained for all six constructs (three linker length 
both N-terminal and C-terminal). However, crystal growth was less efficient for the N-
terminal fusion proteins. This further illustrates the importance of the N-terminus in 
ARNO Sec7 crystallization.  
All structural models generated from the analyzed crystals exhibited no electron density 
that could be attributed to the EGFR JM domain. Indeed the electron density nicely 
resembled published structures (129, 179) and no part of the linker or EGFR JM domain 
was observed for the C-terminal fusion proteins. Up to two amino acids from the linker 
region could be modeled into the electron density map from N-terminal fusion proteins. 
Although this indicates the presence of an N-terminal extension on ARNO Sec7, no 
information regarding the protein complex structure can be deduced from these results.  
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The linker region and the EGFR JM domain account for up to 80 amino acids in the 
fusion constructs (or 140 amino acids for the double JM fusion construct). Thus, they 
represent 30% (up to 40%) of the proteins molecular weight. How is it possible that 
such a big part of the protein cannot be found in the electron density map calculated 
from well diffracting crystals? The parts of a protein that become visible in the electron 
density of a solved crystal structure need to have the same or a very similar position in 
the repeating unit cell of the crystal lattice. If a part of the protein is very flexible it can 
have a different orientation in each unit cell, thereby generating no productive 
diffraction. This results in a lack of electron density in the structural model. The 
orientation of monomers in the ARNO Sec7 crystal leaves a big water filled cavity (129, 
179) and the C-terminus of the protein is pointing towards this “free” space (Fig. 5.6). 
Therefore, the ARNO Sec7 structure can tolerate a flexible part at its C-terminus by 
allowing the localization in the cavity. Extensions at the N-terminus are not directly 
released in the cavity (Fig. 5.6). However, the high flexibility of the employed linker 
region could account for the possible reorientation leading to a conformation that still 
allows for ARNO Sec7 crystal formation. The fact that the N-terminal EGFR JM-ARNO 
Sec7 fusion constructs proved to be more difficult to crystallize supports this 
hypothesis. 
 
 
Fig. 5.6 Crystal packing of an ARNO Sec7 crystal. Single ARNO Sec7 molecules are colored in different 
shades of blue. The left view illustrates that the crystal packing forms a solvent filled cavity. The C-termini 
of single ARNO Sec7 molecules (green sphere representation) are released into this cavity. EGFR JM 
domains fused to the C-terminus of ARNO Sec7 can thus be located there without disturbing the crystal 
packing. The N-termini (red sphere representation) make intermolecular contacts in the crystal packing. 
Hence, modifications at this position disturb crystal formation. However, a sufficiently long flexible linker 
sequence can still allow fusion of EGFR JM to the N-terminus of ARNO Sec7. PDB 1PBV (180). 
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Alternative structural biology approaches include nuclear magnetic resonance (NMR) 
and mass spectrometry (MS) based analysis of crosslinking products. NMR has the 
advantage of determining macromolecular structures in solution. Hence, it avoids the 
problem of difficult to crystallize protein complexes as observed for ARNO Sec7 and the 
EGFR JM domain. Crosslinking of the complex followed by protease digest and MS 
analysis can also be used to obtain detailed information about a protein-protein-
interaction interface (204, 205). This technique is convenient to verify the lysine 
mutagenesis results and obtain a structural picture of the interaction when combined 
with introducing novel crosslinking sites by mutagenesis.  
 
5.2.11 Summary 2 
 
Although crystallographic studies aiming to solve the structure of an ARNO-EGFR 
complex were not successful, it was possible to obtain more information about the 
underlying interaction. The juxtamembrane (JM) domain of EGFR is essential and 
sufficient for binding to ARNO. Given the importance of the JM domain in regulating 
EGFR activity it is valid to speculate that ARNO influences conformational 
rearrangements of this domain and thereby facilitates the formation of an active 
receptor dimer. Crosslinking results suggest that the C-terminus of the ARNO Sec7 
domain is close to the N-terminus of the EGFR JM domain. Together with functional 
assays this supports a “head-to-tail” interaction, in which the JM domain associates with 
a hydrophobic grove in ARNO Sec7 that serves as binding site for Arf proteins during 
nucleotide exchange reactions. Covering of exposed hydrophobic amino acids in the 
EGFR asymmetric dimer and release of inhibition mediated by plasma membrane 
interactions are potential mechanisms of ARNO dependent receptor activation.  
Structural data about the complex is required to confirm these ideas. Next to 
crystallographic approaches using other protein constructs, nuclear magnetic resonance 
(NMR) or mass spectrometry (MS) analysis of crosslinked complexes can be employed 
for this purpose. 
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6 Materials and Methods 
 
6.1 Molecular biology 
 
6.1.1 Agarose gel electrophoresis 
 
Analysis of double stranded DNA (PCR products or digested plasmids) was performed 
by agarose gel electrophoresis. Agarose was dissolved in 0.5x TBE buffer by heating in a 
microwave until appearance of a homogenous solution. After cooling to approximately 
60°C, ethidium bromide was added to the agarose in order to stain the separated DNA. 
Gels were run at a constant voltage of 100V for 15-30 min and DNA was subsequently 
visualized by UV irradiation (GelDoc, Bio-Rad). DNA fragment size was compared to the 
DNA 10kbps ruler (Fermentas). 
 
TBE (1x)  
90mM Tris Borate 
2mM EDTA 
 
6.1.2 Polymerase chain reaction (PCR) 
 
Polymerase chain reaction was employed for the amplification of DNA fragments and 
whole plasmids in order to generate expression constructs for protein purification. 
The Phusion DNA polymerase (Thermo Fisher Scientific) was used for all PCR reactions 
and resulting fragments were analyzed on agarose gels to verify the expected size. 
Purification of DNA fragments was done using the NucleoSpin PCR clean up kit 
(Macherey-Nagel) according to the manufacturers instructions. 
 
6.1.3 Cloning of ARNO Sec7 EGFR JM fusion constructs and generation of Arf6 mutants 
 
Generation of the JM-Sec7 fusion proteins was done by PCR amplifying both the EGFR JM 
domain and ARNO Sec7 coding sequences with adjacent restriction sites. The linker 
region was included in the primer as an overhang of the complementary sequences. 
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Restriction digest of the resulting fragments and target plasmid (pET28HT) was done 
using the FastDigest restriction enzymes (Fermentas, Thermo Scientific) for 30’ at 37°C 
(restriction sites from 5’ to 3’on pET28 HT: EcoRI, KpnI, HindIII). Subsequently 
fragments were sequentially ligated to the vector using the Rapid Ligase Kit (Roche 
Applied Science) for 5 minutes at room temperature. Ligation reactions were 
transformed into chemically competent DH5 cells. 
Arf6 mutants were generated in Arf6 in the plasmid pASK IBA 45+ N13Arf6. Primers 
were designed to fully amplify the plasmid (two primers for single strand amplification 
in opposite directions) and one primer contained the respective mutation in the coding 
sequence. Amplified vectors were 5’ phosphorylated using Polynucleotide kinase (PNK, 
NEB) for 1h at 37°C. Subsequently the phosphorylated vectors were ligated with the 
Rapid Ligation Kit (Roche) and transformed into DH5 cells (see below). N-terminal 
truncations of ARNO Sec7 were generated with the same protocol in the plasmid 
pET15b ARNO Sec7. 
 
6.1.4 Transformation of chemically competent E.coli cells 
 
Competent cells were thawed on ice. Up to 5µl ligation reaction or 1ng to 100ng plasmid 
DNA was mixed with 50µl of competent cells and incubated on ice for 30min. After a 
heat shock (42°C) for 45 seconds, 500µl LB medium was added and the resulting 
mixture was incubated at 37°C for 45min. Subsequently the cells were harvested by 
centrifugation (1000g for 5 minutes), the pellet was resuspended in a small volume 
(50µl LB) and distributed on a LB Agar plate containing the appropriate antibiotics. The 
plates were incubated overnight at 37°C and subsequently stored at 4°C. 
 
6.1.5 Preparation of chemically competent E.coli cells 
 
The desired E.coli strain was grown over night in LB medium. The following day, 100µl 
of the culture were added to 20ml TYM medium in a 100ml flask. After growth to an 
OD600 of 0.2-0.8 the whole medium was transferred to 2l flask containing additional 
100ml of TYM. Growth to an OD6000.5-0.9 was followed by further addition of 300ml 
TYM. All incubation steps take place at 37°C and medium is heated to 37°C prior to 
addition. 
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When the final culture reaches an optical density of 0.6 it is rapidly cooled on ice. 
Bacterial cells are centrifuged for 15 minutes at 2000g and 4°C. The resulting pellet is 
resuspended in 100ml ice cold TfBI buffer and spun down for 8 minutes at 2000g and 
4°C. Finally the cell pellet is resuspended in 20ml of TfBII buffer, transferred to small 
reaction vials in appropriate amounts and stored at -80°C after flash freezing in liquid 
nitrogen. 
 
TYM medium (1l)     
20 g  bacto trypton 
5 g  yeast extract 
5.84 g  NaCl 
2.46 g MgSO4 
 
TfBI buffer      TfBII buffer 
30 mM KAc      10 mM NaMOPS pH 7.0 
50 mM MnCl2      75 mM CaCl2 
100 mM KCl      10 mM KCl 
10 mM CaCl2      15 % (v/v) glycerol 
15 % (v/v) glycerol 
 
6.1.6 DNA preparation and validation of sequences 
 
Plasmids were replicated in E.coli DH5 and isolated using the Macherey-Nagel Plasmid 
Mini Prep Kit according to the manufacturer’s protocol. Pure plasmid DNA was sent for 
sequencing and results were analyzed with a sequence alignment tool (EMBOSS Needle). 
 
6.2 Protein Expression and purification 
 
6.2.1 Bacterial culture and induction of protein expression 
 
E.coli BL21 DE3 harboring the expression plasmid of choice were grown over night at 
37°C in Luria Bertani (LB) medium supplemented with the appropriate antibiotics. The 
main culture was inoculated with 1% preculture and grown at 37°C until OD600 
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reached 0.6-0.8. Cells were cooled to 20°C and induced with 0.2mM IPTG (ARNO 
constructs) or kept at 37°C while adding 200 ng/ml anhydrotetracycline (AHT for Arf6 
constructs). Protein expression lasts for 4h at 37°C and over night at 20°C. After 
expression bacterial cell were harvested via centrifugation at 5000g for 15 minutes at 
4°C and the pellets were either immediately used for purification or stored at -80°C for 
up to 6 months. 
 
6.2.2 Cell lysis for protein purification 
 
Bacterial cells or Sf9 cells were resuspended in specific lysis buffer supplemented with 
2mM -mercaptoethanol and protease inhibitor (inhibitor mix (Serva) or 
leupetin/aprotinin and 1mM PMSF). Lysis was performed using a french pressure 
system or a microfluidizer (Microfluidics International Corporation, Newton USA). 
Subsequently the lysate was cleared of insoluble material by centrifugation (25000 rpm, 
4°C, JA 25.50 rotor, Avanti J-20 XP centrifuge from Beckman Coulter Inc.) and filtration 
through a 0.44µm filter membrane (Sigma Aldrich). 
 
Lysis buffer (ARNO constructs)  Lysis buffer (EGFR constructs) 
50 mM HEPES pH 7.8   50 mM Tris pH 8 
500 mM NaCl     500 mM NaCl 
      5 % glycerol 
 
Lysis buffer (Arf6) 
50 mM Tris pH 7.4  
150 mM NaCl 
1 mM MgCl2 
 
6.2.3 Purification of recombinant proteins from cell lysates 
 
Proteins were purified in a multistep procedure either with the help of an ÄKTA liquid 
chromatography system (GE Healthcare) or with the affinity matrix in solution. Arf6 was 
purified using StrepTactin High capacity resin (iba technologies). Cleared lysate was 
incubated for 1h at 4°C with constant mixing. The beads were separated by from the 
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soluble material by centrifugation (at 2000g and 4°C for 10’) and washed twice with 
lysis buffer. Arf6 was eluted with 2.5mM desthiobiotin and stored in final buffer after gel 
filtration using Desalting columns (GE Healthcare). 
For ARNO and EGFR constructs, the cleared lysate was applied to NiNTA columns (Hi-
Trap Chelating HP 5ml, GE Healthcare) using an ÄKTA liquid chromatography system. 
The column was washed with buffer A and up to 5% buffer B and elution was performed 
with a gradient to 100% buffer B. The eluate was collected in fractions and analyzed on 
SDS PAGE gels. The fractions containing the protein of interest were pooled and dialyzed 
over night in the presence of an appropriate protease to remove the affinity tag (TEV or 
Thrombin, Sigma Aldrich). 
 
Buffer A (ARNO)    buffer B (ARNO) 
50 mM HEPES pH 7.8   50 mM HEPES pH 7.8 
500 mM NaCl     50 mM NaCl 
      500 mM Imidazol 
 
Buffer A (EGFR)    buffer B (EGFR) 
50 mM Tris pH 8    50 mM Tris pH 8 
500 mM NaCl     50 mM NaCl 
5% glycerol     500 mM Imidazol 
      5 % glycerol 
 
Dialysis buffer (ARNO)   dialysis buffer (EGFR) 
50 mM HEPES pH 7.8   50 mM Tris pH 8 
100 mM NaCl     100 mM NaCl 
2 mM  mercaptoethanol   2 mM  mercaptoethanol 
 
Thrombin concentration for cleavage    
 
2.5 units/ mg of protein (Sigma Aldrich, Munich)  
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TEV concentration for cleavage 
 
TEV was purified via Ni affinity chromatography (expression plasmid was a gift of A. 
Itzen, TU Munich; (160)). The activity was tested for each batch and the amount of 
protease required for digest of target protein was determined according to the obtained 
test results. 
 
After dialysis the protein solution was cleared from precipitates by centrifugation (10’, 
5000 rpm, 4°C, Eppendorf Centrifuge 5804R, rotor: A-4-44) and the supernatant was 
applied to the NiNTA column to remove uncleaved protein and His tagged TEV protease. 
The flowthrough was collected and fractions analyzed on SDS PAGE gels. Fractions 
containing the desired proteins were pooled and concentrated to a final volume of 2ml 
before the final purification step via size exclusion chromatography (SEC). The resulting 
protein solution was concentrated and stored at -80°C in appropriate aliquots. 
 
SEC buffer/storage buffer (ARNO)  SEC buffer/storage buffer (EGFR) 
20 mM HEPES pH 7.8    20 mM Tris pH 8 
100 mM NaCl      100 mM NaCl 
1 mM DTT      1 mM DTT 
 
SEC columns 
Superose 12 column  
Hi-Load Superdex 75/200 16/60 (GE Healthcare) 
 
Material used for proteins concentration 
Vivapore 10/20 Solvent Absorption Concentrators (Sartorius, Göttingen, Germany) 
Amicon Ultra Centrifugal filter units (Merck Millipore, Darmstadt, Germany) 
 
6.2.4 Purification of JIP4 LZII 
 
The construct JIP4 LZII (392-462) was expressed as a GST fusion protein (expression 
plasmid was a kind gift of J. Menetrey). The cleared lysate was incubated with 
glutathione agarose for 1h at 4°C and washed twice with buffer B1 and B2. Subsequently 
the resin was resuspended in Buffer C and TEV protease was added to the solution. After 
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over night cleavage at 4°C the supernatant was collected, concentrated to a final volume 
4ml and applied to a SEC column for final purification. Free JIP4 LZII elutes very late and 
forms a double peak. The first peak contains the desired protein as illustrated in figure 
6.1. The final protein was concentrated (molecular weight cutoff (MWCO) of 10kDa is 
applicable due to dimer formation of JIP4 LZII) and stored at -80°C. The protein Mig6 
EBR S1 was purified using the same protocol. 
 
Lysis buffer     storage buffer 
50 mM Tris pH 8    20 mM HEPES pH 8 
250 mM NaCl     150 mM NaCl 
10 % glycerol    2 mM MgCl2 
1 mM MgCl2 
 
Buffer B1     Buffer B2 
50 mM Tris pH 8    50 mM Tris pH 8 
300 mM NaCl     150 mM NaCl 
5 mM MgCl2     5 mM MgCl2 
2 mM DTT     2 mM DTT 
 
 
Fig. 6.1 Size exclusion 
chromatography elution profile of 
JIP4 LZII. Crude JIP4 LZII after over 
night digest of the GST tag is injected 
into a SEC column (Superdex 200 
material, column volume: 50ml).The 
protein elutes very late and a double 
peak is observed (a). Only the first 
peak contains JIP4 LZII as shown by 
analyzing the collected fractions on 
Coomassie stained SDS PAGE gels (b). 
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Buffer C 
50 mM Tris pH 8 
300 mM NaCl 
5 mM MgCl2 
2 mM  mercaptoethanol 
 
Resin 
Glutathione Agarose 4B (Macherey-Nagel) 
 
6.2.5 Purification of other protein constructs 
 
The following other constructs are used in this study and purified according to one of 
the above described protocols: 
The GEF domain of the bacterial protein DrrA (DrrA (340-533)) and the small GTPase 
Ran were purified like ARNO Sec7 constructs. 
MIG6 EBR S1 was purified using the protocol for JIP4 LZII. 
PLC SH2 GST was purified in a single step GST affinity purification followed by SEC into 
the final storage buffer. 
Erk2 and N17Arf1 were purified using NiNTA resin and SEC. 
 
Lysis/wash buffer (DrrA and Ran) lysis/wash buffer (Erk2 and 
N17Arf1) 
50 mM Tris pH 7.6     20 mM Tris pH 7.8 
300 mM NaCl      300 mM NaCl 
2 mM MgCl2      2 mM MgCl2 
20 mM Imidazol     20 mM Imidazol 
 
Lysis/wash buffer (MIG6 EBR S1 GST and PLC SH2 GST) 
20 mM HEPES pH 7.8 
500 mM NaCl 
 
Proteins were stored in 20mM HEPES (with appropriate pH) + 100mM NaCl and 1mM 
DTT. 
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6.2.6 Protein concentration determination and purity control 
 
Concentration of protein solutions was determined with the Bradford reagent (Bio-Rad) 
according to the manufacturer’s instructions. Pure protein was analyzed by measuring 
the absorbance at 280nm and using their specific extinction coefficient () and the 
following equation: 
A = c**d 
 
A: absorbance of the sample at 280nm 
c: concentration of the sample in mol/l 
d: path length in cm 
: molar extinction coefficient in l mol-1 cm-1 
 
Purity of proteins was controlled by separation on SDS PAGE gels and staining with 
Coomassie Brilliant Blue. 
 
6.2.7 SDS Polyacrylamide gel electrophoresis (PAGE) 
 
Analytical separation of proteins was performed according to the protocol by Laemmli 
(205). Separating and stacking gel solutions were independently prepared and 
sequentially poured between two appropriately spaced glass plates after induction of 
polymerization with tetramethylethylenediamine (TEMED) and ammonium persulfate 
(APS). Samples were mixed with SDS loading buffer, heated to 95°C for 5’ and loaded on 
the gel for separation in SDS running buffer. 
 
Stacking gel buffer     separating gel buffer 
0.5 M Tris, pH 6.8     1.5 M Tris pH 8.8 
 
SDS loading buffer (5x)    Tris-Glycine running buffer (10x) 
50 mM Tris pH 6.8     250 mM Tris 
30 % glycerol     2 M glycine 
15 % SDS      1 % SDS 
600 mM DTT 
Bromophenol Blue 
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Example recipe for a 12% SDS PAGE gel 
Acrylamide mix (30%)  2000 µl 
Separating buffer   1250 µl 
Water     1700 µl 
SDS (10% stock)   50 µl 
TEMED    2.5 µl 
APS (10%)    25 µl 
 
6.2.8 Tricine SDS PAGE 
 
Tricine SDS PAGE was performed according to a published protocol (206). In brief an 
acrylamide-bisacrylamide (AB) solution was prepared and used to cast the gels. 
Electrophoresis is performed with tricine instead of glycine in the running buffer (only 
at the cathode). 10 % gels were used for the separation of JIP4 LZII and gels were 
further treated as described below. 
 
Cathode buffer (10 x)    Anode buffer (10 x) 
1 M Tris      1 M Tris 
1 M Tricine      0.225 M HCL 
1 % SDS 
 
AB solution      Gel buffer (3 x) 
48 g Acrylamide     3 M Tris 
1.5 g Bis Acrylamide     1 M HCl 
in 100 ml water     0.3 % SDS 
 
 
4 % stacking gel     10 % separating gel 
1 ml AB solution     6 ml AB solution 
3 ml Gel buffer     10 ml Gel buffer 
8 ml water      3 ml glycerol 
       11 ml water 
90 µl APS (10%)     150 µl APS (10%) 
9 µl TEMED      15 µl TEMED 
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6.2.9 Coomassie staining 
 
SDS PAGE gels covered with Coomassie staining solution and stained for 30’ at room 
temperature or heated in a microwave for 1’ at 600W. Subsequently the gels were 
destained over night in Destaining solution. A paper towel was added to the solution to 
adsorb free dye and improve destaining. 
 
Coomassie staining solution   Destaining solution 
10 % acetic acid     10 % acetic acid 
30 % methanol     30 % methanol 
700 mg/l Coomassie Brilliant Blue G250 
 
6.2.10 Western Blot and immunodetection of proteins 
 
Proteins separated by SDS PAGE were transferred onto nitrocellulose membranes by a 
semi dry Western Blot. For this purpose the gel and the membrane are equilibrated in 
transfer buffer and mounted in between four buffer soaked pieces of Whatman paper. 
Transfer was achieved by applying 1 mA/cm2 of gel for 45 minutes.  
After blotting, the membrane was blocked in 5 % BSA in TBS-T for 30 minutes. 
Appropriate dilutions of primary antibody in 5 % BSA in TBS-T were subsequently 
added and incubated at 4°C. Incubation times ranged from 1h to over night. The 
membrane was thereafter washed three times with TBS-T and incubated with the 
fluorescently labeled secondary antibody (in 5 % BAS in TBS-T) for 1h. After three more 
wash steps the membrane was scanned using a Licor Odyssey Gel documentation 
system. 
 
Transfer buffer     TBS-T 
25 mM Tris      100 mM Tris/HCl pH 7.4 
200 mM glycine     150 mM NaCl 
0.1 % SDS      0.1 % Tween 20 
20 % methanol 
 
 
 MATERIALS AND METHODS  
 108 
6.3 Protein modification 
 
6.3.1 Labeling of JIP4 LZII with IAA fluorescein 
 
The purified JIP4 LZII domain contains one cysteine residue that was modified using 
iodoacetamido fluorescein (IAA fluorescein, Sigma Aldrich). A five times molar excess of 
labeling reagent was incubated with the protein for 2 h at room temperature. Labeled 
proteins were desalted using a Desalting column (GE Healthcare) and an Äkta FPLC. 
Separation on Tricine SDS PAGE gels and visualization using UV irradiation (BioRad 
GelDoc) was employed to evaluate labeling efficiency and removal of free IAA 
fluorescein. 
 
6.3.2 Covalent modification of proteins with biotin and detection via DotBlot 
 
Proteins used in biochemical assays that required immobilization on a streptavidin-
coupled matrix (pulldowns or ALPHA screen) were modified on free amine groups using 
NHS-LC-Sulfo-Biotin (Pierce Protein Science). The protein was incubated with 5 times 
molar excess of reagent in an appropriate buffer (HEPES or phosphate buffered 
solutions) for 1 h at room temperature. If protein stability was a concern, the reaction 
was performed on ice for 2 h. The reaction was stopped by the addition of 1 M Tris pH 
6.8 to a final concentration of 1 mM Tris. Subsequently the labeled protein was desalted 
using 5 ml Desalting columns (GE Healthcare) on an Äkta FPLC. 
Biotin modification was evaluated by immobilizing the final protein on a nitrocellulose 
membrane (Whatman) and detection of biotin with FITC coupled biotin reactive 
antibodies (DotBlot).  
 
6.4 Peptide synthesis and modification 
 
Peptide synthesis was done in a Peptidesynthesizer PS3 (Protein Technologies Inc.) 
using standard Fmoc chemistry. A Rink amide AM resin was used as a solid phase 
support and each amino acid coupling included the following steps: 
 
1. Deprotection (2x): 20 % piperidine in dimethylformamide (DMF) for 5 minutes. 
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2. Activation of amino acids, linker or biotin/fluorescein in 0.4 M morpholine in 
DMF by adding O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-
phosphate (HBTU) in a 1:1 molar ratio for 1 minute. 
3. Coupling for 40 minutes at room temperature. 
 
The coupled reagents were added in a 4 x molar excess to the peptide chains and 
washing of the resin after coupling and deprotection was done with pure DMF. After the 
synthesis, the resin is washed with dichlormethane (DCM) and dried over night in a 
vacuum. The resulting peptides are cleaved from the resin with 95 % trifluoroacetic acid 
and 2.5 % triisopropylsilane (TIPS) for 2 h at room temperature. 
The peptide is precipitated with diethyl ether and dried over night in a vacuum. 
Purification of the crude material is done using HPLC and peptide mass was validated by 
mass spectrometry.  
 
6.5 Screening for small molecule inhibitors 
 
The in-house compound library contains approximately 17000 small molecules that are 
stored as 1 mM stock solutions in DMSO at -80°C. The compounds were thawed and 
prediluted to 120 µM in dilution buffer before screening. 
The assays was performed in black 384 well plates in the presence of 0.01 % Triton 
X100 and 10 % DMSO. 320 compounds were screened on one plate next to 32 positive 
and negative control reactions (no compound or no Arf6 respectively). Reagents were 
added to each well in the following order by the TECAN Evolution pipetting robot: 
 
10 µl Arf6 GTP (2 µM) 
5 µl pre-diluted compound solution 
5 µl fluorescein-labeled JIP4 LZII (250 nM) 
 
After two hours incubation at room temperature in the dark, the fluorescence 
polarization (FP) values were measured in a TECAN Ultra plate reader. Robustness of 
the assay was evaluated by repeating the measurement after over night incubation at 
room temperature. No difference due to incubation time was observed. Z’ values (170) 
were calculated for each plate and hit compounds identified by reduction of the FP 
values more than five standard deviation below the mean. 
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Screening buffer     Dilution buffer 
1.33 x PBS pH 7.4     31.8 % DMSO 
2.66 mM MgCl2     0.05 % Triton X100 
 
6.6 Crystallization of proteins and x-ray diffraction analysis 
 
Crystallization of macromolecules and subsequent analysis of x-ray diffraction patterns 
is an elegant method to obtain information about the structure of a molecule with 
atomic resolution. In this study, constructs of ARNO Sec7 were crystallized in the 
presence of 2-20 fold molar excess of the EGFR JM peptide. Furthermore, fusion proteins 
of ARNO Sec7 with EGFR JM were employed in independent screens for crystallization 
conditions. All proteins were used in concentrations of 8 – 10 mg/ml in all screens and 
subsequent refinement of crystallization conditions.  
Initial screens were performed using the Qiagen crystallization kits (JCSG Core I-IV 
Suites, Classics Suite, PACT Suite, PEG I+II Suite, Protein Complex Suite) and the sitting 
drop vapor diffusion method. Identified conditions that allowed crystal formation were 
reproduced in a 24-well plate using the hanging drop method. The obtained crystals 
were picked using a nylon loop and frozen in liquid nitrogen. Initial diffraction was 
analyzed in an in house x-ray source (MICROSTAR x-ray source, Bruker AXS Inc., 
Madison USA; Mar345 Image Plate Detector, marresearch, Norderstedt, Germany). Full 
data sets were obtained at the Swiss Light source (X10SA x-ray source, Paul Scherrer 
institute, Villigen, Switzerland) and processed using the XDS software package (207). 
The structures were solved using molecular replacement using the ARNO Sec7 structure 
as a search model (PDB: 1PBV, (180)) and the software package Phaser (208). 
All crystals analyzed belong to the space group P213 (cubic) and diffracted from 1.8 to 
2.6 Å. Unit cell parameters are  =  =  = 90°, a = b = c = 89 Å. 
 
6.6.1 Microseeding of protein crystals 
 
Crystals of fusion constructs between ARNO Sec7 and EGFR JM, which were to small 
after initial screening for conditions and refinement of these conditions, were optimized 
via protein crystal microseeding (209). Therefore, the obtained crystals were diluted in 
50 µl of mother liquor and vortex heavily to break the macrocrystals into smaller 
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microseeds. Bigger fragments were removed by centrifugation (5’ at room temperature 
and 6000 rpm in an Eppendorf table top centrifuge). The supernatant was sequentially 
diluted from 1:10 to 1:10000 and the resulting microseed stock solutions were mixed 
with fresh protein in a hanging drop. The concentration of added protein was reduced (4 
– 8 mg/ml). This facilitates crystal growth and reduces the de novo generation of seeds. 
Therefore, growing of crystals from the microseed stock is enhanced. Crystals for 
diffraction analysis appeared after 4 days of growth in a 1:100 dilution of microseeds 
both with 6 mg/ml and 8 mg/ml fresh protein. 
 
6.7 Cell culture 
 
6.7.1 General handling of mammalian cells and cell lines 
 
Adherent mammalian cells were grown at 37°C in the presence of 5 % CO2 and passaged 
every 2-3 days to maintain confluence below 90 %. For culture maintenance, the cells 
were grown in their respective culture medium supplemented with 10% fetal calf serum 
(FCS). For passage cells were rinsed with PBS and subsequently detached from the 
surface via the addition of Trypsin-EDTA solution. The cell suspension was 
appropriately diluted and transferred to new culture flasks. 
 
6.7.2 Stimulation with growth factors or serum 
 
Normal growing cells were transferred to FCS free medium 24 h prior to stimulation. 
After this starvation the desired growth factor was diluted in fresh serum free medium 
and added to the cells for 2-4 h. For serum stimulation, medium was exchanged to FCS 
containing medium. 
 
6.7.3 Preparation of cell lysates 
 
Cells used for western blot or pulldown experiments were harvested as follows. The 
growth medium was discarded and the cells were put on ice and immediately washed 
with ice cold PBS. Covered with approximately 1 ml of PBS, cells were removed from the 
plate surface using a Cell scraper (TPP). The cells were transferred into Falcon tubes and 
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pelleted by centrifugation (1000g at 4°C for 5’ in an Eppendorf Centrifuge 5804-R). 
Afterwards the cell pellet was resuspended and lysed in lysis buffer for 15 minutes on 
ice in the presence of a protease inhibitor mix (Serva). Insoluble material was removed 
by centrifugation for 15 minutes at 12000rpm and 4°C in an Eppendorf table top 
centrifuge. Protein concentration was determined using the Bradford assay. 
 
Lysis buffer 
50 mM Tris pH 7.5  
200mM NaCl  
10mM MgCl2 
1 % Igepal 
5% glycerol 
 
6.8 Analytical methods 
 
6.8.1 High performance liquid chromatography (HPLC) 
 
HPLC was employed for the purification of solid phase synthesized peptides. Up to 1 ml 
of crude peptide solution was loaded onto a Nucleosil 100 – 5C18 reverse phase column 
and eluted in a gradient from 0 – 60 % buffer B in 40 minutes with a constant flow of 5 
ml/minute. The column was rinsed with 100 % buffer B and equilibrated in 100 % 
buffer A using a rapid gradient. All steps were performed on an Agilent 1200 series 
HPLC (Agilent Technologies). Peptide containing fractions were collected and the 
solvent was removed by evaporation in a SpeedVac. The resulting peptide pellet was 
resuspended in the desired buffer and analyzed using ESI-MS (see below).  
 
Buffer A      Buffer B 
0.1 % formic acid     0.1 % formic acid 
in water      in acetonitrile  
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6.8.2 Analytical Size Exclusion Chromatography (SEC) 
 
Proteins were mixed and incubated for 20 minutes at room temperature to allow 
complex formation (EGFR construct ICD1022 was incubated on ice for 45 minutes due 
to protein stability). Analysis of complexes was done using a Waters HPLC system 
(Waters Corporation, Milford, USA) and Superdex 75 10/300 GL or Superdex 200 
10/300 GL SEC columns (GE Healthcare, Munich). A total volume of 40 µl was injected 
and run for 60 minutes at 0.5 ml/min. The BioRad molecular weight standard was 
employed as a reference.  
For SDS PAGE analysis of elution fractions, they were collected with a fraction collector 
(Waters Corporation, Milford, USA), separated on a 12 % SDS PAGE gel and further 
analyzed by Coomassie Brilliant Blue staining. 
 
analytical SEC buffer 
50 mM Tris pH 7.8 
100 mM NaCl 
 
6.8.3 Electrospray Ionization Mass spectrometry (ESI MS) 
 
Recombinantly expressed proteins were separated and desalted on a C4 reverse phase 
column (Grace Vydac 214TP C4 5µ)by running a gradient from 20 % to 70 % buffer B 
(see buffers used for HPLC analysis above) in 10 minutes (flow: 200 µl/min). MS 
analysis was done in a Finnigan LCQ Advantage Max Mass spectrometer. Spectra were 
analyzed using the software Xcalibur (Thermo Fisher Scientific Inc., Waltham, USA) and 
MagTran (210). 
Purified solid phase synthesized peptides were separated on a MultoHigh 100 RP 18 5µ 
reverse phase column and analyzed in a Bruker Esquire HCT Electron Spray Mass 
Spectrometer. Obtained spectra were analyzed with the Compass software (Bruker). 
 
6.8.4 Dynamic Light Scattering (DLS) 
 
Buffers used for DLS measurements were filtered and degassed before the experiment. 
Proteins were diluted to 1 mg/ml in assay buffer (20 mM Tris pH 8, 100 mM NaCl). 
Measurements were performed in a Quartz cuvette using the DynaProTitan (Wyatt 
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Technology) DLS detector. The count rate measuring the scattered light intensity should 
be stable before the actual measurement. All values were obtained with 50 % light laser 
intensity and analyzed using the DynaProV6 Dynamic software. 
 
6.8.5 Circular dichroism (CD) spectroscopy 
 
Far UV CD spectroscopy was employed to evaluate the secondary structure of the 
purified proteins. The measurements were performed in a Jasco J-815 CD spectrometer 
at 25°C. Protein solutions were prepared in 20mM HEPES pH 8, 100mM NaCl, 2mM 
DTTto a final concentration of 0.5 mg/ml. Spectra were obtained between 178nm and 
260nm (50nm/min and 1nm steps). The molar ellipticity was calculated using the 
following formula: 
 
MRW,, =  * MRW / 10 * c * d 
 
MRW,, : molar ellipticitydeg dmol-1 cm2  
:  measured ellipticity  deg 
MRW:  average molecular weight of the amino acids in the protein g mol-1 
c:  concentration of protein g ml-1 
d:  path length cm 
 
6.9 Biochemical assays 
 
6.9.1 ALPHA screen 
 
Alpha Screen measurements were performed using Streptavidin coupled donor beads 
and either fluorescein detecting (for the JIP4 LZII Arf6 in vitro interaction) or protein A 
coupled (for the GTPase activation sensor) acceptor beads (Perkin Elmer). The beads 
were diluted to a final concentration of 100 µg/ml. All pipetting steps were performed 
under subdued light conditions to avoid bleaching of Alpha Screen beads. 
For the Arf6 JIP4 LZII interaction assay the indicated concentrations of proteins were 
added to the bead mixture in PBS + 3 mM MgCl2 in the presence of 0.1 mg/ml bovine 
serum albumin (BSA).  
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Biotinylated effector protein (GGA3 or PAK1) was used in a final concentration of 100 
nM and mixed with the indicated amounts of in vitro nucleotide preloaded GTPase (Arf1, 
Arf6 or Rac1) or cell lysate in PBS + 3mM MgCl2.  
The reactions were performed in a white 384-well microtiter plate (Proxiplate, Perkin 
Elmer) and incubated for 2h or over night at room temperature in the dark. All 
measurements were taken on a plate reader equipped with an Alpha Screen module 
(LB940 Mithras, Berthold Instruments) and excitation and emission times set to 0.5 s. 
 
6.9.2 Pulldown of Arf GTPases by immobilized effector proteins 
 
Arf GTPases were preloaded with either GDP or GTP (see Nucleotide Exchange assay). 
10 µl of Glutathione 4B Agarose (Protino, Macherey-Nagel) was incubated with 4 µM of 
GST tagged effector protein (JIP4 LZII or GGA3) and 2.5 µM nucleotide preloaded GTPase 
in Pulldown Buffer. For competition experiments, 20 µM of soluble JIP4 LZII was added. 
Incubation was done over night at 4 °C and constant shaking of the reaction tubes. The 
agarose resin was pelleted by centrifugation (2500 rpm, 5’, 4°C, Eppendorf table top 
centrifuge) and washed two times with 500µl wash buffer. Finally the beads were 
resuspended in SDS loading buffer prior to analyzing the reaction via SDS PAGE and 
Western Blot or Coomassie stain. 
 
Pulldown buffer     Wash buffer 
20 mM HEPES pH 7.4    20 mM HEPES pH 7.4 
150 mM NaCl      300 mM NaCl 
5 mM MgCl2      5 mM MgCl2 
     0.02 % Triton X100 
 
6.9.3 Pulldown of Rac1 GTP from cell lysates 
 
Precipitation of GTP bound Rac1 was facilitated with the help of the effector protein 
Pak1. The Rac binding domain of Pak1 was biotin-modified and immobilized on 
monomeric avidin agarose (Pierce Protein Science). The desired amount of cell lysate 
was added to the immobilized effector (20 µg protein on 10 µl agarose beads) and 
incubated for 1h at 4°C. The beads are separated from the supernatant by centrifugation 
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(2500 rpm, 5’, 4°C, Eppendorf table top centrifuge) and washed three times with wash 
buffer. The beads were finally resuspended in 20µl SDS loading buffer and further 
analyzed by SDS PAGE and Western Blot.  
 
Wash buffer     Antibody 
25 mM Tris pH 8    anti Rac1 (polyclonal, Millipore)  
30 mM MgCl2     1:1000 
40 mM NaCl     anti-mouse IgG GAM800 (polyclonal, Licor)  
1 mM DTT     1:20000 
 
6.9.4 Fluorescence Polarization (FP) 
 
Fluorescein labeled proteins (JIP4 LZII or ARNO Sec7) were incubated with increasing 
concentrations of interaction partners or control proteins in a black 384 well plate. For 
JIP4 LZII, a final concentration of 100 nM fluorescein labeled protein was sufficient 
while 200 nM of ARNO Sec7 fluorescein was used in the assays. 100 mM bovine serum 
albumin (BSA) was added to the reactions containing ARNO Sec7 fluorescein to reduce 
unspecific binding. The reactions were incubated at room temperature for 1 h or at 4 °C 
for 2 h if EGFR ICD constructs were present. Fluorescence polarization was measured in 
a TECAN Ultra plate reader (TECAN, Crailsheim, Germany).  
 
FP buffer (JIP4 LZII)   FP buffer (ARNO Sec7) 
PBS pH 7.4     50 mM HEPES pH 7.8 
2 mM MgCl2     150 mM NaCl 
0.01 % Triton X100    0.01 % Triton X100 
 
6.9.5 Nucleotide Exchange 
 
Arf GTPases were preloaded with GDP. Therefore, the nucleotide binding site was 
destabilized by the addition of 2 mM ethylenediaminetetraacetic acid (EDTA) for 10 
minutes at 37 °C in the presence of 50 µM GDP. Adding 3 mM MgCl2 stabilizes the 
binding pocket and the excess of GDP in the solution results in predominant GDP 
associated GTPase. Preloaded Arf (1 µM) was mixed with ARNO Sec7 (from 12.5 nM to 
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200 nM) in phosphate buffered saline (PBS) supplemented with 2 mM MgCl2. The 
exchange reaction was started by the addition of 50 µM GTP and followed by measuring 
the tryptophan fluorescence in an appropriate plate reader (VarioScan, Thermo Electron 
corporation or Enspire Multimode Reader, Perkin Elmer). This parameter changes 
dependent on the bound nucleotide and is therefore suitable for the detection of the 
catalytic activity. 
The resulting curves were fit using a linear regression model (software: Graphpad 
PRISM) for the early parts of the reaction (the first 150-300 s dependent on the GTPase 
GEF pair). 
 
6.9.6 Thermal Shift 
 
Thermal stability of proteins was evaluated using a fluorescence-based assay that 
monitors the unfolding of the protein of interest in solution. Therefore, 2 – 10 µM of 
protein was incubated with 5x SYPRO Orange (Molecular Probes) in a final volume of 
100 µl.  
A Real Time PCR thermo cycler (Bio-Rad) was used for following the change in 
fluorescence intensity (mant fluorescence) in a temperature gradient from 20 °C to 75 
°C (incremental temperature increase by 1 K). Total intensity (RFU) and change in 
intensity (RFU) were plotted against the temperature. The melting temperature is 
easily visible as the local maximum observed in the RFU plot and is a quantitative 
parameter for evaluating the thermal stability of a protein in the employed buffer 
conditions. 
 
6.9.7 Crosslinking assay 
 
Proteins were mixed in crosslink buffer to obtain final concentrations of 25 µM for 
ARNO Sec7 constructs and 10 µM for EGFR constructs. 25µM bovine serum albumine 
was added to reactions containing EGFR JM peptide variants to reduce unspecific 
binding. The reactions were incubated for 15 minutes at room temperature to allow 
complex formation. Subsequently 5 mM Bis(Sulfosuccinimidyl)suberate (BS3, Thermo 
Scientific) was added and incubated for another 20 minutes at room temperature. The 
reaction was stopped by the addition of SDS loading buffer. EGFR ICD crosslinks were 
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separated on 10 % SDS PAGE gels while EGFR JM crosslinks were separated on 15 % 
SDS PAGE gels. Crosslinks were visualized with Coomassie Brilliant Blue staining and 
detected in a Licor Odyssey gel scanner (Licor). All shown results are representative 
gels. Experiments were performed at least 3 times for each analyzed construct. 
 
Crosslink buffer 
20 mM HEPES pH 8 
150 mM NaCl 
5 mM MgCl2 
0.005 % Triton X100 
 
6.9.8 Kinase assay for EGFR constructs 
 
For the evaluation of enzymatic activity for EGFR constructs an in vitro phosphorylation 
assay was employed. 0.5 µM EGFR ICD1022 and KC1022 (lacking the JM domain) were 
incubated with 15 µM of the SH2 domain of PLC at 25 °C. ATP was added to a final 
concentration of 500 µM to start the reaction. Samples were taken after 1, 2 and 5 
minutes for ICD1022 and 10, 30 and 60 minutes for KC1022.  
Adding SDS loading buffer and boiling the sample stopped the reaction. The samples 
were separated on a SDS PAGE gel, blotted onto a nitrocellulose membrane and 
phosphorylation was detected using phospho-tyrosine specific antibodies (pY-99, Santa 
Cruz). 
 
Kinase reaction buffer 
20 mM HEPES pH 7.4 
150 mM NaCl 
5 mM MgCl2 
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6.10 Materials 
 
EQUIPMENT, TYPE MANUFACTURER 
Agarose gel chamber Institue for chemistry, Bonn, Germany 
Äkta, FPLC GE Helathcare 
Äkta, Prime plus GE Helathcare 
Analytical balance Sartorius AG 
Avanti J-20 XP centrifuge  Beckman Coulter 
Balance Sartorius AG 
Blot chamber, Semi Dry Bio-Rad 
CD spectrophotometer, J-815 Jasco 
centrifuge, 5417C Eppendorf 
centrifuge, 5804R Eppendorf 
centrifuge, 5810R Eppendorf 
DynaProTitan Wyatt Technology 
Eppendorf Mastercycler Gradient Eppendorf 
Esi MS, esquire HCT Bruker Daltonics 
Esi MS, Finnigan LCQ Advantage Max Thermo Scientific 
French press Thermo Scientific 
gel documentation system, Odyssey LICOR 
Hi Trap Desalting columns GE Healthcare 
Hi-Load Superdex 200 26/60 prep grade GE Healthcare 
Hi-Trap Chelating HP columns GE Healthcare 
HPLC, 1100 Serie Agilent 
HPLC, 1200 Series Agilent 
Impressa Xr50 Jura 
incubator, Hera Cell Heraeus 
Mar345 Image Plate Detector Marresearch GmbH 
Microfluidizer Microfluidics International Corporaton 
MicroMax 007 HF x-ray source Rigaku 
multimode platereader, Enspire Perkin Elmer 
Nanodrop, ND-1000 PeqLab 
Peptide synthesizer PS3 Protein Technologies Inc. 
pH electrode MP220 Mettler Toledo 
Pipetting robot, Freedom Evo Tecan 
Pipetting robot, mosquito TTP Labtech 
platereader infinite M 200  Tecan 
platereader TECAN Ultra Tecan 
platereader Varioscan Thermo electron corporation 
real-time PCR Cycler; iCycler iQ5 Bio-Rad 
rotors, JLA 8.1000,JA 25.50  Beckman Coulter 
Shaker/Incubator innova 4430 New Brunswick Scientific 
SpeedVac, Concentrator 5301 Eppendorf 
sterile hood, HeraSafe Heraeus 
Superdex 200 10/300 GL GE Healthcare 
Superdex 75 10/300 GL GE Healthcare 
VersaDoc 5000 CCD camera Bio-Rad 
Waters HPLC system Waters 
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CHEMICALS AND REAGENTS MANUFACTURER 
 
Standard chemicals were purchased from Roth 
or Sigma unless otherwise stated.  
  
1,4-Dithiothreitol (DTT) Sigma Aldrich 
1000 bp DNA ladder PeqLab 
2-mercaptoethanol Sigma Aldrich 
Agarose Invitrogen 
Ampicillin Sigma Aldrich 
AMPPNP (Adenylyl-imidodiphosphate) Roche 
Bis(Sulfosuccinimidyl)suberate (BS3) Thermo Scientific 
Bradford Reagent Bio-Rad 
BSA (bovine serum albumin) AppliChem 
Chloramphenicol Sigma Aldrich 
Coomassie Brilliant Blue G250 AppliChem 
Ethidium Bromide Roth 
EZ-link Sulf- NHS-LC Biotin Pierce 
FITC detection Kit PerkinElmer 
Fluorescein Isothiocyanate (FITC) Roth 
Gel filtration MW standard Bio-Rad 
Glutathione (reduced) Roth 
Iodoacetamido (IAA) fluorescein Sigma Aldrich 
Kanamycin Sigma Aldrich 
LB medium mix Roth 
Low Molecular Weight Protein Marker GE Healthcare 
NHS fluorescein Sigma Aldrich 
PAGE Ruler Prestained Plus Thermo Scientific 
Protease Inhibitor Mix Serva 
Protein A detection kit PerkinElmer 
SYPRO Orange (5000x) Molecular Probes 
TEMED (N-N-N'-N'-tetramethylethylenediamine) Merck 
Triton X-100 Merck 
 
 
CONSUMABLES MANUFACTURER 
384 well plate, black Greiner Bio One 
96 well plate, black, half area Greiner Bio One 
Amicon concentrators Millipore 
Dialysis tubes Spectrum Laboratories Inc. 
filter membrane, 45 µm Sigma Aldrich 
Glutathione Agarose 4B Protino, Macherey-Nagel 
Nitrocellulose membrane Schleicher and Schuell 
PCR purification kit Macherey-Nagel 
Plasmid mini präp kit Macherey-Nagel 
Proxi Plate, 384 well, white Perkin Elmer 
Strep Tactin Superflow High capacity resin iba  
Whatman filter paper Schleicher and Schuell 
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CELL CULTURE MANUFACTURER 
DMEM PAA 
Dulbecco's PBS PAA 
Fetal Calf Serum (FCS) Lonza 
Penicillin/Streptomycin (100x) PAA 
RPMI Gibco 
Trypsin/EDTA (10x) PAA 
 
 
SOFTWARE MANUFACTURER 
Adobe Illustrator Adobe Systems 
CCP4 
STFC Rutherford Appleton 
Laboratory 
Compass Bruker Daltonics 
DynaPro V6 Dynamic Wyatt Technology 
Empower Waters 
i-control Tecan 
Mac PyMol Schrödinger, LLC 
Rock Maker Formulatrix 
Xcalibur 2.0.7 Thermo Fischer Scientific 
XDS MPI, Heidelberg 
 
 
ANTIBODIES MANUFACTURER 
Arf1, mouse, monoclonal Millipore 
Arf6, mouse, monoclonal Santa Cruz (sc-7971) 
Bitotin, mouse, monoclonal, FITC coupled Sigma Aldrich 
mouse-IgG, goat, NIRD (800) coupled (GAM800) Thermo Scientific 
phospho-tyrosine, mouse, monoclonal Santa Cruz (sc-7020) 
Rac1, mouse, polyclonal Millipore 
Rac1, rabbit, polyclonal Santa Cruz (sc-95) 
 
 
CELL LINES AND BACTERIAL STRAINS USED FOR: 
  
Hela cells GTPase activation experiments 
NIH 3T3 cells GTPase activation experiments 
  
E.coli BL21 (DE3) protein expression 
E.coli DH5  
molecular biology and plasmid 
propagation 
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7 Appendix 
 
7.1 Supplementary Figures 
 
 
 
Supplementary Figure 1. Fluorescence polarization assay with Arf6 mutants locking the GTPase in 
the active or inactive conformation. Fluorescein labeled JIP4 LZII was incubated with increasing 
concentrations of Arf6 Q67L (“active”) or Arf6 T44N (“inactive”). As a negative control, BSA was employed 
and results in no increase of the FP signal. Results are mean +/- SEM (n=5). 
 
 
 
 
Supplementary Figure 2. Chemical crosslinking of ARNO Sec7 and EGFR ICD1022 in the presence of 
SecinH3. The indicated proteins were incubated with the chemical crosslinker BS3 in the presence of 
increasing concentrations of SecinH3 or DMSO. Crosslinks were visualized on SDS PAGE gels stained with 
Coomassie Brilliant Blue. 
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Supplementary Figure 3. Chemical crosslinking of ARNO Sec7 and EGFR ICD1022 in the presence of 
different adenine nucleotides. The indicated proteins were incubated with the chemical crosslinker BS3 
in the presence of ATP or the non-hydrolysable nucleotide AMPPNP. Crosslinks were visualized on SDS 
PAGE gels stained with Coomassie Brilliant Blue. 
 
 
Supplementary Figure 4. Nucleotide exchange activity of ARNO Sec7 constructs employed in this 
study. Arf1 preloaded with GDP was incubated with the indicated ARNO Sec7 constructs in the presence 
of excess GTP. The change in tryptophan fluorescence is measured and fitted to a linear regression model. 
The slope is plotted as mean +/- SEM (n=4). 
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Supplementary Figure 5.Chemical crosslinking of N-terminally modified EGFR JM with ARNO Sec7. 
The N-terminus of EGFR JM was modified with fluorescein (“FL”,a) or biotin (b). Thus, the primary amine 
was removed as a potential crosslinking site in experiments with lysine reactive crosslinker reagents. The 
resulting constructs were crosslinked to ARNO Sec7 with BS3. A scrambled version of EGFR JM (“sc”) and 
DrrA were used as controls. Crosslinks were visualized on SDS PAGE gels stained with Coomassie Brilliant 
Blue.  
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Supplementary Figure 6.Chemical crosslinking of EGFR JM A and EGFR JM B with ARNO Sec7. EGFR 
JM can be divided into an N-terminal part (JM A) forming a helical structure involved in EGFR dimer 
formation and a C-terminal part (JM B) that stabilizes the asymmetric dimer. Both JM A and JM B and the 
full length JM domain were crosslinked to ARNO Sec7 using the chemical crosslinker BS3. Crosslinks were 
visualized on SDS PAGE gels stained with Coomassie Brilliant Blue.. 
 
 
 
 
Supplementary Figure 7. Fluorescence polarization assay with fluorescein labeled ARNO Sec7 and 
EGFR constructs. ARNO Sec7 was labeled with fluorescein and incubated with increasing concentrations 
of EGFR ICD1022 and EGFR KC1022resulting in an increase in fluorescence polarization. No binding to 
GST was observed.Values are mean +/- SEM (n=2). 
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Supplementary Figure 8. Analytical gel filtration analysis of ARNO Sec7 with EGFR JM. ARNO Sec7, 
EGFR JM40 (40 amino acids of the juxtamembrane domain of EGFR) and a mixture of both proteins 
incubated for 30 minutes at room temperature were separated on a Superdex 75 size exclusion 
chromatography column (b). The eluted proteins were analyzed by SDS PAGE and Coomassie Brilliant 
Blue staining (c). No co-elution of ARNO Sec7 and EGFR JM is observed. A molecular weight standard (Bio-
Rad) was used as a size reference (a). 
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Supplementary Figure 9. Chemical crosslinking of DrrA with different EGFR constructs. The 
indicated proteins were incubated with the chemical crosslinker BS3. All three EGFR constructs form 
crosslinks with DrrA independent of the presence of the juxtamembrane domain. Crosslinks were 
visualized on SDS PAGE gels stained with Coomassie Brilliant Blue. 
 
 
 
 
Supplementary Figure 10. Chemical crosslinking of ARNO Sec7 constructs used for crystallization 
with EGFR JM. The indicated proteins were incubated with the chemical crosslinker BS3. Both ARNO Sec7 
constructs crosslink to EGFR JM. Crosslinks were visualized on SDS PAGE gels stained with Coomassie 
Brilliant Blue. 
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7.2 Plasmids 
 
vector constructs 
pASK IBA 45+ N delta 13 Arf6 and mutants 
pET 15b ARNO Sec7 52-256 and N-terminal truncations 
pET19mod DrrA (340-533) 
pET28 HT ARNO Sec7 EGFR JM fusion constructs 
pGEX_2T_TEV Rac1 
pGST1 JIP4 LZII (392-462) 
pIBA 101 HT ARNO Sec7 61-246 
 
7.3 Primer 
 
primer sequence used for: 
Arf6 T44N for 5' ACCATTCCCAACGTGGGTTTCAAC 3' Arf6 mutagenesis 
Arf6 T44N rev 5' GGTCACCGACTGGCCCAGCT 3' Arf6 mutagenesis 
Arf6 Q67L for 5' GCGGCCTGGACAAGATCCGG 3' Arf6 mutagenesis 
Arf6 Q67L rev 5' CCACATCCCATACGTTGAACTTGACA 3' Arf6 mutagenesis 
 
   
ARNO HT for 
5' phosphate CGGAACCGGAAGATGGCAA 
TGGGC 3' ARNO Sec7 truncations 
ARNO HT+2 for 
5' phosphate TTGCAACGGAACCGGAAGA 
TGGCAATGGGC 3' ARNO Sec7 truncations 
ARNO HT+4 for 
5' phosphate AAGACCTTGCAACGGAACC 
GGAAGATGGCAATGGGC 3' ARNO Sec7 truncations 
ARNO HT+6 for 
5' phosphate GGCAGTAAGACCTTGCAAC 
GGAACCGGAAGATGGCAATGGGC 3' ARNO Sec7 truncations 
ARNO HT+8 for 
5' phosphate AATGAGGGCAGTAAGACCT 
TGCAACGGAACCGGAAGATGGCAATGGGC 3' ARNO Sec7 truncations 
ARNO 
truncations rev 
5' phosphate CGTCTCAGACTGAAAATACA 
GGTT 3' ARNO Sec7 truncations 
 
 
   
N Sec7 for 
5' GTTGTTGAATTCGCCAATGAGGGCAGTA 
AGACCTTG 3' JM-Sec7-fusion 
N Sec7 rev 
5' GTTGTTGGTACCGGAGTGGGTCACGTCA 
TTCCCGTC 3' JM-Sec7-fusion 
N JM LL 15 for 
5' GTTGTTGGTACCAACCTGTCTTCCGACTC 
TAACTCCCCGGGTATCGAAGGTCTGTCTACG 
CGACGCCACATCGTCCGGAAGCGCACT 3' JM-Sec7-fusion 
N JM LL 23 for 
5' GTTGTTGGTACCAACCTGTCTTCCGACT 
CTTCCCTGTCTTCCCCGTCCGCTCTGAACT 
CCCCGGGTATCGAAGGTCTGTCTACGCGAC 
GCCACATCGTCCGGAAGCGCACT 3' JM-Sec7-fusion 
N JM rev 
5' GTTGTTAAGCTTTTAGATCCGCAGCAGAG 
CTTGGTTCGG 3' JM-Sec7-fusion 
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C JM for 
5' GTTGTTGAATTCCGACGACGCCACATCGT 
CCGGAAGCGC 3' Sec7-JM-fusion 
C JM LL 15 rev 
5' GTTGTTGGTACCAGACAGACCTTCGATAC 
CCGGGGAGTTAGAGTCGGAAGACAGGTTG 
ATCCGCAGAGCTTGGTTCGGAGCTTC 3' Sec7-JM-fusion 
C JM LL 23 rev 
5' GTTGTTGGTACCAGACAGACCTTCGATAC 
CCGGGGAGTTCAGAGCGGACGGGGAAGAC 
AGGGAAGAGTCGGAAGACAGGTTGATCCG 
CAGAGCTTGGTTCGGAGCTTC 3' Sec7-JM-fusion 
C Sec7 for 
5' GTTGTTGGTACCGCCAATGAGGGCAGTAA 
GACCTTG 3' Sec7-JM-fusion 
C Sec7 rev 
5' GTTGTTAAGCTTTTAGGAGTGGGTCACGT 
CATTCCC 3' Sec7-JM-fusion 
LL37 extend for 
5' phosphate TCCACTGCTTCTAACTCCCCG 
GGTATCGAAGGTCTGTCT 3' 
linker extension fusion 
proteins 
LL37 extend rev 
5' phosphate GTTCAGAGCGGACGGAGAGG 
ACAGGGAGTTCAGAGCGGACGGGGA 3' 
linker extension fusion 
proteins 
 
   
N Vec for 
5' phosphate TCCGCTCTGAACTCCCCGGGT 
ATCGAAGGTCTGTCTCGACGACGCCACATC 
GTCCGGAAG 3' 
double JM fusion 
proteins 
N Vec rev 
5' GAAGAAGAGCTCGAATTCCATGGCGCCC 
TGAAAATA 3' 
double JM fusion 
proteins 
N JM for 
5' GAAGAAGAGCTCCGACGACGCCACATCG 
TCCGGAAG 3' 
double JM fusion 
proteins 
N JM rev 
5' phosphate CGGGGAAGACAGGGAGAGG 
TCGGAAGACAGGTTGATCCGCAGCAGAGC 
TTGGTTCGG 3' 
double JM fusion 
proteins 
C Vec for 
5' GAAGAAGAGCTCTAAAAGCTTCTCGAGC 
ACCACCAC 3' 
double JM fusion 
proteins 
C Vec rev 
5' phosphate CGGGGAAGACAGGGAAGAG 
TCGGAAGACAGGTTGATCCGCAGCAGAGC 
TTGGTTCGG 3' 
double JM fusion 
proteins 
C JM for 
5' phosphate TCCGCTCTGAACTCCCCGGG 
TATCGAAGGTCTGTCTCGACGACGCCACAT 
CGTCCGGAAG 3' 
double JM fusion 
proteins 
C JM rev 
5' GAAGAAGAGCTCGATCCGCAGCAGAGC 
TTGGTTCGG 3' 
double JM fusion 
proteins 
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